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Abstract 
 
Molecular modelling on the GSK-3β protein was carried out to identify a library of suitable 
electrophilic warhead containing ligands that have the necessary interactions with the binding 
site. Several series of novel irreversible inhibitors for GSK-3β with potential anti-Alzheimer‟s 
disease activities were then synthesised. In total, eleven compounds were successfully 
synthesised.  The compounds have been fully characterised using standard spectroscopic and 
analytical techniques. 
 
The scaffold, 5-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazin-2-amine, was equipped  
with an α,β-enone Michael acceptor, that allowed for the coupling of various side chains using 
substitution chemistry. A library of two different series with an internal Michael acceptor was 
synthesised. The synthesis of the third series that consisted of a terminal Michael acceptor or a 
halomethylketone was attempted but proved futile.  
 
Suzuki-Miyaura chemistry has been thoroughly explored to find the best conditions to offer the 
products in acceptable yields. Pd(dppf)Cl2 as a catalyst, in a solvent system of 
toluene:ethanol:water, was found to be the best candidate for the Suzuki-Miyaura reactions to 
synthesise the aforementioned scaffold. 
 
The compounds were tested against the human recombinant GSK-3β and were found to have 
weak to good activity (GSK-3β IC50 range: 0.12 - >10 μM). The most active compound (GSK-3β 
IC50: 0.12 μM) consisted of a pyridine ring and the carbonyl of the Michael acceptor is situated 
directly next to the aminopyrazine core. The results showed that the libraries have the potential 
to be expanded into a second generation of new compounds. 
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Opsomming 
 
Deur gebruik te maak van molekulêre modellering was verskeie nuwe reekse onomkeerbare 
inhibitore vir GSK-3β gesintetiseer wat potensiële aktiwiteit bevat vir die bestryding van 
Alzheimer se siekte.  Elf molekules was suksesvol gesintetiseerd en volledig gekarakteriseerd 
met behulp van spetroskopiese en analitiese tegnieke. 
 
Die raamwerk, 5-{4-[(4-metielpiperasien-1-iel)sulfoniel]feniel}pyrasien-2-amien, was verbind 
aan „n elektrofiliese “lokval”. Verskeie sykettings was dan gekoppel deur gebruik te maak van 
SN2 substitusie. Twee reekse molekules met „n interne α, β-enoon Michael ontvanger is 
gesintetiseer. Die sintese van die derde reeks wat „n terminale Michael ontvanger of „n 
halometielketoon bevat, het probleme opgelewer en was nie suksesvol nie.  
 
Die Suzuki-Miyaura chemie was deeglik ondersoek om die beste kondisies te vind wat die 
produkte in aanvaarbare opbrengste sal lewer. Pd(dppf)Cl2 as katalis in „n oplosmiddel sisteem 
van tolueen:etanol:water was bepaal as die beste kandidaat vir die Suzuki-Miyaura reaksies om 
die bogenoemde raamwerk te sintetiseer. 
 
Die molekules was getoets op die menslike rekombinante GSK-3β en die aktiwiteite was bepaal 
as matig tot goed (GSK-3β IC50 reeks: 0.12 - >10 μM). Die mees aktiefste molekuul (GSK-3β 
IC50: 0.12 μM) bevat „n piridien ring en die karboniel van die Michael ontvanger is direk 
gekoppeld aan die aminopiperasien kern. Die resultate het ook gewys dat die molekules die 
potensiaal het om onomkeerbaar te bind aan GSK-3β. Gebaseerd op die positiewe resultate, het 
die reekse ook die potensiaal om verder uitgebrei te kan word. 
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Chapter 1 
Introduction 
 
1.1 Overview 
This chapter is concerned with the roles of various hypotheses in Alzheimer’s disease (AD) and 
to introduce key findings on drug development to address AD. In addition, key aspects of the 
biology and biochemistry associated with the role of Aβ and tau in AD are also summarised. 
Lastly, several clinical trials on promising anti-AD drug candidates are discussed in this chapter.  
(This chapter is a minor adaptation of a review paper currently in peer review.)   
 
1.2 Background 
Most people seek to live as long as possible, staving off death with medical treatments. Life 
expectancies have improved dramatically since the beginning of the 20
th
 century in most 
industrialised countries.
1
 The increase in longevity has been made possible by the enormous 
advancement within scientific and medical domains. The gain in years of life does not always 
mean that there is good quality of life throughout, as the increase in life span is not without 
complications. The prevalence of degenerative diseases such as dementia, Parkinson’s disease 
and AD have been increasing with increasing life expectancy. Millions of people around the 
world suffer from these diseases. Degenerative diseases are currently costing the caregivers over 
$200 billion annually to provide the necessary aid and treatment for those suffering from these 
illnesses.
1
 With the increasingly aged population and no viable cure or treatment for the 
degenerative diseases, the cost in both financial and human terms looks set to increase 
dramatically in coming decades. 
The principal risk factor for AD is age. The accumulation of misfolded proteins in the aging 
brain results in oxidative and inflammatory damage, which in turn leads to synaptic dysfunction 
and eventually death.
2
 In 2012, the worldwide number of AD cases stood around 36 million and 
is expected to triple by 2050.
3
 Furthermore, AD is one of the diseases that cannot yet be 
prevented, cured or slowed down and one out of three individuals older than 60 years dies of 
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AD.
1
 The average period of survival is approximately eight years after initial diagnosis.
4
 Most 
cases occur later in life (>65 years old), although around 5% of cases occur in patients under 60 
years old.
5
 These cases are termed early-onset familial Alzheimer’s disease (FAD) and are the 
result of the inheritance of gene mutations on chromosome 14 and 21. The most defined 
mutations are located on the β-amyloid precursor protein gene (APP) and presenelin genes.6, 7 
The rest of the cases are termed late-onset sporadic Alzheimer’s disease (SAD) and have one 
important risk factor, namely the carriage of the ε4 allele of the apolipoprotein (APOE).8 
Inheritance of a single ε4 allele increases the likelihood of developing AD by 2–5-fold and two 
ε4 alleles may increase risk by 10-fold or more.9, 10   
AD is characterised by progressive loss of multiple higher cortical functions including thinking, 
memory, orientation and language skills.
6, 11
 Furthermore, a loss in brain weight is observed that 
appears to be due to shrinkage and loss of neuronal processes.
12
 It has been suggested that AD 
does not destroy neuronal networks, but rather disrupts the neuronal activity that might interfere 
with delicate processes underlying cognitive functions.
3
 Experiments carried out on plaque-
bearing mice with AD have shown that memory formation at synapses are impaired. The aged 
mice, containing a mutant APP gene that generates amyloid beta (Aβ) plaques, showed profound 
neuritic dystrophy and extensive activation of microglial cells compared to control aged mice. In 
addition, the maximum synaptic field potentials in the aged transgenic mice were much smaller 
(55%).
13
 Subsequent to these findings, signalling molecules critical to memory, are inhibited due 
to the disrupted release of presynaptic neurotransmitters.
14, 15
 Due to the activities of the 
abnormal neuronal network, some AD patients experience non-convulsive epileptic episodes.
16
      
There are several hypotheses as to what causes AD and this will be explained in this chapter, 
along with the current treatments. Because of the vast number of papers on AD, this chapter 
focuses on key papers and recent works that illustrate the main features of the subject in the 
following sections.   
 
The aforementioned mutations and risk factors are associated with abnormal production or 
clearance of Aβ, a 39- to 43-residue peptide that eventually forms senile plaques. The discovery 
of Aβ in senile plaques,17, 18 mutations in APP19 and presenilin genes20, 21 that leads to the 
accumulation of Aβ, has resulted in the formulation of the “Amyloid Cascade Hypothesis”.22, 23 
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1.3 The amyloid precursor protein (APP) and the amyloid β-peptide 
(Aβ) 
Aβ is a 39- to 43-residue peptide that is cleaved from a much larger peptide, the amyloid 
precursor protein (APP), and is found in the membrane of cells and organelles such as 
mitochondria.
24, 25
 The function of APP is still unclear, but it has been suggested that it could 
play a role in regulating metal ion transport and homeostasis.
26
 Recently, a report has 
demonstrated that APP facilitates the efflux of iron and increases the stability of ferroportin on 
the cell surface.
27
 It is also thought that APP plays a role in synaptic formation and repair, 
signalling and cell adhesion.
28
  
The cleavage of the APP by proteases is done in two different pathways, namely, the    
non-amyloidogenic- and amyloidogenic pathways. In the non-amyloidogenic pathway, the APP 
is cleaved by α-secretase between residues K687 and L688 of the protein to form a large soluble 
fragment (sAPPα). In the amyloidogenic pathway, the APP is cleaved by β-secretase (BACE1) 
between residues M671 and D672 to form another soluble fragment (sAPPβ). The remaining 
membrane-bound fragments of the APP of the two pathways are then further cleaved by the   
γ-secretase (GS) to produce monomeric Aβ peptides of varying lengths. From the amyloidogenic 
pathway, the cleaved Aβ1-42, with the length of 42 amino acids, is not very soluble and tends to 
aggregate and form the fibrils that are characteristic of AD.
25, 26
 These fibrils are also known as 
senile plaques and are deposited extracellularly in the brain.
29
 
 
1.4 Inhibitors of Aβ aggregation 
Aβ aggregation can be inhibited in two ways: either through binding to Aβ monomers and 
prevent oligomerisation or by reacting with Aβ oligomers to promote clearance. Tramiprosate, 1 
(Fig. 1.1), has been showed to maintain Aβ in the nonfibrillar state and increase cognitive ability 
in mild AD. However, Phase III clinical trials have been inconclusive due to variability in drug 
studies, low CNS bioavailability and, consequently, further studies were terminated.
30-32
  
Scyllo-inositol, 2 (Fig. 1.1), an orally-administered stereoisomer of inositol that can cross the 
blood-brain barrier (BBB), binds to Aβ and modulates its misfolding. The aggregation of Aβ is 
thereby inhibited and dissociation of aggregates is stimulated. Studies carried out on animals 
have shown that scyllo-inositol 2 reduces the concentration of soluble and insoluble Aβ, plaque 
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burden and synaptic loss while improving spatial memory function.
32
 Results of Phase I clinical 
trials suggested that the compound is well tolerated, but in Phase II trials there were serious 
adverse events among patients in the high dose groups (1000 mg and 2000 mg) that included 
nine deaths. Therefore, further trials were restricted to lower dose groups (250 mg and 500 mg). 
Unfortunately, no viable cognitive or functional improvements were observed at 500 mg/day 
doses and the trials were subsequently aborted.
32, 33
  
 
 
Figure 1.1. Aβ aggregation inhibitors: Tramiprosate 1 and scyllo-inositol 2 
 
Curcumin, 3 (Fig. 1.2), is a well-known ingredient found in turmeric. This polyphenol has the 
ability to cross the BBB, inhibits the formation of Aβ oligomers and binds to already existing 
plaques.
34, 35
 For optimal activity, structure-activity relationship (SAR) studies suggested two 
phenyl groups containing polar substituents on one side for hydrogen bonding and a spacer of  
8–16 Å containing less than two sp3-hybridised carbons.36 Owing to these attractive findings, a 
large database of curcumin derivatives have been developed over the years. Longvida, a 
curcumin dietary supplement, is currently being evaluated in a Phase II trial (NCT01001637).
37
 
Recently, a promising curcumin derivative, 4 (Fig. 1.2), has been reported to significantly bind 
Aβ aggregates with reduced cell toxicity. Furthermore, it has been suggested that a substituent on 
the spacer could improve the efficacy of the compound.
38
 In addition, the poor aqueous solubility 
of curcumin (<0.1 mg/ml), was overcome by substituting the methoxy functional groups with 
dimethylamine, affording 5 (Fig. 1.2). This allows the derivative to be converted into a 
hydrochloride salt, where the aqueous solubility improved to 16.7 mg/ml. Not only was the 
solubility improved, but also the half-life of the derivative and the potential to inhibit Aβ 
aggregation.
39
 Unfortunately, new studies have shown that curcumin is a notorious false positive 
compound for inhibiting Aβ aggregation. It was suggested that the activity was due in large part 
to compound-mediated fluorescence interference in assays.
40
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Figure 1.2. Optimisations of curcumin 3 that led to derivatives 4 and 5 with enhanced water 
solubility and activity 
 
The first rational design of non-peptidic, small molecule Aβ aggregation inhibitors was derived 
from the KLVFF peptide, an Aβ16-20 fragment.
41
 In this work, Tjerenberg et al. reported that the 
KLVFF peptide was able to bind to full length Aβ1-42 and arrest the aggregation of Aβ to toxic 
fibrils.
42
 Using the KLVFF peptide as the starting point, a pharmacophore was developed that 
comprised the side-chains of Leu, Val and Phe residues. Two small non-peptidic inhibitors, 6 
and 7 (Fig. 1.3), were designed and reported to diminish the formation of large oligomers and 
fibrils of Aβ1-42. In addition, by using the thioflavin-T (ThT) dye assay, the aggregation 
inhibitory activity of inhibitors 6 and 7, at a concentration of 50 μM each, were measured as 71% 
and 47% against Aβ1-42 (10 μM), respectively.
43
   
 
 
Stellenbosch University  https://scholar.sun.ac.za
6 
 
Figure 1.3. The first non-peptidic inhibitors developed by Tjerenberg et al.
42
 
1.5 Designing secretase inhibitors 
Although the APP cleavage enzymes, beta secretase (BACE1) and gamma secretase (GS), has 
been known for a long time, it has been a challenging task to develop secretase inhibitors that 
penetrate the BBB and specifically inhibit the cleavage of APP. In addition, the inhibitors should 
not affect the cleavage of Notch signalling pathway and voltage-gated sodium channel  
subunits.
3, 44-46
 It has been found that a variety of GS inhibitors have the potential to inhibit the 
cleavage of Notch which could have an adverse effect on the regulation of cellular   
signalling.
47, 48
 Non-selective inhibition of the GS developed adverse side effects that included 
hematological and gastrointestinal toxicity, skin reactions and hair colour changes.
32
 In addition, 
presenilin-1 (PS1) and presenilin-2 (PS2) are directly involved in the GS cleavage event and it 
has been suggested that PS is the catalytic core of GS.
47
 
Whereas in BACE1, the large active site and the fact that it is less hydrophobic than other 
aspartyl proteases, makes it extremely difficult to develop small molecule inhibitors that have the 
ability to cross the BBB.
45, 49, 50
 
 
1.5.1 Beta secretase (BACE1) 
Since the discovery of BACE1, small peptide-based mimetics of the APP cleavage site,  such as 
statine, 8 (Fig. 1.4) were developed in the 2000s.
45
 (S)-Statine inhibited the activity of BACE1 
with an IC50 of ~40 μM. Modification of the (S)-statine through acetylation or replacement of the 
(S)- with the (R)-statine enantiomer resulted in diminished activity.
51
 One of the first potent 
BACE1 inhibitors, OM99-2, 9 (Fig. 1.4), was created based upon an octapeptide BACE1 
substrate, where the scissile peptide bond had been replaced by a Leu-Ala hydroxyethylene  
transition-state isostere.
52
 The Ki value for OM99-2 on recombinant BACE1 was reported to be  
1.6 nM.
52
 An example of another potent BACE1 inhibitor is the cell permeable statine-derived 
BACE1 inhibitor, 10 (Fig. 1.4), that displayed effective inhibition against the BACE1    
(IC50 = 0.12 μM) and Aβ formation (EC50 = 4.0 μM) in transfected human embryonic kidney 
(HEK-293) cells. The absolute configuration of the active diastereomer was not determined.
53
 
Optimisation of the statine-derived scaffold, by inserting oxygen, led to the development of new 
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phenyloxy- and benzyloxy residues. As an example, the benzyloxy statine-derived compound, 11 
(Fig. 1.4), inhibited BACE1 with an IC50 of 13 nM.
54
  
 
Figure 1.4. Statine, 8, and statine-derived peptide-based mimetic inhibitors 
 
Other peptidomimetic inhibitors, based on piperazinone and imidazolidinone scaffolds, were 
developed through molecular modelling and X-ray crystallography. In particular, piperazinones 
were determined to be tolerant to a wide diversity of modifications. Compound 12 (Fig. 1.5) 
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induced potent inhibition of BACE1 (IC50 = 3 nM), but modest reduction of Aβ1-40 
(cell IC50 = 300 nM). The imidazolidinone-based compound, 13 (Fig. 1.5), displayed similar 
results (BACE1 IC50 = 5 nM, cell IC50 = 1100 nM). It was suggested that the introduction of the 
carbonyl in the scaffold improved the potency of the compounds and this was confirmed by an 
X-ray crystal structure that showed a hydrogen bond between the carbonyl moiety and Thr72 
NH.
55
 
 
 
Figure 1.5. Peptidomimetic inhibitors based on piperazinone and imidazolidinone scaffolds 
 
One of the major challenges in the design of protease inhibitors is the transition from 
peptidomimetics to small molecules. This task has proven to be quite challenging in the case of 
BACE1. The large size of the active site and the need for efficient brain penetration created 
additional challenges for the design of small non-peptidic inhibitors.
50
 Nonetheless, a wide 
variety of novel small molecule non-peptidomimetic BACE1 inhibitors have been developed 
through fragment-based discovery. BACE1 fragment screening methods have been distributed 
among nuclear magnetic resonance (NMR) spectroscopy,
56-59
 X-ray crystallography,
59-62
 surface 
plasmon resonance (SPR),
59, 63
 in situ chemistry and biochemical enzyme assays.
59, 64
 Several 
groups have reported the identification of fragment hits using NMR methods such as HSQC,
56
 
waterLOGSY
58
 and 
19
F NMR spectroscopy.
65
 Using these techniques, three major structural 
classes, isothiourea 14, 2-aminopyrimidinone 15 and aminoquinoline 16 (Fig. 1.6), were 
discovered as BACE1 fragment hits. Over 200 isothiourea analogues were selected for a focused 
screen in a BACE1 HTRF assay. The most potent analogue in this series, compound 17 (Fig. 
1.6), dose-dependently inhibited BACE1 with an IC50 of 210 μM in the BACE1 HTRF assay. An 
X-ray crystal structure of the complex between the isothiourea 17 and BACE1 showed hydrogen 
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bonds between the NH groups of the isothiourea moiety and two catalytic aspartates (Asp32 and 
Asp228) in the active site.
56
 Folmer and co-workers focused on optimising the 
aminopyrimidinone fragment hit through BIAcore assay format after a NMR spectroscopy 
screen on a 2000-compound general fragment library. The best BACE1 inhibitor, compound 18 
(Fig. 1.6), had a modest affinity for BACE1 (Kd = 0.66 mM), but bound efficiently to BACE1 
and was therefore deemed a suitable starting point for chemical optimisations.
58
  
In another NMR spectroscopy approach, a library of 1200 fluorine-containing fragments was 
screened by 
19
F NMR.
65
 One of the hits, an aminoquinoline fragment 16, was investigated with 
different hydrophobic substituents at the 6-position. The fluorine moiety resulted in better Kd 
values (SPR Kd = 1.2 mM) in comparison to the -CF3 group (SPR Kd = 3.9 mM), which was 
likely due to the reduced hydrophobic effects and/or the significant decrease in the van der 
Waal’s (VDW) volume. Further hydrophobic substitutions at the 6-position of aminoquinoline 
16 led to potencies in the low micromolar range. Compound 19 (Fig. 1.6), a trifluorinated   
aryl-aminoquinoline, with a SPR Kd value of 200 μM was mixed with 
19
F-containing compounds 
to identify potential candidates for fragment linking. 
19
F-
19
F {
1
H decoupled}-NOESY NMR 
spectroscopy experiments suggested that compounds 19 and 20 (Fig. 1.6) bind close in space and 
may be successfully combined which provided the inspiration to synthesise compound 21  
(Fig. 1.6). This compound had a greater than 100-fold increase in potency when compared to the 
original fragment 19.
65
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Figure 1.6. Development of inhibitors after fragment-based screening 
 
In 2014, novel tetrahydropyran (THP) chromene inhibitors, armed with spirocyclic motifs, were 
developed that overcame the aforementioned BACE1 challenges. Guided by the SAR studies, 
8-THP chroman, 22 (Fig. 1.7), equipped with the aminooxazoline motif, showed great potential 
in terms of inhibiting BACE1 (IC50 = 45 nM) and had a 1300-fold selectivity over cathepsin D 
(CatD), which possesses a similar active site. Furthermore, compound 22 showed sufficient cell 
permeability in the apical to basolateral direction (Papp AB = 19 10
-6 
cm/s), but demonstrated a 
moderate efflux ratio in LLC-PK1 cells transfected with human MDR1 (P-gp). In addition, 
pharmacodynamic studies carried out on rats with compound 22 demonstrated a 69% reduction 
of Aβ1-40 in cerebrospinal fluid (CSF).
66
  
 
Eli Lilly identified isothiourea hits with potential in a fragment-based screening assay of 
approximately 8000 fragments. Modification of the amino-benzothiazine scaffold to include a 
sp
3
 carbon led to the development of the chiral compound 23 (Fig. 1.7). The fluorine atoms were 
added to enhance the metabolic stability of the compound.
67
 The BACE1 inhibitor showed 
promising results (IC50 = 240 nM with high cell permeability) and was the first of the amidine 
class to reach Phase I clinical trials. In healthy volunteers, the inhibitor demonstrated long-
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lasting Aβ reductions in lumbar CSF after oral dosing of 30 and 90 mg. Unfortunately, further 
clinical trials were discontinued as a result of the development of off-target retinal pathologies.
61, 
68, 69
  
AstraZeneca evaluated a series of bicyclic aminoimidazoles as potent BACE1 inhibitors to  
fine-tune the properties of the amidine moiety by introducing substituents on the bicyclic ring. 
The basicity of the aminoimidazole group (pKa >8) was lowered by introducing fluorinated 
substituents to improve blood-brain permeability. Aminoimidazole 24 (Fig. 1.7), with  
fluorine-propyl ether and difluoromethoxy substituents on the bicyclic rings, showed good 
membrane permeability (Caco-2 cells, 8   10-6 cm/s). Furthermore, compound 24 showed low 
nanomolar potency against BACE1 with an IC50 of 7.5 nM and reduced brain- and plasma Aβ1-40 
levels with 17% and 76%, respectively in wild-type mice when co-administered with efflux 
inhibitor GF120918.
70
  
 
 
Figure 1.7. A series of the amidine inhibitors developed through fragment-based screenings  
 
In another attempt to improve selectivity for BACE1 over CatD without affecting CNS 
penetration, compound 23 was redesigned. As shown in Figure 1.8, a thorough analysis of the 
structure of BACE1 and CatD resulted in subtle differences being observed that could potentially 
be exploited to design compounds to improve selectivity for BACE1. The flap loop conformation 
represented by BACE1 Tyr71 and Trp76 is similar to that in CatD (region III), but the 
substitution of Trp76 by Leu (CatD) in the flap loop prevents hydrogen bond formation to Tyr78 
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(by Trp). Instead, Tyr78 engages Trp40, which is not within the flap loop, likely creating greater 
rigidity in this region in CatD. Using this strategy, the pyrimidine side chain of compound 23 
was removed and the amidine scaffold 25 (Fig. 1.9) was expanded to fill the space of S2ʹ. 
Compound 26 (Fig. 1.9), with a tetrahydropyran (THP) ring fused to the amidine scaffold, was 
developed with the fluoromethyl moiety occupying the S2ʹ pocket. Selectivity over CatD 
increased significantly (76-fold) with similar potency (BACE1 whole cell assay (WCA)   
IC50 = 61 nM) when compared to compound 23 (BACE1 WCA IC50 = 50 nM). Furthermore, the 
fused THP compound 26 exhibited good brain penetration and, in rat toxicology assessment, no 
signs of autofluorescent material accumulation in retinal pigment epithelium at two doses   
(75 and 25 mg/kg) were observed.
71
   
 
 
Figure 1.8. X-ray crystal structure of the amidine scaffold 25 (green ball and stick) with BACE1 
(light blue ribbon) with a model of 25 (orange ball and stick) in cathepsin D (yellow ribbon). 
Residues in the areas of interest are labelled with BACE1 residue names and numbers (light 
blue) following by the corresponding CatD residue names (yellow)
71
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Figure 1.9. Attachment of a fused THP ring on the amidine scaffold 25 to improve the 
selectivity towards BACE1 over catD  
 
1.5.2 Gamma secretase (GS) 
DAPT, 27, (Fig. 1.10) was the first peptidomimetic compound with GS inhibitory activity when 
tested in vivo.
72, 73
 This compound inhibited Aβ production in cells, with an IC50 of 115 nM, but 
high doses (100 mg/kg) were needed to lower Aβ in the brain of young APP transgenic    
mice.
72, 74
 Unfortunately, DAPT was found to be an inhibitor of the Notch signalling pathway, 
and pharmacokinetic (PK) profiling revealed potential acid instability of the t-butyl ester 
group.
73, 75
 Using a SAR strategy, the acid-labile t-butyl ester group was replaced with a more 
robust imidazole side chain 28 (Fig. 1.10). For this compound, cellular potency was greatly 
increased (WCA IC50 = 0.4 nM) with significant reductions of brain, plasma, and CSF Aβ in 
guinea pigs after an acute dose.
75
     
 
 
Figure 1.10. The first peptidomimetic GS inhibitor 27 and the optimisation of the acid-labile 
side chain that led to the development of 28. 
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Eli Lilly developed a non-selective GS inhibitor, semagacestat, 29 (Fig. 1.11), that inhibits APP 
and Notch cleavage (APP IC50 = 15 nM and Notch EC50 = 49 nM).
76
 In Phase I human trials, the 
drug showed a maximum inhibition of plasma Aβ1-40 (73% reduction) at six hours after the 
administration of the 140 mg dose. A rebound effect on plasma Aβ1-40 levels was observed  
8-12 hours after administration.
76
 Unfortunately, in Phase III human trials, semagacestat, 29, did 
not improve cognitive status and was associated with adverse events, including skin cancers and 
infections. In comparison to the placebo, patients receiving higher doses (140 mg) had 
significant worsening of functional ability and the trial was terminated before completion.
77
 
Inspired by the semagacestat series, the Hoffman-La Roche group developed a potent, 
metabolically-labile malonamide GS inhibitor, 30 (Fig. 1.11), that inhibited Aβ1-40 with an IC50 
of 22 nM in a cell-free GS assay derived from human embryonic kidney (HEK) cells.
78
 
Replacement of the metabolically-labile difluorobenzyl group with the pentafluoropropyl group, 
in addition to changing the malonamide into its carbamate analogue, afforded 31 (Fig. 1.11), 
which demonstrated improved solubility and stability. However, compound 31 potently inhibited 
Notch processing (Notch-1 IC50 = 1.7 nM) in an HEK cellular assay.
78, 79
  
 
 
Figure 1.11. Semagacestat 29 and associated Hoffman-La Roche inhibitors  
 
Using high throughput screening (HTS) in a whole cell assay (SHSY5Y cells), a Merck group 
identified the benzodiazepine lead, 32 (Aβ1-40 IC50 = 33 nM) (Fig. 1.12) as a GS inhibitor.
80
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Modification to the benzodiazepine substituent and the hydrocinnamate side chain, in an attempt 
to improve membrane permeability and potency, offered analogues such as 33       
(Aβ1-40 IC50 = 4 nM) (Fig. 1.12).
76
 A QSAR analysis of this series of GS inhibitors revealed that 
inhibitory activity increased in parallel with increasing lipophilicity.
81
 Further optimisation of 
this series led to the potent GS inhibitor 34 with picomolar activity (Aβ1-40 IC50 = 60 pM)   
(Fig. 1.12). Unfortunately, no Notch-sparing selectivity data for 34 were reported.
82
   
 
 
Figure 1.12. Merck’s benzodiazepine-based GS inhibitors 
 
In 2007, Bristol-Myers Squibb identified lead GS-inhibiting arylsulfonamides from an HTS 
campaign.
83
 In this campaign, which employed a cellular assay (hAPPsweH4 cells), compound 35 
(Fig. 1.13) was identified to be a modest inhibitor of GS (IC50 = 850 nM). A significant increase 
in potency (~ 10 fold) was observed when compounds were branched with an α-methyl group at 
the point of attachment to the sulfonamide nitrogen, as observed in the case of the cyclohexyl 
derivatives 36 (Aβ1-40 IC50 = 1000 nM and 37 (Aβ1-40 IC50 = 190 nM) (Fig. 1.13). Further SAR 
studies led to the potent 4-chlorophenyl analogue, 38 (Aβ1-40 IC50 = 5 nM) (Fig. 1.13). Three 
hours after oral administration of a single 500 μmol/kg dose of 38 to Tg2576 βAPP-Swedish 
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transgenic mice, tests showed a 25% reduction in brain Aβ. Furthermore, this compound had a 
low brain Aβ level of 5.2 μM and a plasma level of 1.6 μM. 
 
Figure 1.13. Bristol-Myers Squibb’s first generation of arylsulfonamides GS inhibitors 
 
To improve the in vivo efficacy, various nitrogen-appended analogues of 38 were next 
synthesised.
84
 Methanesulfonamide 39 (Fig 1.14) proved to be one of the most potent inhibitors 
in this series (Aβ1-40 IC50 = 320 pM in hAPPsweH4 cells). When this compound was orally 
administered to Tg2576 mice at 200 μmol/kg, a 27% reduction in brain Aβ was observed. This 
represents a similar reduction in brain Aβ, but at less than half the dose of 38. However, the 
brain/plasma ratio of sulfonamide 39 was relatively poor (0.06) with respect to that of 38 (3.25). 
Replacement of the methylsulfonamide functional group with a tetrazole group afforded 
analogue 40 (Fig. 1.14) with similar potency (Aβ1-40 IC50 = 510 pm in hAPPsweH4 cells), but with 
improved efficacy (41% reduction in brain Aβ in Tg2576 mice at 200 μmol/kg) and a better 
brain/plasma ratio of 0.21.   
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Figure 1.14. Bristol-Myers Squibb’s second generation of arylsulfonamide GS inhibitors 
 
Wyeth and ArQule employed HTS screening on their compound collections in a cellular assay 
(hAPPCHO cells) with respect to Aβ production, to furnish two lead GS inhibitors, 41 (Aβ1-40 
IC50 = 5449 nM) and 42 (Aβ1-40 IC50 = 2214 nM) (Fig. 1.15).
85
 Furthermore, both leads had 
moderate Notch-sparing selectivity of 3.7-fold and 9-fold, respectively. Replacing the butyl 
chain of 41 with a 3-pentyl group afforded 43 (Fig 1.15), a structural modification that greatly 
improved the potency (Aβ1-40 IC50 = 294 nM) and Notch-sparing selectivity (14-fold). A further 
increase in potency (Aβ1-40 IC50 = 25 nM) was observed for 44 (Fig 1.15), in which the     
4-chlorophenyl moiety had been replaced with the 5-chlorothiophene group. Not only was 44 a 
potent GS inhibitor, it also had promising Notch-sparing selectivity (10-fold). Compound 44,  
in vivo, reduced brain Aβ1-40 and Aβ1-42 by ~25% when administered at 100 mg/kg to TG2576 
mice. Furthermore, compound 44 had good solubility (6.7 mg/mL) and exhibited high membrane 
permeability (Caco2 assay: (A-B), Papp = 50 x 10
6
 cm/s; (B-A), Papp = 42 x 10
6
 cm/s) and good 
brain/plasma ratio (2.0). Unfortunately, the metabolic stability of 44 was low [t1/2 = 1 min (rat), 
t1/2 = 2 min (mouse), 8 min (human)]. The primary sites of metabolism were found to be the 
oxidation of the terminal methyl group of the 3-pentyl group and glucuronidation of the primary 
hydroxyl group. To improve the metabolic stability, the side chain was shortened and the labile 
methyl groups were replaced with trifluoromethyl groups to afford begacestat, 45 (Fig 1.15), 
which has high potency (Aβ1-40 IC50 = 15 nM) and Notch-sparing selectivity (14-fold). Increased 
metabolic stability for begacestat was observed in mice and human microsomes [t1/2 = 3 min 
(rat); t1/2 = 48 min (mouse); t1/2 = >90 min (human). Begacestat has shown promising results in 
preclinical trials and is currently under clinical evaluation for AD treatment.
86
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Figure 1.15. The development of begacestat 45 
 
Further improvement of the pharmacokinetic properties through HTS and SAR exploration on 
the aryl sulfonamide series led to the development of avagacestat (BMS-708163) 46 (Fig 1.16).
87
 
For this compound, brain penetration and metabolic stability improved significantly through the 
incorporation of the bioisosteric oxadiazole and the trifluoromethyl group.
87
 In a Phase I clinical 
trial, avagacestat reduced cerebrospinal fluid concentrations of Aβ1-38, Aβ1-40 and Aβ1-42 at daily 
doses of >50 mg/day for 28 days without any sign of potential Notch toxicity.
88
 After the 
promising results of the Phase I clinical trial, avagacestat was subjected to Phase II clinical trials. 
Unfortunately, the results were disappointing as cognitive performances at daily doses of 25 and 
50 mg were comparable to the placebo over 24 weeks. In addition, higher doses (100 and 125 
mg) of avagacestat led to adverse GI and dermatological effects.
89
 
 
 
Figure 1.16. Avagacestat 
 
In 2006, Merck developed a series of 4-substituted cyclohexyl sulfones which inhibited GS   
in vivo in the low nanomolar range. Investigation of substitution at the 4-position of the 
cyclohexane moiety led to the development of a potent sulfone, 47 (Fig. 1.17), that demonstrated 
a robust decrease of brain Aβ1-40 levels in APP-YAC mice 4 hours after oral dosing of 1 mg/kg.
90
 
Sulfone 47 was also found to have significantly higher inhibition (37-fold) of the isoform of GS 
composed of PS1 than that of PS2.
91
 In addition, chronic dosing with sulfone 47 in mice did not 
cause Notch-mediated side effects as reported with other GS inhibitors.
92
 The good safety profile 
of sulfone 47 made it an attractive starting point for further optimisation.  
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Through conformational analysis, the sulfone series was expanded to include tricyclic 
compounds.
93
 Preliminary results of tricyclic sulfones showed a much improved in vitro potency 
and in vivo CRND8 mouse PK profile. An example is the tricyclic triflate, 48 (Fig. 1.17), which 
inhibited membrane Aβ1-40 with an IC50 of 27.1 nM and inhibited cortex Aβ1-40 by 42% three 
hours after a single oral dose of 30 mg/kg.
93
 Furthermore, this series had lower Notch-related 
side effects in comparison to other GS inhibitors.  
Based on these results, Merck went on to develop the next generation of tricyclic sulfones with 
improved SAR.
94
 By shifting the sulfonamide group to position 7 of the tricyclic core structure, 
alkyl sulfonamide 49 (Fig. 1.17) showed improved bioactivity by inhibiting membrane Aβ1-40 
with an IC50 of 13 nM and this compound involved 69% inhibition of Aβ1-40 in the brain, three 
hours after a single oral dose of 10 mg/kg.
94
 
In 2015, Merck developed a spirocyclic series based on the SAR data of the aforementioned 
sulfone GS inhibitors.
95
 To improve the stability of the chair conformation, the sulfonamide 
group was replaced with a spirocycle. For example, cyclic phosphonate 50 (Fig. 1.17) inhibited 
the membrane Aβ1-40 with an IC50 of 9.5 nM and had 33-fold selectivity for presenilin-1 over 
presenilin-2. Also, phosphonate 50 demonstrated improved pharmacokinetic properties when 
compared to sulfone 47 and the phosphonate cycle appeared stable in vivo. The improved 
stability of the phosphonate 50 and high selectivity for PS1 paves the way for safer GS inhibitors 
in the future.
95
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Figure 1.17. Merck’s rational design strategy resulted in spirocyclic phosphonate GS   
inhibitor 50 
 
The discovery that nonsteroidal anti-inflammatory drugs (NSAIDs) such as (R)-ibuprofen 51, 
indomethacin 52, sulindac sulfide 53 and (R)-flurbiprofen 54 (Fig. 1.18) selectively lower the 
Aβ1-42 formation in favour of Aβ1-38, without inhibiting Notch cleavage, has encouraged the 
development of NSAIDs-like GS inhibitors.
96, 97
 However, their weak in vitro potencies   
(Aβ1-42 IC50 >10 μM) have limited their development. Nonetheless, (R)-flurbiprofen 54 was 
advanced into clinical studies and was moderately successful in Phase II clinical trials.
97, 98
 
Unfortunately, during Phase III clinical trials, (R)-flurbiprofen 54 failed to slow down cognitive 
decline or loss of ability to carry out daily activities in patients with mild AD.
99
 Nevertheless, 
these results encouraged further research into how NSAIDs inhibit GS. An example would be the 
confirmation that sulindac sulfide 53 noncompetitively inhibits GS at a concentration of    
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10–30 μM.100 (R)-Flurbiprofen 54 has also been shown to inhibit GS noncompetitively    
(IC50 = 307 μM).
101
 
 
 
Figure 1.18. Structures of NSAIDs that decrease the formation of Aβ1-42 
 
These findings have prompted the development of a second generation of NSAID derivatives 
with improved potency while removing the cyclooxygenase (COX) inhibition that is associated 
with NSAIDs. The company, Chiesi, used (R)-flurbiprofen 54 as starting point and replaced the 
methyl substituent with a cyclopropyl group and added substituents on the terminal phenyl group 
to yield compound 55 (Aβ1-42 IC50 = 41 μM) (Fig. 1.19), which was found to be 7-fold more 
potent than (R)-flurbiprofen 54 (Aβ1-42 IC50 = 305 μM).
102, 103
 However, brain penetration for 
compound 55 was found to be poor, with a brain/plasma ratio of about 5% in mice after 100 or 
300 (mg/kg)/day for 4-5 days.
103
   
 
 
Figure 1.19. Chiesi’s second generation NSAID derived GS modulator 
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A Japanese-based company, Eisai, developed a series of NSAID-piperidine derivatives with the 
aim to improve brain penetration. Replacement of the aryl ring with piperidine led to the 
development of isoamyl derivative 56 (Fig. 1.20) that demonstrated good penetration of the CNS        
(brain concentration = 4.2 μM at a 5 mg/kg oral dose after 2 h). In addition, 56 inhibited Aβ1-42 at 
a pIC50 of 6.5. It was suggested that lipophilicity plays a crucial part in terms of the compound’s 
potency and brain penetration.
104
 To improve the pharmacokinetic properties of the piperidine 
acetic acid series, researchers at Merck incorporated fluorine onto the piperidine ring.      
The resultant 3,3-difluoropiperidine 57 (Fig. 1.20) demonstrated good in vitro activity against 
Aβ1-42 with a selective inhibition (IC50 = 230 nM) relative to Aβ1-40 (IC50 = >10 000 nM).
105
 The 
shift of the carboxylic acid to the 3- position led to the development of 4,4-difluoropiperidine 58 
(Fig. 1.20) that showed similar activity (Aβ1-42 IC50 = 600 nM, Aβ1-40 IC50 = >10 000 nM). When 
the  APP-YAC transgenic mice were dosed with 57 and 58 (10 mg/kg, oral, 7 h), both 
compounds showed potent Aβ1-42 reduction (of 84% and 64% respectively).
105
 
 
 
Figure 1.20. NSAID-piperidine derived GS modulators 
 
Around 2006, researchers at Eisai worked on a non-NSAID-derived GS modulator, called the 
cinnamide series.
106-109
 This work culminated in the development of E-2012, 59 (Fig. 1.21), and 
a number of patent applications involving salts,
110
 processes
111, 112
 and prodrugs
113
 have been 
found in the patent literature. In terms of activity, E2012 59 inhibits Aβ1-42 with an IC50 of 92 nM 
and Aβ1-40 with an IC50 of 330 nM. In rat CSF, E2012 59 significantly decreased Aβ1-42 levels by 
17% and 47% at doses of 10 and 30 mg/kg, respectively. Furthermore, the reduction of Aβ1-42 
levels in rat brain at doses of 10 and 30 mg/kg were 17% and 43%, respectively. In addition, no 
evidence of adverse effects on Notch were seen in vitro up to 3 μM.114 Based on these promising 
results, modifications on the scaffold core emerged. Replacing the cinnamide olefin, which is a 
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potential Michael acceptor, and lowering the lipophilicity, Pfizer came up with a 
dihydrobenzofuran amide core.
115
 From this group of compounds, benzofuran 60 (Fig. 1.21) 
demonstrated improved CNS physicochemical properties (clogP = 3.96, Topological Polar 
Surface Area (TPSA) = 78, Lipophilic Efficiency (LipE) = 4.18, Central Nervous System 
Multiparameter Optimization (CNS MPO) = 4.8) in comparison to E2012 59 (clogP = 4.8, TPSA 
= 47, LipE = 2.19, CNS MPO = 3.7). In addition, benzofuran, 60, achieved good in vitro potency 
(Aβ1-42 IC50 = 188 nM) and was found to be inactive against Notch (IC50 >50 μM).
115
 The rat PK 
profile of benzofuran 60 showed good oral bioavailability and moderate clearance with moderate 
liability for CYP inhibition (CYP3A4 and CYP2D6 IC50 >30 μM). Benzofuran, 60, reduced  
Aβ1-40 and Aβ1-42 significantly in vivo in guinea pigs with 16% and 36% respectively (100 
mg/kg, oral dose, 4 hours).
115
 Based on these results, Pfizer went on to improve membrane 
permeability and brain penetration.  A conformational lock on the molecule was introduced and 
the number of rotatable bonds, as well the number of hydrogen bond donors, were reduced.
116
 
Replacing the amide with a lactone gave rise to two possible regioisomers, shown by 61 and 62 
(Fig. 1.21). Complete loss of activity was observed for 62 (Aβ1-42 IC50 = >16 μM), whereas 61 
preserved some Aβ1-42 activity (Aβ1-42 IC50 = 3.4 μM). This finding provided valuable insight 
into the pharmacophore, as it suggested that the two polar functional groups need to be situated 
on opposite sides of the scaffold. The scaffold was then converted into pyridopyrazine-1,6-dione 
to afford the desired polar functional groups. Compounds 63 and 64 (Fig. 1.21) showed 
substantially improved activity (Aβ1-42 IC50 = 252 nM and 101 nM, respectively) over 61 and 62. 
Furthermore, 63 had 100% oral bioavailability in rats and showed excellent membrane 
permeability (Ralph Russ Canine Kidney (RRCK) Papp,A-B = 17.7   10
-6
 cm/s and Multidrug 
Resistance (MDR)A-B = 13.1   10
-6
 cm/s). Both compounds were less lipophilic with respect to 
E-2012 59 and demonstrated good CNS physicochemical properties. Compound 64 was able to 
reduce 68% of Aβ1-42 in vivo in guinea pigs in oral doses of 90 mg/kg after 4 hours.
116
 Further 
optimisation on the right side of the pyridopyrazine-1,6-dione core, to improve the ADME 
profile, led to the development of compound 65. This compound exhibited potent in vitro 
inhibition (Aβ1-42 IC50 = 6 nM), good rodent brain penetration (brain to plasma ratio of 0.8 and an 
unbound brain to unbound plasma ratio of 0.4) and as well robust in vivo Aβ1-42 lowering in 
guinea pigs (42% reduction after 3 h for 60 mg/kg oral dose).
117
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Figure 1.21. Optimised pyridone analogues 
 
There has been an enormous effort by scientists to identify potent secretase inhibitors that do not 
possess adverse side effects. Various pharmacophores have been identified with varying degrees 
of success. Several compounds have advanced into clinical trials, but no sign of a successful 
drug has emerged yet. However, there is still ongoing activity in the development of safe and 
potent secretase inhibitors. 
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The next section of this chapter will discuss the hypothesis of metal dyshomeostasis and 
oxidative stress. This section will also discuss the development of metal chelators and 
antioxidants to address AD.  
 
1.6. Metal dyshomeostasis and oxidative stress 
The lack of clinical success of antiamyloid drugs has led to the modification of the amyloid 
cascade hypothesis or to the development of a new hypothesis.
32, 118, 119
 Approximately 20 – 40% 
of cognitively normal elderly people have enough Aβ plaque deposit to cause AD based on the 
autopsy studies that have been carried out. This finding suggests that the presence of Aβ plaque 
deposit alone, even in large quantities, is not sufficient to produce AD-related abnormalities.
120
 
Furthermore, the toxic mode of Aβ has not been found to be a direct cause of AD.121 Early 
research has indicated that transition metals are abnormally distributed in AD and that elevated 
levels of zinc, iron and copper are found in senile plaques.
122, 123
 It has been confirmed that metal 
ions bind to Aβ and influence Aβ toxicity through multiple mechanisms that include Aβ 
aggregation accelerator, Fenton-like reactions and the generation of reactive oxygen species 
(ROS). Aβ could then damage biomolecules or overwhelm antioxidant mechanisms leading to 
increased oxidative stress and inflammation.
124
 In the diseased state of the organism, the natural 
antioxidant defence mechanisms may malfunction, leading to ROS accumulation and oxidative 
stress.
125
 
The loss of mitochondrial function that is prevalent in the early events of AD, associated with the 
accumulation of ROS, plays an important role in synaptic dysfunction.
126, 127
 There is evidence 
that suggests that the oxidation of mitochondrial DNA renders it more susceptible to somatic 
mutation.
128
 These mutations may lead to the formation of pathological Aβ.129   
It has also been suggested that in AD, metal ions are likely mislocalised from the intracellular to 
extracellular environment around the synapses and that the free metal ions bind to the Aβ fibrils 
due to its affinity for copper and zinc.
130
 The above findings and later observations
131-134
 formed 
the basis of the metal dyshomeostasis hypothesis, which showed that AD correlated with the 
dyshomeostasis of metal ions. 
Metals such as copper, iron and zinc have defined physiological functions in living organisms 
that maintain normal cellular processes.
135
 Many key enzymes such as ceruloplasmin, dopamine 
β-hydroxylase and carbonic anhydrase rely on metals for their catalytic activity.136-138 Metals 
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also play key roles in gene expression, single electron transfer, regulation of synaptic functions 
and many more important functions.
139-141
 
Transition metals, though crucial to many biochemical neuronal processes are abnormally 
regulated in AD.
142, 143
 The levels of Aβ are controlled by metal ions at both the APP and Aβ 
processing levels.
24, 144
 Dysfunctional levels of metal ions in the brain have been shown to 
promote the precipitation of Aβ and the induction of Aβ aggregation in senile plaques.145  
Furthermore, iron levels are much higher in AD neuropils with respect to healthy neuropils  
(the region between neurons where synaptic connections form) and iron is abnormally 
concentrated in amyloid plaques.
24
  Deregulated levels of copper have been shown to interfere 
with the processing of APP and reduce the clearance rate of Aβ, which leads to the precipitation 
of Aβ plaques.146 
Aβ has also been determined to be redox active, and since metal ions such as Cu2+ and Fe3+ are 
enriched in AD neuropil and plaque deposits, they undergo reduction to Cu
+
 and Fe
2+
 
respectively. Hydrogen peroxide, a freely permeable molecule, is then produced through the 
subsequent reduction of molecular oxygen as Cu
2+
 and Fe
3+
 reform.
147
 It has been suggested that 
Aβ deposition could act as a sink for trapping potentially harmful transitional metal ions that 
would otherwise catalyse the oxidation of biomolecules. The formation of amyloid plaques could 
thus be considered as a compensatory mechanism to reduce oxidative stress.
148
 Copper and zinc 
have been found to play key roles in regulating synaptic function by modulating receptors of the 
glutamatergic system. Copper and zinc released into the synapse are weakly coordinated and 
readily exchangeable. Aβ has also been reported to interact with receptors of the glutamatergic 
system, in a manner which interrupts processes regulating cognition and memory. Therefore, the 
synaptic space is an ideal location for metal-Aβ interactions that may lead to neuron 
apoptosis.
123, 149, 150
 
The role of calcium dyshomeostasis in AD has been determined via mutants in presenilin 
genes
151
 and increased intraneuronal [Ca
2+] is correlated with Aβ-plaque formation, APP 
mutations and tau hyperphosphorylation.
152
 Impaired calcium homeostasis reduces synaptic 
plasticity and memory deficits in AD and may also contribute to the synaptic loss and reduction 
of dendritic spine density in pyramidal neurons.
153, 154
 Furthermore, caspases that mediate cell 
apoptosis directly depend on calcium homeostasis and are found to be activated in aging 
people.
155, 156
 In patients with AD, an enhanced capacity for the transport of calcium from the 
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endoplasmic reticulum (ER) to the mitochondria is observed. This may lead to mitochondrial 
calcium overload and a collapse of the mitochondrial membrane potential. This results in the 
potential collapse of the proton gradient, which in turn suppresses ATP synthesis and triggers 
apoptosis.
154
  
Finally, it has also been suggested that the sequestration of zinc by Aβ deposits leads to reduced     
intra-neuronal zinc levels, or in some cases, excess zinc in neighbouring neurons. The abnormal 
levels of zinc destabilise microtubules, leading to neurofibrillary tangles (NFT) and cognitive 
impairment.
157
 
 
1.6.1 Metal homeostatic therapy 
The brain requires metal ions for a number of cellular processes. For that reason, the brain 
contains a high concentration of several transition metals such as iron, copper and zinc. These 
transition metals are involved in the neuronal activity within the synapses and also in various 
metalloproteins. Therefore, cells have developed a sophisticated mechanism for controlling 
metal-ion homeostasis. In the case of a breakdown of these mechanisms, or absorption of metals 
with no known biological function, the ionic balance is altered and can result in a disease state 
such as AD.
158
 
Although metal dyshomeostasis is not the only cause of AD, therapeutic interventions aimed at 
restoring metal homeostasis is a viable strategy for the treatment of AD. The development of 
metal chelators as sequestering agents for metal overload is well known.
134, 159
 The chelator drug 
must have certain properties such as low molecular weight, able to cross the BBB, stable, low 
toxicity and target a specific metal.
158
 Furthermore, the chelator drug should be able to 
coordinate a metal ion with two or more points of attachment. This chelation effect provides the 
necessary stability to the corresponding metal complexes. For the metal chelate complex to 
remove metal ions in overload situations, the complex should thus have a high thermodynamic 
stability and also not depend on dilution effects.
159
 
 
1.6.1.1 Metal overload chelation therapy 
Desferrioxamine 66 (Fig. 1.22) was one of the first compounds used to treat iron and aluminium 
overload in AD patients. A clinical trial of two year intramuscular injections showed that 
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desferrioxamine slowed down the clinical progression of AD. Unfortunately, many patients 
suffered side effects such as anemia and weight loss.
160
 
Several other chelating agents have been investigated for their ability to sequester copper and 
zinc. For example, the in vitro treatment of extracted Aβ deposits in a phosphate-buffered saline 
medium with three different chelating agents, bathocuproine 67, EGTA 68 and TPEN 69   
(Fig. 1.22) at concentrations from 4 μM, found that they were able to redissolve Aβ deposits.161  
 
 
Figure 1.22. Early metal chelators used to treat metal overload 
 
1.6.1.2 Rare metal complex chelators 
The three His residues near the N-terminus of the Aβ sequence (His-6, His-13 and His-14) form 
a high affinity metal binding site for copper, zinc and iron. These metal interactions affect  
peptide aggregation and toxicity.
162
 Therefore a different strategy was examined with rare metal 
complexes as metal chelators. Pt(II) complexes have been determined to be stable and redox 
inert when present in biological systems. The association of slow kinetics with substitution 
reactions at the Pt(II) centre makes it difficult to displace the Pt(II) metal when bound to a 
target.
163
 Targeting the imidazole side chains of the His residues of Aβ with Pt(II) complexes 
was suggested.
163
 Three platinum phenanthroline derivatives, Pt(1,10-phenanthroline)Cl2 70, 
Pt(4,7-diphenyl-1,10-phenanthroline)Cl2 71 and Pt(4,7-diphenyl-1,10-phenanthroline 
disulfonate)Cl2 72 (Fig. 1.23) were evaluated for their ability to inhibit the metal-dependent 
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biochemical and cellular actions of Aβ. The binding of the platinum complexes with Aβ1-42 were 
confirmed with SELDI-TOF mass spectrometry and NMR spectroscopic experiments showed 
strong interactions between the platinum complexes and the imidazole side chains of the      
His-6, -13 and -14 residues. With the confirmation that the platinum complexes bind to Aβ 
peptides, primary mouse cortical neuronal cell cultures were treated with 10 μM Aβ1-42 for four 
days and resulted in a 35% cell viability reduction. Treatment of the affected cultures with the 
platinum complexes 70, 71 and 72 at a concentration of 5 μM restored neuronal viability with 20 
to 35% improvement.
163
 These data suggest that the interaction between the platinum complex 
and Aβ, mediated by the His residues, blocks copper, zinc and iron binding to Aβ and 
consequently prevents metal-mediated phenomena such as ROS. It was suggested that the 
coordination of the Pt(II) complexes to Aβ inhibited the aggregation of the peptide and leads to 
precipitation of amorphous aggregates rather than toxic amyloid fibrils.
162
    
In 2010, ruthenium complexes were proposed as a better alternative to platinum complexes for 
selective inhibition of Aβ-histidines. Ruthenium has a stronger tendency to coordinate with 
imidazole nitrogen atoms and ruthenium compounds are typically accompanied by a more 
favourable toxicity profile compared to platinum compounds.
164
 In this research, spectroscopic 
analysis of fac-[Ru(CO)3Cl2(N1-thz)] 73 (Fig. 1.23) showed strong binding of the ruthenium 
complex, {Ru(CO)3}
2+
, to the His residues of the Aβ1-28 model, after the release of chloride and 
thiazole ligands. However, no in vitro results were published regarding Aβ inhibition.164  
Murphy and co-workers have suggested that ruthenium complexes of the         
2,3-bis(2-pyridyl)benzoquinoxaline bridging ligand interact with DNA via intercalation of the 
ligand.
165
 Studies have also shown that DNA binding capabilities of the Pt(II) complexes could 
be increased by incorporating another metal moiety through bridging ligands.
166-168
  These 
observations resulted in the idea of developing a complex with a bridging ligand that interact 
with Aβ.166 Rangachari and co-workers166 have thus developed a heterobimetallic complex, 
containing Pt(II) and Ru(II) metal centres, that is based on Pt(II) complex 72. The introduction of 
a Ru(II) metal centre with a hydrophobic bipyridyl (bpy) ligand to Pt(II) complex 72 led to the 
development of the binuclear complex [Ru(bpy)2(dpp)2PtCl2]2 74 (Fig. 1.23). The hydrophobic 
surface of the bipyridyl ligands may enhance the ability of the complex to interact with similar 
surfaces present in Aβ peptide. Furthermore, two molecules of complex 74 were determined to 
bind to Aβ1-42, suggesting the presence of more than one binding site. Therefore, it was 
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concluded that 74 may alter the random coil conformation of Aβ1-42 to a more compactly folded 
form and thereby inhibit the formation of amyloid fibrils.
166
   
 
 
Figure 1.23. Metal complexes as chelators to inhibit amyloid fibrillation 
 
Metal complexes containing Group 9 metals such as iridium and ruthenium have also been 
shown to bind to histidine-rich proteins, and have been applied to luminescent protein 
staining.
169
 Two Group 9 metal-based inhibitors were thus developed to target the His-residues 
of Aβ1-40. Iridium 75 and rhodium 76 complexes (Fig. 1.23) possess labile co-ligands (H2O), 
which can be displaced by the imidazole N-donor moiety of the His-residues of Aβ1-40. Both 
complexes were able to inhibit Aβ1-40 at 5 μM and prevent misfolding of the Aβ peptide. 
Rhodium complex 76 was determined to be the most active with an IC50 of 25 – 50 μM on the 
neuroblastoma cell line (SH-SY5Y). Both complexes demonstrated significant enhancement in 
emission intensity in the presence of Aβ1-40 peptide. It was suggested that the coordinative bond 
formation between the group 9 metal centre and the His-residues of the Aβ1-40 peptide produced 
this phenomena.
170
 
 
Stellenbosch University  https://scholar.sun.ac.za
31 
 
Unfortunately, most of the Pt(II) complexes tend to have poor bioavailability and BBB 
penetration that make the likelihood of their clinical development questionable.
171, 172
 The orally 
bio-available Pt(IV) complex cancer drug, satraplatin
173
 77 (Fig. 1.24), has inspired the 
development of Pt(IV) complexes for Aβ inhibition. Pt(IV) complexes undergo slow substitution 
in a biological system, are stable in the acidic environment of the stomach and are able to cross 
the gut membranes intact. The prodrug, [Pt(IV)(N,N-dimethyl-2-[2-(quinolin-8-yl)-1H-
benzimidazol-1-yl]ethanamine)Cl4] 78 (Fig. 1.24), was found to be reduced in vivo by natural 
reductants such as glutathione, to the active Pt(II) complex. Treatment of Tg2576 mice with the 
Pt(IV) complex 78 for 18 weeks at a dose of 15 mg/kg/day by oral gavage reduced Aβ plaque by 
29%. Also, high levels of Pt were found in the blood plasma (1.7 ± 0.8 μmol) and in the brain 
tissue (0.006 ± 0.002 μg/g of body weight). These data suggested a high bioavailability for the 
Pt(IV) prodrug 78.
172
 
 
 
Figure 1.24. Pt(IV) complexes with improved bioavailability 
 
1.6.1.3 8-Hydroxyquinoline-based chelators 
Clioquinol (CQ) 79 (Fig. 1.25) was used in the 1960s as an oral anti-parasitic agent for the 
treatment and prevention of intestinal amebiasis, but was later withdrawn from the market due to 
reports of neurotoxicity. However, CQ 79 has re-emerged as a potential therapy for AD.
174
 The 
hydrophobic CQ 79 selectively binds to zinc and copper with greater affinity when compared to 
calcium and magnesium [K1(Zn) = 7.0; K1(Cu) = 8.9; K1(Ca) = 4.9; K1(Mg) = 5.0] and can cross 
the BBB freely. Tg2576 mice that were treated with CQ 79 at 20 mg/kg by gavage for 12 weeks 
showed a 65% decrease in sedimental Aβ. At a higher dose of 30 mg/kg/day for 9 weeks, the 
older 21-month-old mice experienced a 41% decrease in levels of Aβ in the brain pellet.175, 176 In 
a small Phase II clinical trial, oral administrations of CQ, in moderately severe AD patients, for 
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36 weeks slowed the rate of cognitive decline and reduced plasma Aβ1-42 levels when compared 
to the placebo controls.
121
 CQ 79 has a nanomolar affinity for Cu
2+
 and Zn
2+
, which facilitates 
the dissociation of these metal ions from the low affinity metal binding sites of Aβ.121 These 
results are promising and suggest a possible unique approach for the treatment of Aβ plaques.   
Prana Biotechnology Ltd. developed PBT2 80 (Fig. 1.25), a second generation        
8-hydroxyquinoline (8HQ) derivative of CQ 79, with a greater BBB penetration and Aβ plaque 
reduction. Transgenic AD mice that was treated with PBT2 80, showed improved 
performance.
121
 Unfortunately, a Phase II clinical trial failed to show significant improvement in 
cognitive functions.
177
 
It should be noted that the 8HQ scaffold has inspired scientists to make further modifications, all 
with the aim of making more bioactive compounds. Most of the modifications have been done 
around the phenolic ring.
159
 
 
 
Figure 1.25. The first 8HQ metal chelators 
 
Recently, Schiff-base derivatives have been reported as antioxidants and modulators of   
copper-mediated Aβ peptide aggregation. Hydrazinecarbothioamide 81 and 
hydrazinecarboxamide 82 (Fig. 1.26) were found to form stable complexes of 1:1 and 1:2  
metal-to-ligand ratios with copper under physiological conditions. In the Trolox Equivalent 
Antioxidant Capacity (TEAC) test, both compounds demonstrated roughly a 3-fold improvement 
in quenching the 2,2ʹ-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) radical cation (ABTS•+) 
when compared to CQ 79. It was suggested that the potent antioxidant properties observed for 
the Schiff bases are due to the negative inductive effect of the Cl and I ring substituents in CQ 
79, which decrease the stability of the hydroxyl radical. Furthermore, the extended conjugation 
in the Schiff bases increases the stability of the hydroxyl radical. In the turbidity assay, both 
compounds induced a significant decrease in aggregation of Aβ1-40 in the presence of Cu(II), 
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thereby indicating that these Schiff bases could limit oligomer formation by sequestering 
Cu(II).
178
 
 
 
Figure 1.26. Schiff bases as metal chelators 
 
Cyclodextrins (CycD) are a family of sugars well known for their ability to alleviate undesirable 
properties of drug molecules by forming inclusion complexes. Furthermore CycD can bind to the 
surface membrane of the cells, which may improve drug absorption across biological barriers.
179
 
CycD also has the ability to quench hydroxyl radicals, which suggests that it has antioxidant 
properties.
180
 The coupling of the CycD moiety with the 8HQ scaffold was explored to improve 
the aqueous solubility, antioxidant activity and pharmacokinetic properties of the hybrid 
compounds. Three CycD conjugates, 83 - 85 (Fig. 1.27), were reported to exhibit strong ability 
to scavenge the free radical ABTS•+ in the TEAC experiment. The activities were also found to 
be higher than the known antioxidant, Trolox. Furthermore, all three CycD compounds 
possessed the ability to quench the radical in presence of Cu(II). On five different cell lines, the 
CycD compounds demonstrated IC50 values of greater than 100 μM, even in the presence or 
absence of Cu(II). This indicates that high concentrations could be used without the anticipated 
toxicity on healthy tissues.
181
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Figure 1.27. Cyclodextrin-8HQ conjugates as metal chelators 
 
Conjugation of sugar moieties such as trehalose with 8HQ showed similar results as observed 
with the CycD conjugates.
182
 Trehalose is known to protect proteins and cells against 
environmental stresses and oxidative damage. In addition, trehalose has been reported to disrupt 
amyloid fibril formation and reduce cytotoxicity, thereby increasing cell viability in presence of 
Aβ aggregates.182 In the TEAC studies, trehalose-8HQ conjugates 86 and 87 (Fig. 1.28) showed 
significant ability to quench the ABTS•+ radical in the presence of Cu(II) and Zn(II). Both 
compounds were more active than CQ and Trolox. The free radical scavenging ability of the 
trehalose compounds could be attributed to the high reactivities of the hydroxyl substituents. In 
the turbidimetric measurement studies of Aβ1-40 with Cu(II), trehalose 86 and 87 were able to 
inhibit Aβ aggregation [Abs (405 nm): <0.025]. The disaccharide moiety alone failed to inhibit 
Aβ aggregation, suggesting that it plays no role in metal chelation. In addition, with Zn(II), both 
trehalose compounds significantly inhibited Aβ1-40 aggregation [Abs (405 nm): <0.015]. These 
results suggest that glycoconjugation is a valid option to allow the quinoline moiety to exert its 
metal-binding capability in aqueous solution.
182
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Figure 1.28. Trehalose-8HQ conjugates as metal chelators 
 
It has been determined that an increase in oxidative stress is correlated with a decrease in levels 
of the antioxidant glutathione (GSH), which suggests that the presence of GSH offers 
neurological protection. In fact, the addition of GSH precursor to Aβ protein reduced oxidation 
in neuronal cells. The presence of Aβ has also been shown to lead to GSH depletion in various in 
vitro cell models. These findings suggest that glutathione plays a critical role in AD 
pathogenesis.
183
 
Therefore, the use of a GSH-based substrate with the 8HQ scaffold is potentially a viable option 
in developing an antioxidant chelator with neuroprotective activity. GSH can also be used as a 
BBB shuttle for the delivery of the metal chelator drug. In this respect, GSH-8HQ 88 (Fig. 1.29) 
has a very high water solubility (12 g/mL) and is stable in acid (pH <5). Based on the hydrolysis 
studies in 80% human plasma, compound 88 may also be stable enough to arrive at the BBB 
intact. Lastly, compound 88 was found to have the potential to remove both Cu(II) and Zn(II) 
from the Aβ-peptide without causing any copper or zinc depletion in vivo.184  
 
 
Figure 1.29. Glutathione-8HQ conjugate as metal chelators 
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1.6.2 Natural metal chelators and antioxidants 
A wide variety of natural compounds are known to have antioxidant and metal-chelating 
properties. Many of such compounds can be found in nature or can be obtained as part of a 
diet.
185
 
Gingko biloba has been the subject of much attention for its medicinal and antioxidant 
properties. Its clinical effects in dementia have been studied and it has been suggested that the 
extract offers neuroprotection.
186-188
 It should be noted that mixed results have been reported 
about the use of Gingko biloba as treatment for AD. A Cochrane review
189
 claimed this extract 
offered improvement in cognition and activities of daily living, but no significant differences 
between Gingko biloba and placebo were determined in short clinical trials.
190
  
The consumption of curry is associated with improved cognitive function and a lower prevalence 
of AD in some populations, putatively due to the curcumin 3 (Fig 1.2) found in curry. It has also 
been suggested that 3 has antioxidant properties. The enol structure with the intramolecular 
hydrogen bond is suggested to be involved with the free radical scavenging activity. 
Furthermore, 3 has been observed in vitro and in vivo to have the ability to complex with metal 
ions via the diketone and pairs of phenol and methoxy groups.
191, 192
 
Epidemiological studies have shown that moderate consumption of alcohol is associated with 
lowered risk of AD.
185
 Red wine contains antioxidants such as resveratrol 89 (Fig. 1.30), a 
flavonoid, that scavenges ROS and up-regulates cellular antioxidants including GSH. In rat 
studies, 89 was observed to protect astrocytes in hippocampal slices from H2O2-induced 
oxidative stress by increasing GSH levels. Piceatannol 90 (Fig. 1.30), a metabolite of 89, occurs 
in many resveratrol-containing solutions, but at lower concentrations. It is a more efficient 
scavenger of ROS than 89 due to the additional phenol group and has also been considered for 
application as treatment in neurodegenerative diseases.
185, 191
  
Green tea leaves contain polyphenolic compounds, with catechins as the major constituents. 
Catechins are well known for their antioxidant, ROS scavenger and metal ion-chelating 
abilities.
191
 Epigallocatechin gallate (EGCG) 91 (Fig. 1.30) is the main catechin of green tea and 
contains several sites for the bidentate coordination of metal ions via the phenol groups. EGCG 
is BBB-penetrable and binds effectively to Fe(II), Cu(II) and Zn(II).
24
 
Melatonin 92 (Fig. 1.30), a natural hormone, is a BBB-penetrable compound involved in 
maintaining the circadian rhythm and memory formation in the hippocampus. Lower levels of 
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melatonin are found in older people, which results in numerous biological changes that includes 
the generation of ROS.
193, 194
 Transgenic mice that were treated with melatonin for ~5 months 
were protected from cognitive impairment. Furthermore, significant reduction of brain Aβ 
deposit and elevated levels of soluble Aβ in blood were observed.195 
Ginsenoside Rg1 93 (Fig. 1.30), a natural product extracted from Panax ginseng, has been 
reported to exert neuroprotective activities. Rg1 93 reduced the cytotoxicity induced by 400 μM 
of H2O2 in PC12 cells at a concentration of 0.1 – 10 μM. It was suggested that 93 could protect 
the cells from oxidative stress, but further research on this topic is needed.
196
 In a different study 
on PC12 cells that were treated with Aβ25-35 for 48h, 93 reduced the ROS production by 17% and 
28% at a concentration of 0.1 μM and 10 μM respectively. This study also showed that 93 
prevented the increased concentration of Ca(II) in PC12 cells that were treated with 50 μM of 
Aβ25-35.
197
 
Sesame glucosides (SG), found in sesame seeds, have also been shown to inhibit endogenous 
lipid peroxidation, as well as oxidative DNA damage in rat liver and kidney cells.
198
 In vitro 
experiments have also showed that SG exhibited the ability to scavenge peroxyradicals.
198
 Mice 
that were fed on a diet of 0.5% weight SG showed a complete blockage of oxidative DNA 
damage in Aβ25-35 induced brain tissue.
199
 Lastly, the generated ROS of 50 μM Aβ25-35-induced 
PC12 cells was completely reduced with 50 μg/mL of SG. These data suggests that SG could 
have a protective effect on Aβ-induced neuronal cell death via its antioxidant properties.198 
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Figure 1.30. Natural metal chelators and antioxidants 
 
Disturbances in the distribution of metals are central to the aggregation pathology of Aβ 
associated with AD. In addition, elevated levels of metals at the sites of Aβ oligomer formation 
could promote the generation of hydrogen peroxide that leads to oxidative stress. Several 
compounds have been identified that could reduce the Aβ pathology, improve memory and 
cognition. Clinical trials have shown some positive results, however, further research is required 
to determine whether the reduction of metal levels could provide relief against AD. 
 
The next section of this chapter describes the hypothesis of how the formation of neurofibrillary 
tangles (NFT) could promote AD. Different strategies have been developed to counteract the 
formation of NFT and will be discussed next in more detail. 
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1.7. Tauopathy  
(For the purposes of this dissertation – the focus of the design and synthesis of molecules 
described herein, falls under this category) 
 
Two types of aggregates are found in AD: extracellular amyloid plaques that were discussed 
earlier and intracellular NFT.
200
 The microtubule-associated protein tau was identified as the 
main component of NFT that accumulates inside neurons and their processes in AD brains.
201, 202
 
In AD patients, the protein tau is abnormally hyperphosphorylated and in this modified state, 
forms the NFT.
203
 NFTs are aggregations of paired helical filaments, which are made up of 
abnormally phosphorylated tau.
204
 Studies have shown that normal tau contains approximately 
two moles of phosphate per mole of the protein but in the AD-affected brain, tau is 
hyperphosphorylated roughly three times more.
205
  
Partially phosphorylated tau protein plays a role in maintaining neuronal integrity and 
stabilisation of microtubules to ensure their function as tracks for axonal transport and as 
cytoskeletal elements.
206-208
 In the case of hyperphosphorylated tau, the protein destabilises the 
microtubules and consequently interferes with tubulin binding.
207
 The density and length of the 
microtubules in AD neurons are greatly reduced and declines with aging in normal 
individuals.
209
 Only a small part of tau is involved in the abnormal aggregation process. One or 
two “hexapeptide motifs", which consists of approximately 31 imperfectly repeated amino acids, 
may be absent owing to alternative splicing.
29
  It should be noted that the complete loss of tau 
function does not lead to cytoskeletal collapse in transgenic mice but, a decrease in cytoskeletal 
function.
210
  
The phosphorylation of a protein is one of the main activities of protein kinases and 
phosphatases acting on it. Hyperphosphorylated tau can be dephosphorylated by phosphatases, 
but in AD brains the activities of phosphatases are reduced. Therefore, the decline of activity in 
phosphatases could be one of the causes of abnormal tau phosphorylation in AD.
211
 
However, the removal of tau in mice does not induce neurological deficits or cell death, but 
instead, makes the tau knockout more resistant to seizures, suggesting that the neuronal 
dysfunction is not due solely to a loss of tau function. Even though the mechanism by which 
neuronal cell death is caused by tau aggregates is unknown, there is a large body of evidence 
showing that aggregated tau acquires a toxic function in which tau oligomers are the    
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culprit.
212, 213
 Mutations of tau can influence tau either at the mRNA level, changing the 
alternative splicing of tau, or at the protein level, by changing the binding characteristics of tau 
with microtubules.
214
  
There are two major approaches that can be employed for the inhibition of tau aggregation. The 
first approach is the search for inhibitors of kinases that phosphorylate tau, based on the 
assumption that abnormally phosphorylated tau aggregates more readily.
215, 216
 The second 
approach is the development of inhibitors that disrupt the tau aggregation process.
29
 
 
1.7.1 Glycogen synthase kinase (GSK-3) 
Glycogen synthase kinase-3 (GSK-3) was first discovered approximately three decades ago as a 
glycogen synthase responsible for phosphorylating activity in rabbit skeletal muscle.
217
 GSK-3 is 
the last enzyme in the glycogen biosynthesis pathway that phosphorylates and inactivates 
glycogen synthase.
218
 Nowadays, GSK-3 is known to be involved in other biological functions 
such as cell division, stem cell renewal, insulin action and transcription. Furthermore, GSK-3 is 
believed to play a role in many diseases and disorders such as cancer, AD, diabetes, immune 
disorders, metabolic disorders, bipolar disorder, mood disorders, Parkinson’s disease and heart 
disease.
219, 220
 There are two GSK-3 genes, GSK-3α and GSK-3β, which account for all GSK-3 
activity in mammals. Both kinases have distinct roles, but are highly conserved and share 98% 
identity within their catalytic domains.
220
 GSK-3 is active under resting conditions and is rapidly 
inhibited by diverse stimuli and signalling pathways.
219, 220
 Many of its cellular targets are held in 
an inactive state through inhibitory phosphorylation.
220
 
Over activity of GSK-3 results in hyperphosphorylation of substrates that give rise to many 
diseases as mentioned earlier. Studies have shown that signal transduction plays a critical role in 
controlling the activity of GSK-3. Wingless-type MMTV integration site family member (Wnt) 
and insulin signalling are related to GSK-3 and increases its activity, which results in substrate 
hyperphosphorylation.
221
 Since the insulin signalling levels are decreased in AD brain, AD was 
suggested to be regarded as diabetes type III.
222
 This may be the reason behind the 
hyperphosphorylation of tau, one of the GSK-3 substrates, which eventually lead to the 
formation of NFT.
221
 In addition, increased GSK-3 activity may induce increased Aβ formation 
through its action on GS and thereby give rise to the senile plaque formation in AD.
223
 
Furthermore, studies have shown that GSK-3β interacts with presenilin, a critical molecule for 
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GS activity. Therefore, the inhibition of GSK-3β may alter the γ-cleavage of APP and 
subsequently inhibit the hyperphosphorylation of tau.
224
 Several studies have demonstrated that 
the inhibition of GSK-3 leads to decreased Aβ production and a reduction in tau 
hyperphosphorylation.
225
 
 
1.7.1.1 Designing GSK-3β inhibitors 
GSK-3β is highly enriched in the brain and several publications have reported that GSK-3β is 
responsible for the hyperphosphorylation of tau.
226-228
 Under normal conditions, GSK-3β is 
negatively regulated, but in the diseased state, GSK-3β is activated by the elimination of 
inactivation signals, leading to neurodegeneration. Based on this assumption, the development of 
a GSK-3β inhibitor as a therapeutic drug against AD is an attractive option.229 
The homology of the ATP-binding pocket in GSK-3α and GSK-3β presents a challenge for the 
development of isoform selective inhibitors.
207, 230
 In addition, the GSK-3 also has a co-factor 
Mg
2+
 binding site.
231, 232
 Inhibitors have to be designed in such a way that it interacts with Lys85, 
Glu97 and Asp200, the amino acids that are required for ATP recognition. Furthermore, 
establishing hydrogen bonds with the backbone atoms of Asp133 and Val135 in the hinge 
region, greatly improves the selectivity for GSK-3β.207, 230 The majority of the designed GSK-3β 
inhibitors are ATP competitive, have low molecular weight (<600 g/mol), contain heterocycles 
and are reasonably planar.
221
 The non-ATP competitive inhibitors do not compete with the high 
intracellular ATP concentration and could offer distinct pharmacological advantages since 
complete inhibition of GSK-3β will result in adverse events.207 It should also be noted that over 
500 kinases have been identified so far and that the GSK-3β inhibitor should be selective and not 
affect the other kinases.
233
  
 
1.7.1.2 Metal cation inhibitors 
Lithium chloride (LiCl) was the first inhibitor discovered that selectively inhibits GSK-3. In vitro 
experiments showed that at a concentration of 1-2 mM, LiCl caused a reversible dose-dependent 
inhibition of GSK-3β. Intact cells that were treated with LiCl were shown to possess GSK-3β 
with a reduced ability to phosphorylate tau.
234, 235
 One of the hypotheses was that lithium (Li
+
) 
acts as a competitive inhibitor of GSK-3 with respect to magnesium (Mg
2+
).
236
 The other 
suggested that Li
+
 inhibits GSK-3 under low potassium (K
+
) conditions.
237
 Some clinical trials 
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have shown that continuous treatment with lithium improved cognition and memory scores in 
patients with dementia.
238
 However, there have been other trials involving patient treatment with 
lithium in which no such improvement of cognition or reduce tau phosphorylation in AD patients 
was reported. Finally, lithium has been found to have toxic side effects in some elderly patients. 
This has essentially put an end to further exploration of the use of lithium chemotherapy in AD 
treatment.
238
 
Beryllium (Be
2+
) has been found to be a more potent GSK-3β inhibitor than Li+ and competes for 
both Mg
2+
 and ATP. In addition, results suggested that GSK-3 has two magnesium-binding sites 
based on the experiments where two inhibitors (Be
2+
 and Li
+
) were used. One binding site was 
found to be Li
+
 sensitive, the other Li
+
 insensitive and interacting with the Mg:ATP binding 
site.
239
  
Zinc (Zn
2+
) is also a more potent (IC50: ~15 μM) GSK-3β inhibitor than lithium and elevates 
cellular β-catenin levels.240 It is noteworthy that abnormal zinc levels are linked with major 
depression and mental functions. Patients that were treated with dietary supplements of zinc 
showed improved mood behaviour. Therefore it is tempting to speculate that the improvement in 
mood behaviour and cognitive functions is mediated by zinc’s ability to inhibit GSK-3β. 
However, it is important to remember that zinc is a co-factor of many enzymes and may initiate 
many cellular effects independently of GSK-3.
238
 
Remarkably, sodium tungstate (Na2WO4) has also been reported to inhibit GSK-3β in neural 
cells (neuroblastoma cell line SH-SY5Y) and consequently decreases tau phosphorylation. 
Experiments have demonstrated that tungsten inhibits the GSK-3-dependent phosphorylation 
sites of tau.
241
 Sodium tungstate has a low toxicity profile, but only one human clinical trial (as 
an anti-obesity agent) has been performed to date.
242
  
 
1.7.1.3 Purine, pyrimidine, pyrazolo and pyrazine derivatives 
Purine derivatives, developed by Chiron, were one of the first synthetic molecules reported as 
GSK-3 inhibitors. Purine derivative 94 (Fig. 1.31) showed a 63% inhibition of GSK-3 activity at 
1 μM.243 Chiron went further to develop a series of pyrimidine analogues: CHIR98014 95, 
CHIR98023 96 and CHIR99021 97 (Fig. 1.31) that inhibit GSK-3 within the nanomolar range. 
Pyrimidine derivatives 95 and 97 exhibited 500- to 10 000 -fold selectivity for GSK-3 versus 20 
other kinases tested.
244, 245
 It should be noted that the majority of the studies have been tested in 
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diabetic models. Nevertheless, these inhibitors showed potential to reduce tau phosphorylation in 
cultured neurons and the rat brain.
246
 
A high-throughput phenotypic cell-based screen of kinase-directed combinatorial libraries led to 
the discovery of a pyrrolopyrimidine, TWS119 98 (Fig. 1.31), that can bind to GSK-3β and 
modulates its activity. In addition, the inhibition of GSK-3β with TWS119 98 at 10 μM resulted 
in an 11-fold increase of β-catenin activation.247 
 
 
Figure 1.31. Some of the early purine and pyrimidine inhibitors 
 
A search in the publicly available protein data bank for GSK-3β structures that interact with 
Lys85 resulted in the development of methoxy pyrimidine 99 (Fig. 1.32). In vitro studies showed 
that 99 possesses potent GSK-3β inhibitory activity (IC50 5.9 nM). The pyrimidine N lone pair 
was thought to allow greater freedom for the two rings to maintain co-planarity, which is 
required for effective occupation of the binding site. X-ray crystallography studies also showed 
the favourable interaction of Lys85 with the carbonyl oxygen of the amide. Further modification 
to replace the methoxy group with an isopropyl derivative subsequently yielded a more potent 
inhibitor, 100 (IC50 = 0.83 nM) (Fig. 1.32).
248
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Wang and co-workers started with purinone 101 (Fig. 1.32) that had been identified from the 
screening of a kinase compound collection. The in vitro GSK-3β inhibitory activity was 
determined to be moderate (IC50 = 2.4 μM). Several modifications on the purinone core and 
phenyl rings failed to provide significant gains in potency. From the same screening process, a 
different core, nitropyrimidine 102 (Fig. 1.32) was determined to be more active     
(GSK-3β IC50 = 0.15 μM). Replacement of the phenyl group with an adamantyl group resulted in 
a potent inhibitor, 103 (GSK-3β IC50 = 3 nM) (Fig. 1.32).
249
 However, studies have shown that 
aryl nitro moieties pose a potential risk for the in vivo generation of toxic metabolites.
250-253
 
Therefore, alternative groups were substituted for the nitro functionality, but all failed to show 
acceptable potency. A different strategy was then employed with the electron-poor diazonium 
moiety to form a 5,6-fused ring system. Azapurine 104 (Fig. 1.32) displayed poorer potency 
(GSK-3β IC50 = 628 nM) than the nitropyrimidine series even in the absence of the carboxylic 
acid group. A further search involving other fused pyrimidine ring systems to improve the 
potency of the pyrimidine series then led to the development of pyrazolopyrimidine 105   
(Fig. 1.32). The fused pyrimidine ring with a halogen functionality inhibited GSK-3β with an 
IC50 of 180 nM. Lastly, a further investigation with the adamantyl moiety resulted in the 
development of 106 (Fig. 1.32). The replacement of the nitro group with trifluoromethyl group 
showed that a nitro group was not essential for potency (GSK-3β IC50 = 41 nM). Based on these 
results, it was suggested that the potency rank order correlated inversely to the electron density 
of the pyrimidine core.
249
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Figure 1.32. Pyrimidine-based derivatives as GSK-3β inhibitors 
 
GlaxoSmithKline identified a novel class of pyrazolopyrimidine derivatives from HTS that 
inhibits GSK-3. The original screening hit, 107 (Fig. 1.33), was determined to be an    
ATP-competitive inhibitor for GSK-3β (IC50 = 100 nM). The in silico docking showed that the 
hydrazone hydrogen interacts with the carbonyl of Val135 in the hinge region and that the 
pyrimidine nitrogen interacts with NH of Val135.  In addition, the hydrophilic phenol group is 
exposed to the solvent front and that the phenyl group on the pyrazole core is buried deep inside 
the binding pocket towards Lys85. Based on these findings, the SAR of the aromatic groups 
were explored. For example, the hydrophilic aromatic moieties demonstrated better potency 
compared to hydrophobic aromatic moieties. From the SAR studies, compound 108 (Fig. 1.33) 
was found to be one of the most active GSK-3β inhibitors (GSK-3β IC50 = 6.2 nM).
254
 A second 
generation of GSK-3β inhibitors was then developed using compound 108 as springboard. The 
second generation required a co-planar arrangement between the pyrazole core and the aromatic 
ring. Replacing the methoxy-phenyl group with a benzimidazole group resulted in compound 
109 (Fig. 1.33) that showed improved potency (GSK-3β IC50 = 4 nM). It was suggested that the 
NH of the benzimidazole could interact with Lys85. Furthermore, 109 showed better cellular 
permeability in a MDCK cell line (212 nM/s) compared to compound 107 (127 nM/s).
255
 Further 
modifications of the pyrimidine scaffold led to the development of pyrrolopyrimidine 110  
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(GSK-3β IC50 = 5 nM) and pyrazolopyrimidine 111 (GSK-3β IC = 5 nM) (Fig. 1.33). Ab initio 
calculations suggested that the S-cis hydrazone conformation is preferred due to an 
intramolecular hydrogen bond.
256
   
 
 
Figure 1.33. Pyrimidine derivatives developed by GlaxoSmithKline 
 
Furopyrimidine 112 (Fig. 1.34) was identified by GlaxoSmithKline as a GSK-3β inhibitor 
having an IC50 value of 81 nM. Molecular modelling studies suggested that the aminopyrimidine 
core interacts with the hinge region of the ATP binding site. To improve the affinity for GSK-3β, 
a series of acylated furopyrimidines was developed. From this initiative, compound 113   
(Fig. 1.34) was found to inhibit GSK-3β with an IC50 of 32 nM. Based on further molecular 
modelling studies, the cyclopentyl group was found to have a unique binding interaction with 
Pro136 in the hydrophobic pocket. In addition, the methoxyphenyl group was located close to 
Lys85 and exposed to the solvent system. Replacing the methoxyphenyl group with a pyridine 
resulted in a more potent inhibitor 114 (GSK-3β IC50 = 5 nM) (Fig. 1.34). Compound 114 
displayed excellent selectivity against 25 kinases including CDK-2, which was inhibited with an 
IC50 of 457 nM. The high selectivity over CDK-2/Cyclin A can be prescribed to the steric clash 
between the cyclopentyl group and its interacting site in CDK-2. Lastly, compound 114 was 
examined in a glycogen accumulation assay in L6 cells and displayed excellent induction of 
glycogen accumulation (EC50 = 390 nM).
257
 The furopyrimidine series was then expanded to 
include amide and sulfonamide moieties. Based on molecular docking studies, it was suggested 
that 112 could be “flipped” to fit better inside the ATP binding-pocket of GSK-3β. To achieve 
that, an amide side chain was attached to the 5 position of the furopyrimidine core. Amide 115 
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(Fig. 1.34) showed moderate potency (GSK-3β IC50 = 1.6 μM) and the sulfonamide 116 (Fig. 
1.34) displayed potent GSK-3β inhibitory activity (IC50 = 30 nM). The docking of 116 into the 
ATP binding site of GSK-3β showed that one nitrogen and the NH2 of the aminopyrimidine are 
anchored to the carbonyl moiety and NH of Val135 via hydrogen-bonding interactions, 
respectively. In addition, the 3-pyridine moiety is located close to Lys85 of the conserved salt 
bridge (Lys85/Glu97). Sulfonamide 116 displayed good selectivity against CDK-2 and eight 
other kinases.
258
   
 
 
Figure 1.34. Furopyrimidine derivatives developed by GlaxoSmithKline 
 
A library of 8-arylated purine derivatives bearing an alkyl moiety at position 6 displayed good 
GSK-3β inhibitory activity, with good selectivity over ten kinases. The three purine derivatives, 
117, 118 and 119 (Fig. 1.35), showed moderate potency of 26%, 49% and 43% enzyme 
inhibition, respectively on human GSK-3 cells. Naphthalene 120 (Fig. 1.35) was the most active 
of the set (91% enzyme inhibition) and had an IC50 of 169 nM against GSK-3β in the presence of 
10 μM ATP. Molecular modelling showed that inside the GSK-3β ATP binding pocket, the 
naphthyl group occupied the adenine pocket, whereas the purine core occupied the phosphate 
location. The carboxamide substituent interacted with Lys183 and is exposed to the solvent 
system. Significantly, naphthalene 120 at 10 μM in presence of 10 μM ATP displayed good 
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selectivity for GSK-3β (82% inhibition). All other enzyme activity, with the exception of a weak 
activity against CK2α (41% inhibition) and TYRO3/SKY (22% inhibition), was unaffected.259 
 
 
Figure 1.35. Purine derived GSK-3β inhibitors 
 
One of the earliest pyrazolo derivatives that inhibits GSK-3β was reported by Mitsubishi Pharma 
Corporation with IC50 values of below 14 nM on rabbit GSK-3β. The most potent inhibitor from 
this collection was compound 121 (Fig. 1.36) with an IC50 value of 0.61 nM.
260
 In another 
pyrazolo example, the oral inhibitor, compound 122 (Fig. 1.36), inhibited GSK-3β with an IC50 
value of 2 nM in the presence of 500 nM ATP. In addition, 122 displayed 230-fold selectivity 
against 27 kinases. JNPL3 mice that were treated with 122 (10 mg/kg twice daily by oral gavage) 
showed reduced tau phosphorylation in primary neuronal cells and brain tissue.
261
 
In 2016, a series of pyrazolopyridine compounds were developed through HTS analysis and 
cellular assays in an attempt to improve kinome selectivity. Compound 123 (Fig. 1.36) inhibited 
GSK-3β with an IC50 value of 54 nM. A co-crystal structure of 123 bound to human GSK-3β 
showed that 123 binds in the ATP-binding domain and is anchored to the hinge residues via 
tridentate hydrogen-bonding interactions within the pyrazolopyridine core. It was suggested that 
this unique tridentate interaction enhances affinity towards GSK-3 and provides broader kinome 
selectivity. Further design led to compound 124 (Fig. 1.36) that displayed potent inhibitory 
activity (GSK-3β IC50 = 4 nM), but proved to be synthetically challenging to make. Replacing 
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the trifluoro group with a cyclopropyl substitute resulted in compound 125 (Fig. 1.36), which 
retained the desired potency (GSK-3β IC50 = 5 nM) while improving the synthetic viability of the 
route. Furthermore, 124 and 125 displayed concentration-dependent inhibition of tau in    
SH-SY5Y cells with cellular EC50 values of 1.00 and 1.76 μM, respectively. Finally, 124 
demonstrated good selectivity against 10 kinases.
262
 
 
 
Figure 1.36. Pyrazolo-derived GSK-3β inhibitors 
 
AstraZeneca developed a series of aminopyrazine derivatives that have a strong interaction with 
Val135 in the hinge region of the ATP-binding pocket. One of the most active compounds of the 
series, aminopyrazine 126 (Fig. 1.37), inhibited GSK-3β with an IC50 value of 4.9 nM and has a 
110-fold selectivity over CDK2. Although this compound showed excellent potency and 
selectivity, it was determined that 126 exhibited lower selectivity against SGK and DYRK1A. A 
co-crystal structure of 126 bound to GSK-3β showed that the methylpiperazine moiety protruded 
into the solvent. Of note was that transfected 3T3 fibroblast cells treated with 126 showed 
reduced ability to phosphorylate tau in a dose-dependent fashion (tau inhibition IC50 = 76 nM). 
Lastly, 126 demonstrated good BBB permeability in bovine endothelial cells (15   10-3 
cm/min).
263
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It has been determined that many CDK inhibitors are also excellent inhibitors of GSK-3β. An 
example is the pyrrolopyrazine compound, Aloisine A 127 (Fig. 1.37), that inhibits GSK-3β with 
an IC50 value of 650 nM. Kinetic studies showed that aloisines act as competitive inhibitors for 
ATP in the ATP binding pocket. Furthermore, the molecule forms two hydrogen bonds with the 
backbone nitrogen and oxygen atoms of Leu83.
264
 
 
 
Figure 1.37. Pyrazine-derived GSK-3β inhibitors 
 
1.7.1.4 Azole derivatives 
Vertex Pharmaceuticals was one of the first to develop azole-based GSK-3 inhibitors. A large 
library of pyrrole-pyrazole inhibitors were developed and tested on various kinases such as JNK, 
JAK, Aurora, AKT, KDR, ERK and GSK-3. Compound 128 (Fig. 1.38), one of the most potent 
GSK-3 inhibitor in this series, inhibited GSK-3 with an IC50 value of <10 μM. Information 
regarding which GSK-3 isoform it inhibits was not disclosed.
265
 
Novo Nordisk developed a library of 2,4-diaminothiazole derivatives for the treatment of 
metabolic disorders such as diabetes. A large number of these derivatives, including thiazole 129 
(Fig. 1.38), inhibited GSK-3β with the activity of 129 being IC50 <5 μM.
266
 
AR-A014418 130 (Fig. 1.38) has been described as a potent GSK-3β inhibitor      
(GSK-3β IC50 = 104 nM) and inhibits endogenous Ser396 phosphorylation of tau in 3T3 cells, 
which stably express human four-repeat tau protein.  When treated with 50 μM Aβ over 4 days, 
hippocampal neurons displayed significant reduction in neuronal loss (>50%) when pre-treated 
with 10 μM of 130. In addition, 130 also showed superior selectivity over CDK2 and CDK5   
(IC50 = >100 μM).
267
   
Novo Nordisk identified a novel class of triazole derivatives that inhibit GSK-3β with IC50 values 
in the range of 0.1 to 10 μM. Triazole 131 (Fig. 1.38) inhibited GSK-3β with an IC50 value of 
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0.28 μM in the presence of 100 μM ATP, and against a panel of 31 kinases 131 showed high 
selectivity for GSK-3β in the presence of 10 μM ATP.268 
 
 
Figure 1.38. Some of the early azole derived GSK-3β inhibitors 
 
Takeda Pharmaceuticals identified dioxolane 132 (Fig. 1.39) as a GSK-3β inhibitor with an IC50 
value of 65 nM by HTS. The X-ray co-crystal structure of 132 with GSK-3β confirmed the 
interaction with the ATP-binding site (Fig. 1.39). One oxygen atom of the dioxolane and a 
neighbouring hydrogen atom formed hydrogen bonds with the amide NH hydrogen and carbonyl 
oxygen of Val135 in the hinge region. In addition, the nitrogen atoms of the oxadiazole formed a 
unique hydrogen-bonded network between Lys85-Glu97-Asp200 through two water molecules 
(Fig. 1.39).
262
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Figure 1.39. X-ray co-crystal structure of dioxolane 132 in complex with GSK-3β262 
 
By keeping the 1,3,4-oxadiazole core, further derivatisation of the fused heterocyclic rings 
offered improved potency. Compounds 133 – 136 (Fig. 1.40) demonstrated low nanomolar 
potency against GSK-3β (IC50 < 7 nM). Compound 136 (GSK-3β IC50 = 2.3 nM) was evaluated 
against a panel of 23 kinases and determined to have more than a 1000-fold selectivity against all 
the tested kinases including CDK1, CDK2 and CDK5.
269
  
Further modification of dioxolane 132 led to the development of a more potent version of the 
1,3,4-oxadiazole series. As a result, compound 137 (Fig. 1.40) showed excellent inhibitory 
activity against both isoforms of GSK-3 (GSK-3α IC50 = 4 nM, GSK-3β IC50 = 14 nM). 
Replacement of the dioxolane core with a fused amide heterocycle afforded compound 138 (Fig 
1.40) that showed similar potency (GSK-3α IC50 = 2 nM, GSK-3β IC50 = 17 nM) to 137.
270
 
 
Stellenbosch University  https://scholar.sun.ac.za
53 
 
 
Figure 1.40. Series of 1,3,4-oxadiazoles that demonstrated sub-nanomolar potencies against 
GSK-3β  
 
1.7.1.5 Maleimide derivatives 
Studies have shown that the bisindolyl-maleimide derivatives of staurosporine, GF 109203x 139 
and Ro 31-8220 140 (Fig. 1.41) are potent inhibitors of GSK-3 with IC50 values in the nanomolar 
range. Maleimide 139 inhibited GSK-3β with an IC50 value of 190 nM, and maleimide 140 
demonstrated stronger activity with an IC50 of 2.8 nM. The proposed mechanism of action for the 
maleimides is thought to be through competition with ATP for the binding site of GSK-3β.271, 272 
Replacing one of the indole groups with a heterocycle revealed good potencies against GSK-3β. 
Pyrazole-maleimide 141 (Fig. 1.41) inhibited GSK-3β at a Ki value of 48 nM and six-member 
heteroaryls such as pyrimidine-maleimide 142 (Fig. 1.41) also exhibited excellent potency   
(GSK-3β Ki = 6 nM). Furthermore, the insertion of a heterocycle instead of a heteroaryl to the 
maleimide resulted in compound 143 (Fig. 1.41), but it exhibited lower potency       
(GSK-3β Ki = 84 nM). At concentrations of 10 μM, compounds 141 and 142 inhibited GSK-3β 
kinase activity by 92% and 96% respectively, in the presence of 100 μM ATP. Meanwhile, 
compounds 141 and 142 exhibited very weak inhibition against 74 other kinases and moderate 
inhibition against CDK, RsK and PKB.
273
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Figure 1.41. Examples of the early indolyl-maleimide derivatives 
 
The introduction of a triazolo-pyridine ring to the indolyl-maleimide produced a series of  
GSK-3β inhibitors that exhibited IC50 values in the low nanomolar range. The insertion of a 
suitable hydrophilic side chain at the N-position of the indole ring, which can form hydrogen 
bonds with GSK-3β, provided inhibitors with enhanced activity. Compound 144 (Fig. 1.42), with 
an imidazole group, exhibited potent GSK-3β inhibitory activity with an IC50 value of 36 nM. 
Replacement of the imidazole group with a hydroxyl moiety, as in 145 (Fig. 1.42), resulted in a 
3-fold loss in potency (GSK-3β IC50 = 121 nM). In addition, introduction of an alkyl side chain 
such as isopropyl group on the indole nitrogen in 146 (Fig. 1.42) at the N-position of the indole 
led to 37-fold increase in potency (GSK-3β IC50 = 13 nM). This suggests that a hydrophobic side 
chain on the N-position of the indole is necessary for enhanced potency. It should be noted that, 
in a Western blot assay, compound 146 inhibited the phosphorylation of tau in primary 
neurons.
274
    
Replacement of the triazolo-pyridine ring with a furo-pyridine ring resulted in similar 
observations as for the triazolo-pyridine ring. Isopropyl derivative 147 (Fig. 1.42) displayed the 
most potent inhibitory activity against GSK-3β of the furo-pyridine series, with an IC50 value of 
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19 nM. No information was disclosed regarding kinase selectivity or whether 147 has the ability 
to inhibit tau phosphorylation.
275
 
 
 
Figure 1.42. Triazolo-pyridine and furo-pyridine maleimide derivatives 
 
1.7.1.6 Indirubin derivatives 
Indirubins are indole derivatives and related to the naturally-occurring indigo dyes. Indirubin 148 
(Fig. 1.43) inhibits GSK-3β with moderate activity with an IC50 value of 600 nM. The insertion 
of a halogen on the 5-position of 148 dramatically improved the inhibitory activity.        
5-Chloroindirubin 149 (Fig. 1.43) was determined to be the most potent GSK-3β inhibitor  
(IC50 = 50 nM) for the series of halogenated indirubins. The incorporation of a monoxime group 
to the halogenated indirubins further improved the potency. 5-iodoindirubin-3ʹ-monoxime 150 
(Fig. 1.43) exhibited the most potent activity against GSK-3β with an IC50 value of 9 nM. 
However, compound 150 demonstrated poor selectivity against CDK1 and CDK5.
276
    
Further modifications on the monoxime side chain improved the selectivity against the CDK 
family. Hydroxyethyloxime 151 (Fig. 1.43) exhibited strong inhibitory activity against   
GSK-3α/β (IC50 = 30 nM) with more than 300 times selectivity against the CDK family. 
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Replacement of the hydroxyl group with piperazine, as in 152 (Fig. 1.43), improved the potency 
by ten times (GSK-3α/β IC50 = 3.3 nM), but with a 5-fold drop in selectivity over the CDK 
family.
277
 Improved selectivity of the CDK family was achieved by the attachment of an acetate 
onto the oxime functional group. Acetateoxime 153 (Fig. 1.43) exhibited improved results 
(GSK-3α/β IC50 = 7 nM) and over 4000 times selectivity over the CDK family.
278
 In 2007, 
Meijer et al. patented this class of indirubins derivatives and this patent also lists in vivo studies 
on several compounds.
279
 
 
 
Figure 1.43. Indirubin derivatives that demonstrate potent inhibitory activity against GSK-3β 
 
1.7.1.7 Paullone derivatives 
Paullones have been reported as potent ATP competitive inhibitors of GSK-3β and as inhibitors 
of tau phosphorylation. Alsterpaullone 154 (Fig. 1.44) inhibits GSK-3β with an IC50 value of 4 
nM in the presence of 15 μM ATP, but showed poor selectivity (about nine times) against the 
CDK family. 154 also had the ability to inhibit tau phosphorylation of expressed human tau23 in 
Sf9 cells in vivo.
280
 Furthermore, alsterpaullone demonstrated the potential to revive death motor 
neurons.
281
  
Inserting a hydrophilic side chain on the paullone scaffold resulted in improved selectivity 
against the CDK family. Gwenpaullone 155 and C3-paullone 156 (Fig. 1.44) inhibited GSK-3β 
with IC50 values of 40 nM and 30 nM respectively, with slight improvement in selectivity (about 
12 times against the CDK family).
282
 Further modifications on the side chain resulted in 
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compound 157 (Fig. 1.44) that demonstrated remarkable potent GSK-3β activity with an IC50 
value of 0.8 nM. The selectivity against CDK1 was poor (three times) but was good against 
CDK5 about 38 times). Unfortunately, molecular docking studies could not provide a completely 
satisfactory explanation for the potency of 157.
283
  
 
 
Figure 1.44. Paullone derivatives that inhibit GSK-3β 
 
1.7.1.8 Non-competitive and irreversible GSK-3β inhibitors 
The human kinome has over 500 protein kinases that share a high degree of homology in the 
catalytic site within the ATP-binding pocket. Achieving kinase selectivity is therefore one of the 
major hurdles in the search and design of protein kinase inhibitors.
284
 Designing ATP     
allosteric GSK-3 inhibitors affords a way to overcome the kinase selectivity problem, since they 
should bind to unique regions within the kinase providing a more subtle modulation of kinase 
activity than simply blocking ATP entrance.
238
  
The first reported family in this class was the small heterocyclic thiadiazolidinones (TDZD). 
TDZD-8 158 (Fig. 1.45) exhibited modest inhibitory activity against GSK-3β with an IC50 value 
of 2 μM, but showed superior selectivity against four other kinases (over 50 times). Kinetic 
experiments with varying levels of ATP suggested that 158 acts as a non-competitive inhibitor of 
ATP binding.
285
 Although the exact mechanism of action remains unclear, a possible role has 
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been postulated for interactions with Lys205, Tyr216 and Arg96 residues located in the active 
site of GSK-3β.238, 285 
Tideglusib 159 (Fig. 1.45) is an another TDZD that has reached Phase II clinical trials for the 
treatment of AD and supranuclear palsy.
286
 The GSK-3β inhibitory activity of 159 was moderate 
with an IC50 value of 2.4 μM.
287
 Enzyme kinetic experiments indicated that tideglusib 159 
inhibited GSK-3β irreversibly, as shown by the lack of recovery in enzyme function after 
removal of the unbound drug.
286
 In the preclinical trials, 159 reversed the amyloid load in brain 
tissue, prevented cell loss and reduced spatial memory deficits. Patients with mild-to-moderate 
AD exhibited slight improvement in cognitive function after treatment with 159. However, a 
Phase IIb trial was aborted due to insignificant statistical differences between the treatment 
group and the control group.
288
 
The library of non-competitive ATP GSK-3β inhibitors has been expanded to include       
α-halomethylketones (HMK). For instance, thienyl halomethylketone 160 (Fig. 1.45) inhibited 
GSK-3β with an IC50 value of 1 μM. Kinetic experiments with different ATP and 160 levels 
confirmed that 160 acts as a non-competitive inhibitor of ATP binding. Based on the 
encouraging results, a second series of HMK derivatives, that contained a phenyl group, was 
developed. Phenyl HMK 161 (Fig. 1.45) also showed promising GSK-3β inhibition results with 
an IC50 value of 0.5 μM. It was suggested that the electron-withdrawing properties of the 
halogens play a role in the potency of the inhibitor. No information was disclosed as to whether 
161 binds irreversibly to GSK-3β.289  
 
 
Figure 1.45. Small non-competitive ATP inhibitors of GSK-3β 
 
A theory has been suggested that the inactivation of the GSK-3β is due to the formation of an 
irreversible covalent sulfur-carbon bond between Cys199 located at the entrance to the ATP site 
of GSK-3β, and HMK (Fig 1.46).238, 290 
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Figure 1.46. Representation of 160 in the ATP-binding site of GSK-3β. The carbon atom 
bearing the chlorine is above the sulfur atom of Cys199.
290
 
 
To further prove that Cys199 is involved in the inactivation of GSK-3β by incubation with 
phenyl HMK, known reversible inhibitors were converted into irreversible inhibitors by adding a 
HMK unit at a strategic position. With the aid of molecular modelling, three structurally distinct 
known GSK-3β inhibitors, an analogue of ATP 162 (PDB entry 1J1B) and two reversible 
inhibitors, 163 and 164 (PDB entries 3F88 and 1R0E) (Fig. 1.47), were modified to incorporate a 
HMK group. The predicted poses derived from docking calculations for 165, 166 and 167 
(Fig. 1.47) revealed that the HMK moiety is suitably positioned for chemical modification by 
Cys199. All three HMK derivatives, 165, 166 and 167, inhibited GSK-3β (IC50 = 13.4 μM, 0.58 
μM and 0.005 μM respectively) and covalent bonding to GSK-3β was confirmed by   
MALDI-TOF analyses.
291
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Figure 1.47. Switching from reversible to irreversible GSK-3β inhibitors 
 
1.7.2 Tau aggregation inhibitors 
The NFTs comprise dense double helix fibres occupying the cortical pyramidal cell and neurons 
in the brainstem. These fibres were termed paired helical filaments (PHFs).
292
 The difference in 
the repeat domain fragment from the core of the PHF and from the normal tau is that it is phase 
shifted with respect to the normal repeats. The length of the repeat domain is exactly three 
repeats in length, but the positioning of the alternating tubulin-binding segments and the 
intervening linker segments is reversed. The repeat domain in the PHF core can be used to 
distinguish between the tau-tau binding interactions and those that pertain to the tau-tubulin 
binding. Therefore tau aggregation inhibitors could be developed that selectively target the  
tau-tau binding interaction.
293
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Thionine 168 (Fig. 1.48) was one of the first identified tau aggregation inhibitor that produced a 
linear inhibition of tau-tau binding over the range from 1:1 to 10:1 molar ratio with respect to 
tau.
294
 With 168, the Ki of inhibition of tau-tau binding, based on a solid-phase tau-tau binding 
interaction, was determined to be 98 nM. For tau-tubulin binding, the Ki was found to be 7.9 
mM, an 8000-fold difference.
293
 
In another example, rhodanines were identified as tau aggregation inhibitors through HTS. 
Rhodanine-furan 169 (Fig. 1.48) inhibited the assembly of PHF with an IC50 value of 0.47 μM. 
The analysis of the nature of substituents on the flanking regions of the rhodanine showed 
preference for hydrogen bond donors and acceptors such as carboxylic acids, nitro groups, 
phenols, sulfonates and sulfonamides.
295
 
Furthermore, a ligand-based virtual screening of 200 000 compounds yielded 
phenylthiazolylhydrazide 170 as one of the hits.
296
 Phenylthiazolylhydrazide 170 (Fig. 1.48) 
demonstrated good activity against 10 μM K19 tau protein (IC50 = 1.6 μM and 50% depletion 
concentration, DC50 = 0.7 μM). Analytical data obtained from STD-NMR spectroscopy indicated 
that 170 bound directly to monomeric tau and that this was mediated through the aromatic ring of 
the imidazole. Hydrogen-bonding interactions with the nitro group and imidazole amine were 
also observed.
297, 298
 However, the phenylthiazolylhydrazide core was thought to be susceptible 
to cytochrome P450-mediated oxidative cleavage on the thiazole moiety.
299
 Hydrazine is also a 
potential producer of ROS after oxidative cleavage of the N-N bond.
300, 301
  
In an in vitro experiment of aggregated tau, benzothiazole N744 171 (Fig. 1.48) yielded a  
dose-dependent decrease in filament numbers and mass. The IC50 value for 171 inhibition of 
htau40 fibrillisation at 24 h was 280 ± 20 nM. It was suggested that 171 potentially interferes 
with both nucleation and extension phases of tau assembly.
302
 
From the screening of 292 000 compounds, aminothienopyridazines (APTZs) were identified as 
potent inhibitors of P301L K18 tau aggregation. APTZ 172 (Fig. 1.48) was identified as one of 
the lead candidates (IC50 = 5.1 μM at 15 μM P301L K18 tau). Results of size-exclusion 
chromatography of the supernatant after incubation of tau40 with APTZs showed the presence of 
monomeric tau, and also the presence of stabilised oligomeric species. Therefore, the data 
suggests that APTZs prevent tau aggregation and the formation of potentially neurotoxic fibrils. 
This results in increased availability of tau monomers to stabilise microtubules.
303
 
Stellenbosch University  https://scholar.sun.ac.za
62 
 
Azaphilones, which occur in fungi, have recently been identified through standard biochemical 
assays as potential tau aggregation inhibitors. Azaphilone 173 (Fig. 1.48) demonstrated the best 
activity in the series with an IC50 value of 56 μM for dissolving preformed tau filaments in vitro, 
while partially preserving the ability of tau to bind to tubulin and promote microtubule assembly. 
Quantitative analysis of the filament lengths in the presence of 173 showed no filaments greater 
than 200 nm in length when compared to the control (>200 nm). These promising results indicate 
that the azaphilones could be used as a new scaffold with appropriate biological activity for 
further development.
304
   
 
 
Figure 1.48. Tau aggregation inhibitors 
 
1.8. Acetylcholinesterase  
Cholinergic transmission has a vital role in the sleep-wake cycle, circadian rhythms, learning, 
memory, cognition and cortical activity.
305-308
 Acetylcholinesterase (AChE) is a serine-protease 
that hydrolyses the carboxylic ester of the neurotransmitter acetylcholine to afford choline and 
acetic acid, thus playing an integral part in cholinergic transmission.  AChE is predominantly 
expressed in plasma, red blood cells, nervous tissue and neuromuscular junctions.
309
 
In AD patients, cholinergic neurons undergo extensive degenerative changes, resulting in 
acetylcholine depletion and cholinergic hypofunction. This contributes to progressive memory 
deficit and cognitive decline.
310, 311
 Furthermore, AChE is also one of the proteins that 
colocalises with Aβ deposits and promotes Aβ assembly that aggregates in insoluble plaques.312 
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Therefore, the use of AChE inhibitors to treat symptoms caused by cholinergic imbalances 
represents an attractive option to treat AD. 
AChE predominates in the healthy brain, while butyrylcholinesterase (BChE) is considered to 
play a minor role in the regulation of AChE levels. However, BChE levels increase progressively 
in patients with AD while AChE activity remains unchanged or declines.
313
 While the 
development of BChE inhibitors is an attractive option, its role in the regulation of cholinergic 
transmission is not fully understood, thus AChE remains the main target and AChE selectivity 
over BChE is desired.
314, 315
 
 
1.8.1 Marketed AChE inhibitors 
In 1993, tacrine 174 (AChE IC50 = 167 nM) (Fig. 1.49) was the first AChE inhibitor to hit the 
market for the treatment of AD. Tacrine prescriptions were halted after other AChE inhibitors 
were introduced as it became clear that tacrine caused liver toxicity.
316, 317
 
Donepezil 175 (AChE IC50 = 5.7 nM) (Fig. 1.49) was the second FDA-approved drug for the 
treatment of mild to moderate AD. More than 200 clinical trials with 175 have been carried out 
so far.
317, 318
 This drug interacts within the active site of the AChE through aromatic interactions. 
The benzylpiperidine and indanone groups interact with the indole ring of Trp84 of the anionic 
subsite and with the indole ring of Trp279 at the peripheral site of the enzyme, respectively.
317
 
Rivastigmine 176 (AChE IC50 = 4.15 μM) (Fig. 1.49) is a drug widely used for the treatment of 
AD. This drug belongs to a new generation of cholinesterase inhibitors with a carbamate moiety, 
which has the ability to react covalently within the active site of AChE. Furthermore, 
rivastigmine exhibits a ten-fold selectivity for the brain AChE than for the AChE in the 
peripheral nervous system.
317
 
Lastly, Galantamine 177 (AChE IC50 = 800 nM) (Fig. 1.49), an alkaloid isolated from different 
species of the Amaryllidaceae family, acts as a competitive and reversible AChE inhibitor. 
Galantamine inhibits AChE along with allosteric modulation of nicotinic acetylcholine receptors 
that leads to increased release of acetylcholine.
317, 319
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Figure 1.49. AChE inhibitors currently on the market for the treatment of AD 
 
1.8.2 Tacrine derivatives 
After the introduction of tacrine 174 (Fig. 1.49) as the first AChE inhibitor,
311, 312
 structural 
changes were made to improve its potency and reduce toxicity. Molecular docking studies 
revealed two different binding sites for tacrine 174 in AChE, namely, the catalytic site and the 
peripheral site. The peripheral site is located at the opening of the enzymatic binding pocket and 
far from the catalytic site at the bottom of the pocket.
320
 To exploit this phenomenon, Pang et al. 
introduced an alkyl bridge in tacrine 174 via the NH2 group to join two tacrine molecules. 
Heptamethylene tethered tacrine 178 (Fig. 1.50) inhibited rat brain AChE with an IC50 of 0.4 nM 
with a 980-fold selectivity over BChE. This compound was 1 000 times more active than tacrine 
and 10 000 times more selective towards rat brain AChE. Unfortunately, no information 
regarding its toxicity was disclosed.
320
 
To improve the potency, a protonatable amine group was introduced in the middle of the tether 
to provide additional interactions with aromatic residues in the active site of AChE. To this end, 
compound 179 (Fig. 1.50) delivered better potency (Ki = 0.06 nM), but less selectively against 
BChE (Ki = 6 nM).
321
 
Martinéz et al. synthesised various heterodimers of tacrine or its 6-chloro derivative (for 
interaction with the catalytic site) with an indole moiety (for interaction with the peripheral 
sites), which were linked by a suitable tether with an amide group.
322
 Optimisation of the length 
of the tether and the position of the amide group led to the synthesis of different derivatives with 
IC50 values in the low nanomolar range. For example, compound 180 (Fig. 1.50) was shown to 
possess the highest activity (bovine AChE IC50 = 0.02 nM) and selectivity against bovine BChE 
(145-fold). Furthermore, at a concentration of 100 μM, 180 inhibited 98% of the AChE-induced 
Aβ1-40 peptide aggregation.
322
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Rosini et al. developed tacrine derivatives with antioxidant properties that demonstrated 
additional benefits. Lipoic acid, a known antioxidant, has shown to protect neurons against 
cytotoxicity induced by Aβ and to restore cognitive functions in patients with AD. The 
combination of tacrine with lipoic acid led to the synthesis of lipocrine derivative 181 (Fig. 1.50) 
that inhibits human recombinant AChE with an IC50 value of 0.253 nM and shows 43-fold 
selectivity against BChE. Furthermore, 181 was able to protect SH-SY5Y neuronal cells in a     
dose-dependent fashion against ROS formation by tert-butyl hydroperoxide.
323
 
Tacrine homodimers with piperazine-ethyl spacers also demonstrated potent activity. Compound 
182 (Fig. 1.50) showed an inhibitory activity against human AChE with an IC50 value of   
4.49 nM and a 339-fold selectivity over BChE. The compounds with an amide group in the tether 
demonstrated better inhibitory activities in comparison to the compounds without an amide 
group. This suggested that an amide group in the tether is important for AChE inhibition.
324
  
By using click chemistry as a tool for lead optimisation, Manetsch et al. developed a series of 
triazole-linked AChE inhibitors. Triazole compound 183 (Fig. 1.50) inhibits electric eel AChE 
with a dissociation constant of 99 fM. Co-crystallisation of 183 with AChE revealed hydrogen 
bonding of the triazole ring with Ser203 and Gly121 via a H2O molecule.
325
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Figure 1.50. Tacrine-derived AChE inhibitors 
 
1.8.3 Donepezil derivatives 
The pharmacological profile of donepezil 175 (Fig. 1.49) has spurred researchers to design and 
synthesise donepezil-like compounds through bioisosteric replacements for the indanone ring 
system. Villalobos et al. identified the benzisoxazole ring structure as a suitable bioisostere for 
the indanone ring in donepezil 175. Benzisoxazole 184 (Fig. 51) displayed very high in vitro 
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AChE inhibitory activity (IC50 = 2.8 nM) and also a very high selectivity against BChE (over 
3200 times). In addition, in vivo experiments showed that 184 elevated the acetylcholine levels in 
mouse forebrain after oral administration. Lastly, 184 was able to reverse     
hemicholinium-3-induced amnesia with an average of 90% at doses of 3.2 and 5.6 mg/kg.
326
 
However, 185 (Fig. 1.51) proved to be metabolically labile, partially undergoing hydrolysis of 
the acetamide group to produce the corresponding aniline derivative, which was 7-fold less 
active. To improve the metabolic stability, the acetamide group was converted into a      
5-membered heterocycle. This resulted in the development of 185 that displayed improved 
potency (AChE IC50 = 0.33 nM) and increased selectivity against BChE     
(approximately 22 000 times).
327
 
Ismail et al. used the indole moiety as the bioisostere for the indanone ring in donepezil. In the 
Ellman’s assay,328 compound 186 (Fig. 1.51) showed a slight improvement in AChE inhibition 
(53%) compared with donepezil (40%). When a benzyl moiety was used instead of a phenyl 
group, as in compound 186, 55% AChE inhibition was demonstrated. In addition, molecular 
modelling studies suggested that compounds with the benzyl group were a better fit in the 
receptor.
329
 
Modifications on the benzyl moiety of donepezil to improve potency and selectivity led to the 
synthesis of 187 (Fig. 1.51). The incorporation of a fluorine group on the benzyl ring improved 
the potency slightly (hAChE IC50 = 32 nM, 175 hAChE IC50 = 48 nM), but significantly 
increased the selectivity against hBChE (400 times, 175 = 66 times). This suggested that small 
modifications on the benzyl moiety could enhance the selectivity for AChE inhibition.
330
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Figure 1.51. Donepezil-derived AChE inhibitors 
 
1.8.4 Rivastigmine derivatives 
Bolognesi et al. developed a series of conformationally-restricted analogues of rivastigmine 176 
by changing the dimethylaminoethylphenyl portion to a tricyclic system, as exemplified by 
compound 188 (Fig. 1.52). Compound 188 exhibited potent hAChE inhibitory activity    
(IC50 = 8.11 nM), but exhibited poor selectivity against hBChE (1.3-fold). In this series, it was 
determined that the alkyl substituent at the carbamoyl nitrogen determined the potency of the 
inhibitor, and that longer alkyl chains showed diminished inhibitory activity against hAChE. A 
possible explanation was that the longer alkyl chains experienced steric hindrance in the active 
site.
331
  
Through SAR studies, a series of irreversible carbamate inhibitors were developed by Lin et al. 
that targeted the peripheral active site. As an example, carbamate 189 (Fig. 1.52) inhibited AChE 
the strongest in this series (Ki = 1 μM). The Ki values for electron-withdrawing groups on the 
benzene ring such as NO2, CF3 and Cl were lower than electron-donating groups. The proposed 
mechanism for the irreversible inhibition was that the inhibitor donates electrons to the aromatic 
rings of the peripheral site to form non-covalent adducts. This results in a conformational change 
at Phe330 near the entrance of AChE, causing a partial blockade for the entrance of substrate.
332
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Molecular modelling studies have also shown that the distance between the carbamic carbon and 
the piperidine nitrogen affects the activity of the compound. Experimenting with the chain length 
between the carbamate and the piperidine resulted in compound 190 (Fig. 1.52), one of the most 
active inhibitors in this series (AChE IC50 = 14 nM, BChE IC50 = 124 nM, nine times 
selectivity). The dimethylcarbamates were determined to be more active when the phenyl ring 
was joined to piperidine with a single carbon tether. Increasing the bridge length between the 
phenyl ring and piperidine resulted in diminished activity.
333
 
Other conformationally-constrained derivatives with six- or seven-membered rings were 
developed by Toda et al., as dual inhibitors for AChE and serotonin transporter (SERT). The 
racemic seven-membered ring carbamate 191 (Fig. 1.52) inhibited mouse brain AChE with an 
IC50 value of 66 nM and rat SERT with 63 nM. The (R)-enantiomer 192 (Fig. 1.52) showed 
extremely potent inhibitory activities against both AChE (IC50 = 14 nM) and SERT     
(IC50 = 6 nM), but the (S)-enantiomer 193 (Fig. 1.52) was only somewhat active     
(AChE IC50 = 609 nM, SERT IC50 = 930 nM). No information regarding BChE inhibition was 
disclosed.
334
 
 
 
Figure 1.52. Rivastigmine-derived AChE inhibitors 
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1.8.5 Galantamine derivatives 
Mary et al. developed one of the earliest galantamine derivatives that consisted of bis-interacting 
ligands. In this research, different alkyl linkers with a terminal phthalimido group were 
incorporated on the N-demethylgalantamine and 6-O-demethylgalantamine. N-phthalimidoalkyl 
194 (Fig. 1.53) with an 8-carbon bridge exhibited the most AChE inhibitory activity in the   
N-demethylgalantamine series with an IC50 value of 10 nM. In the 6-O-demethylgalantamine 
series, O-phthalimidoalkyl 195 (Fig. 1.53), with a 10-carbon bridge, was the most active (AChE 
IC50 = 50 nM). Both compounds were also found to be more potent than galantamine (36 times 
and 7 times respectively). The length of the alkyl linkers was determined to have an effect on the 
potency and the best inhibitory activities were achieved with eight to ten methylene groups. It 
was also observed that compounds with a permanent positive charge on the galantamine nitrogen 
atom showed better activity than the neutral compounds, which suggests that an iminium salt is 
necessary for enhanced potency.
335
 
Herlem et al. went on further to synthesise galantamine derivatives with an open D-ring. 
Unfortunately, the compounds in this series showed only weak activity against AChE, with 
compound 196 (Fig. 1.53) being the most active (AChE IC50 = 580 μM, BChE IC50 = 216 μM). 
This suggests that a closed ring system is necessary for high inhibition activity.
336
 
Jia et al. developed a library of N-substituted galantamine derivatives by incorporating terminal 
benzylpiperidine, benzylmorpholine, benzylamide and benzyldiethylamine moieties with 
different alkyl chain linkers. The potency of AChE inhibition was influenced by the chain length 
as well the type of amine function at the end of the alkyl linker. The benzyl piperidine derivative 
197 (Fig. 1.53), with a six methylene bridge, showed the most potent AChE inhibition with an 
IC50 value of 5.62 nM and a 5800 times selectivity against BChE. The morpholine and amide 
derivatives were the least active of all the compounds, which suggested that for these compounds 
the terminal group was situated in a hydrophobic domain.
337
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Figure 1.53. Galantamine-derived AChE inhibitors 
 
1.8.6 Miscellaneous AChE inhibitors 
Huperzine A 198 (Fig. 1.54), a naturally-occurring sesquiterpene alkaloid found in Lycopodium 
species, produces long-term AChE inhibition in rat brain and an increase in acetylcholine levels 
up to 40%. Side effects were determined to be mild even at high doses (2 mg/kg i.m.).
338
    
An example of inhibitors with a unique scaffold was developed by Tumiatti et al.
339
  A series of 
molecules with a benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone linker was synthesised 
to determine whether structural flexibility can influence the potential to inhibit AChE. Results 
revealed that the insertion of a rigid dipiperidino moiety strongly influenced the ability to inhibit 
AChE. Dipiperidino 199 (Fig. 1.54) was the best AChE inhibitor (IC50 = 0.37 nM) with a 5200 
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times selectivity against BChE. Furthermore, 199 was able to inhibit the Aβ-self aggregation 
with an IC50 of 9.69 μM.
339
 
Berberine 200 (Fig. 1.54), an isoquinoline alkaloid from Chelidonium majus L.       
(AChE IC50 = 1.85 μM, 43 times selectivity against BChE),
340
 was used as a basic skeleton for 
the construction of a series of hybrid compounds. In this series, the hybrid compound hydroquine 
201 (Fig. 1.54) demonstrated the best AChE inhibitory activity (IC50 = 123 nM) with a 17 times 
selectivity against BChE. Hydroquine 201 also demonstrated excellent antioxidant effects 
(Trolox equiv. = 3.54), which was stronger than berberine 200 (Trolox equiv. = 0.4), and at a 
concentration of 20 μM, inhibited 85% of Aβ1-42 peptide aggregation.
341
 
Studies have shown that β-Carbolines are excellent inhibitors of both AChE and BChE. Rook 
and co-workers synthesised a series of bivalent β-carboline derivatives as potential dual 
AChE/BChE inhibitors. A structure-activity study revealed that the inhibitory activity of 
quaternary N
9
-bivalent β-carbolines was higher in comparison to the analogues without a 
permanent positive charge. β-Carboline 202 (Fig. 1.54), with a nine methylene unit linker, 
proved to be a potent inhibitor of AChE and BChE (IC50 = 0.5 nM and 5.7 nM respectively). In 
addition, 202 also inhibited the transient glutamate-induced Ca
2+
 excitotoxicity with an IC50 
value of 1.4 μM.342  
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Figure 1.54. AChE inhibitors with different moieties 
 
The AChE inhibitors are one of the main drugs for the management of AD. However, the limited 
availability of clinical AChE inhibitors prompted the need for further research to develop 
effective AChE inhibitors that may treat AD patients in more complete manner. 
 
1.9. Conclusions 
It has been over 100 years since Alois Alzheimer’s observation of the first Aβ plaques and 
tangles in the brain of Auguste Deter. Since then, our knowledge of AD has grown significantly. 
Numerous hypotheses have been constructed and investigated to determine the cause of AD. It is 
clear from these findings that AD is a very complex disease with multiple origins. The fact that 
AD progresses very slowly makes it difficult to diagnose and effective treatment has proved 
elusive. Many drugs have reached clinical trials but sadly, most have failed and those that have 
succeeded only treat the symptoms. 
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In order to obtain effective disease-modifying approaches, it is critical to know the structures 
implicated in the origin and the disease progression. Since the development of the amyloid 
cascade hypothesis, many resources have been invested in the design and development of 
inhibitors for the associated enzymes. However, the failure of clinical trials that target the 
clearance of Aβ deposits and the fact that Aβ production overload does not appear to be directly 
causal of AD, forced researchers to develop other hypotheses that include metal dyshomeostasis, 
tauopathy and acetylcholinesterase. 
These hypotheses provide numerous avenues to explore and to further our understanding of the 
complex etiology of AD, Hopefully, they will also allow for the development of therapeutics that 
are able to offer some degree of relief. In the last ten years, new drug prototype candidates have 
been identified and they are the starting point of a new generation of drugs that has the potential 
to reach clinical trials and, hopefully, the market.  
 
1.10 Aims and objectives 
The aim of this project has been to develop new compounds that have the potential to be 
irreversible GSK-3β inhibitors.  The main scope of the project was to synthesise and characterise 
new compounds using known techniques and synthetic pathways.  For the most part, the 
adaptation of synthetic organic chemistry techniques and pathways were needed to successfully 
synthesise the new compounds.  The final compounds would then be tested for their biological 
activity and as well whether it binds irreversibly to GSK-3β. 
 
The second chapter describes the short introduction to GSK-3β and irreversible inhibitors. The 
molecular modelling studies of the GSK-3β are also discussed. Based on the molecular 
modelling results, three different series of inhibitors were then identified for synthesis. Each 
series will be discussed in the next following chapters. 
 
This is followed by the third chapter, which describes the synthesis of the (E)-3-(3-
aminopyrazin-2-yl)acrylaldehyde derivatives and the quest to find optimal conditions for 
successful Suzuki-Miyaura reactions.       
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The fourth chapter describes the synthesis of the (E)-1-(3-aminopyrazin-2-yl)prop-2-en-1-one 
derivatives. This chapter also discusses the synthetic attempts of coupling the electrophilic 
“warhead” to the aminopyrazine core.  
 
The fifth chapter describes the biological results of the synthesised compounds from chapters 
four and five. The biological results are then compared with the results of the molecular 
modelling studies.  
 
The sixth chapter describes the attempted synthesis of the terminal “warheads”. This chapter 
discusses the different methodologies that were explored to find the optimal conditions to 
synthesise the terminal “warheads”.  
 
The seventh chapter gives an overview of conclusions from the work carried out and suggests 
potential future work that may arise from this project. 
 
The appendix describes additional Plasmodium falciparum biological testing that was carried out 
on the synthesised compounds and the search for the pharmacophore. 
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Chapter 2 
 
Targeting GSK-3β with irreversible inhibitors - short 
introduction and molecular modelling studies 
 
2.1 Kinases as targets and their relation to Alzheimer’s disease 
The sequencing of the human genome has enabled the identification of over 500 kinases.
1
 
Kinases play a dominant role in the regulation of signal transduction and cellular functions in 
eukaryotic cells. These functions include cell metabolism, cycle progression, transcription, 
differentiation, apoptosis and cytoskeletal rearrangement.
1
 It is no surprise then, that the 
deregulation of kinases occurs in a variety of diseases including diabetes, inflammatory, 
cardiovascular and nervous disorders.
2
 Furthermore, kinases are known to regulate the axonal 
transport and modification of the microtubule network through the phosphorylation of 
motors, adapters and cargoes.
3
 Several kinases such as glycogen synthase kinase-3β   
(GSK-3β), cyclin-dependent kinase 5 (CDK5), protein kinase B (Akt) and p38    
mitogen-activated protein kinase (p38 MAPK) are involved in maintaining the integrity of the 
neuronal and microtubule network.
3
 In patients with Alzheimer‟s disease (AD), these kinases 
are deregulated, which results in the loss of microtubule stabilisation and an aberrant 
neuronal network.
4
  
In the 1980s, neurofibrillary tangles (NFT) were shown to comprise microtubule-associated 
protein tau in a hyperphosphorylated, insoluble, and filamentous state. NFT is now known to 
play an important role in neurodegenerative diseases, including AD.
5
 The tau protein is 
phosphorylated by GSK-3β and in AD patients, it is hyperphosphorylated, which results in 
the formation of toxic NFT.
6-8
 A growing body of evidence suggests that the generation of 
toxic NFT may drive the onset and progression of AD.
9
 
These findings make GSK-3β an attractive target. The reduction in hyperphosphorylation of 
tau protein could improve the stability of the microtubule network and thereby ultimately 
prove useful in the development of AD chemotherapy. The focus of this project is thus the 
synthesis and development of GSK-3β inhibitors.    
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2.2 Focusing on GSK-3β as the target 
2.2.1 The multifaceted roles of GSK-3β in cellular signaling 
GSK-3β phosphorylates a large variety of substrates that play a role in signaling systems 
coupled to receptors for insulin, neurotrophins, a variety of growth factors and transcription 
factors. Furthermore, the control of GSK-3β activity is an important part in the regulation of 
the above-mentioned functions, encompassing a wide scope, ranging from survival at the 
cellular level to mood and cognition at the organism level. Therefore, deregulated GSK-3β 
activity plays an integral part in certain psychiatric and neurodegenerative diseases.
10
  
   
Glycogen synthase was the first enzyme to be discovered that is inhibited by GSK-3β, 
through phosphorylation, which halts the glycogen synthesis.
11
 Insulin activates glycogen 
synthase by reducing the phosphate content of this enzyme. Most of the dephosphorylation 
occurs at a cluster of serine residues on the GSK-3β.12   
 
GSK-3β is also involved in the attenuation of insulin signaling by phosphorylation of insulin 
receptor substrate 1 (IRS-1). The phosphorylation of IRS-1 by GSK-3β results in the 
inhibition of the tyrosine phosphorylation of IRS-1 by an insulin receptor, which leads to 
impaired insulin signaling.
13
 
 
GSK-3β phosphorylates several proteins such as tau that contribute to the structural integrity 
of the cells.
10
 Tau is phosphorylated by GSK-3β and binds to microtubules in the 
phosphorylated state.
14
 There is evidence that supports the fact that GSK-3β can regulate the 
binding of tau to microtubules by controlling the degree of tau phosphorylation and thereby 
impacting the neuronal structure and neuronal plasticity.
10
 
 
One of the most important roles of GSK-3β is that the kinase is a key regulator of a broad 
array of transcription factors and has been found to be phosphorylated directly by GSK-3β. 
Transcription factors and GSK-3β are considered key targets of signaling pathways, because 
of their involvement in transferring information from the extracellular environment to the 
nucleus.
10
 However, complete inhibition of GSK-3β is not desired and could lead to potential 
side effects. Only a small percentage inhibition of GSK-3β is required to reset the 
stoichiometry of tau phosphorylation.
15
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2.2.2 Structural insight on GSK-3β  
GSK-3β is a serine/threonine protein kinase and is composed of two domains: an N-terminal 
domain consisting of a closed β-barrel structure and an α-helical domain at the C-terminal 
end. The catalytic site that contains the activation loop is sandwiched between the two major 
domains (Fig. 2.1).
16, 17
  
 
 
Figure 2.1. The structure of GSK-3β. The N-terminal domain (blue) corresponds to the   
β-strand domain and the α-helical domain (purple) corresponds to the C-terminal end.16  
 
Before GSK-3β can phosphorylate a substrate, its β-strand and α-helical domains aligns into a 
catalytically active conformation. The polar residues such as arginine and lysine on the   
β-strand and α-helical domains bind to the phosphate group of the phosphorylated residue 
(that was phosphorylated by ATP)
17
 on the activation loop, which results in the correct 
alignment of the two domains. This opens up the substrate binding groove and allows the 
substrate to bind.
16
 The blocking of the ATP-binding site would thus prevent substrates from 
entering the substrate binding groove. 
 
Aoki and co-workers
17
 have co-crystallised ADP with GSK-3β to gain structural insight 
regarding ATP recognition. In Figure 2.2, a crystal structure of the ADP inside the    
ATP-binding site of GSK-3β is shown. The adenine ring is buried in the hydrophobic pocket 
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formed by Ile62, Val70, Ala83, Val110, Leu132 and Leu188. The -NH2 on the purine ring 
interacts with the O atom on Asp133. A hydrogen bond between the -N atom of the purine 
ring and Val135‟s NH is also observed in the hinge loop (Fig. 2.1). The side chain of Lys85 
that interacts with the α- and β-phosphoryl groups stabilises the phosphoryl groups during 
phosphorylation. The magnesium ion (pink sphere in Fig. 2.2), which coordinates to the   
α- and β-phosphoryl O atoms, creates the correct geometry for phosphoryl transfer.17   
 
 
Figure 2.2. Residues participating in binding of ADP in the ATP-binding site of GSK-3β 
(PDB code: 1J1C, H2O molecules removed)
17
 
 
Over the years, a plethora of GSK-3β inhibitors have been discovered and most of these 
demonstrated good-to-excellent inhibitory activity.
18
 However, given the structural similarity 
of many kinases, selectivity remains a challenge. One of the approaches to overcome the 
challenge is to target the ATP-binding site of the kinase.
19
 The structural analysis of ATP 
inhibitors showed that the establishment of hydrogen bonds with the backbone atoms of 
Asp133 and Val135 are crucial to achieve enhanced affinity for GSK-3β. Furthermore, 
additional interactions with Pro136, Lys85, Glu97, Arg141 and Asp200 may increase the 
activity and selectivity for GSK-3β (Fig. 2.3).18 
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Figure 2.3. Schematic view of the ATP-binding site of GSK-3β that indicates important areas 
for activity and selectivity.
18
 
 
2.2.3 AstraZeneca’s aminopyrazine series 
In 2012, through the use of high throughput screening, AstraZeneca identified the 
aminopyrazine core 203 as a potential starting point for the development of GSK-3β 
inhibitors. Compound 203 (Fig. 2.4) showed an acceptable potency (GSK-3β IC50 = 41 nM), 
which was below 1 μM, and the aminopyrazine core mimics the adenine ring of ATP.20  
 
Figure 2.4. Aminopyrazine analogue identified through high throughput screening.
20
 
 
A series of pyrazine analogues were synthesised to investigate structure-activity relationships 
(SAR) and to determine the selectivity with respect to CDK2, a kinase with close homology 
within the ATP-binding site. From the series, the following pyrazine analogues, 204 – 208, 
showed interesting results (Fig. 2.5). Sulfonamide 204 demonstrated one of the lowest 
Hinge region 
   Activity 
Activity and 
selectivity 
Activity and 
selectivity 
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inhibitory activities (GSK-3β Ki = 12 nM) although, with poor selectivity with respect to 
CDK2 (CDK2 Ki = 100 nM, 8.3 fold). In addition, the Caco2 cell line permeability was 
below detection level, most likely due to the introduction of two additional hydrogen bond 
donors from the sulfonamide.
20
  
 
     
Figure 2.5. Aminopyrazine analogues synthesised by AstraZeneca.
20
 
  
The incorporation of the methoxyethyl side group on the sulfonamide in 205 increased the 
potency (GSK-3β Ki = 2 nM) and the selectivity with respect to CDK2 (48 fold). In the 
Caco2 cell assay, good permeability was determined for 205 (20   10-6 cm/s). The 
replacement of the methoxyethyl group with methylpiperazine resulted in 2-aminopyridine 
206 with lower potency (GSK-3β Ki = 4.8 nM), but improved selectivity with respect to 
CDK2 (110-fold). The permeability of 206 (Caco2 assay = 14   10-6 cm/s) was determined to 
be similar to 205.  
The removal of the -NH2 group on the pyrazine ring of 207 resulted in a dramatic drop in 
potency (GSK-3β Ki = 370 nM). This modification in 207 reduced the number of  
hydrogen-bonding interactions available to the backbone of the hinge region inside the  
ATP-binding site. This finding suggests that the presence of the -NH2 group, or a bioisostere 
thereof, is necessary for potency. 
Modification on the pyridine side chain resulted in pyrrolidine 208, which had one of the best 
potencies and selectivities (GSK-3β Ki = 0.22 nM; selectivity with respect to CDK2 = 591 
fold) in the series, but had a relatively low permeability (Caco2 assay = 2.3   10-6 cm/s). 
 
The X-ray crystal structure of 206 bound to GSK-3β (Fig. 2.6) indicated that a pyrazine 
nitrogen and one of the adjacent hydrogens of the -NH2 formed hydrogen bonds to the 
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backbone NH of Val135 and the backbone carbonyl of Asp133 in the ATP-binding site, 
respectively. In addition, the carbonyl in the amide bond of compound 206 likely forms an 
intramolecular hydrogen bond with -NH2 on the pyrazine ring, thus directing the nitrogen of 
the pyridine ring toward Lys85. This would facilitate the formation of a hydrogen bond 
between the pyridine and the terminal amino group of Lys85. Neither the hydrogen bonds 
with Val135 and Asp133 nor this conformational „locking‟ would occur with 207. This offers 
a plausible explanation for the difference in the potency of 206 and 207. 
 
 
Figure 2.6. X-ray crystal structure of 2-aminopyridine 206 bound to GSK-3β ATP-binding 
site (PDB: 4ACD).
20
 
 
These results suggest that potential lead compounds based on this aminopyrazine scaffold 
could be designed to synthesise novel GSK-3β inhibitors. This project thus focuses on using 
compound 206 as template to design novel irreversible GSK-3β inhibitors. 
 
2.3 The design of irreversible GSK-3β inhibitors 
2.3.1 Background on irreversible inhibitors 
In general, reversible inhibitors are small molecules that fit snugly in the active site and 
inhibit the enzyme for as long as they occupy the active site.
21
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Another class of inhibitors are the irreversible ones, which form a covalent bond to a specific 
nucleophilic amino acid residue located in the ATP-binding site.
22
 These irreversible or 
covalent inhibitors are thus small molecules that contain an electrophilic functional group that 
reacts with a nucleophilic amino acid residue such as cysteine.
23
 Irreversible kinase inhibitors 
generally consist of a heterocyclic core, which fulfills the same role as reversible inhibitors, 
by forming hydrogen bonds with the hinge region inside the ATP-binding site, and an 
electrophilic „warhead‟ that forms a covalent bond with a nucleophilic amino acid residue 
within the ATP-binding site. Irreversible inhibition holds several advantages over ATP 
competitive inhibition. Irreversible inhibitors are not in competition with high endogenous 
concentrations of ATP in cells, which means that irreversible inhibitors operate under   
non-equilibrium binding kinetics, thus the percentage inhibition of the enzyme  would 
increase over time.
24
 Furthermore, irreversible inhibition has a longer duration of effect and 
possesses the ability to deactivate the enzyme even after the free inhibitor has left circulation. 
Irreversible inhibitors are frequently associated with high selectivity profile and target only 
kinases with the appropriate cysteine residue in the correct place to form a covalent bond and 
inhibit irreversibly.
25, 26
 
 
The most frequent warheads present in irreversible inhibitors are Michael acceptors, vinyl 
sulfones, halomethyl ketones, α-substituted carbonyl derivatives, bromodihydroisoxazoles, 
imidazole-1-carboxamides, epoxides, β-lactams and strained lactones (Fig. 2.7).23 
 
  
  
 
 
 
 
 
 
Figure 2.7. Examples of electrophilic functional groups present in irreversible inhibitors.
23
 
 
The mechanism of the covalent bond formation between the warhead and the nucleophilic 
cysteine can be seen in Figure 2.8. Using the Michael acceptor warhead as an example, the 
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electron-rich thiol of the cysteine residue reacts at the electrophilic β-carbon of the Michael 
acceptor. The intermediate enolate then forms the final 1,4-addition product.
26, 27
 
 
 
Figure 2.8. Mechanism of the Michael reaction towards the cysteine residue.
26, 27
 
 
The electrophilic functional group, which is also known as the “warhead” needs to be 
suitably positioned to allow the formation of a covalent bond with the nucleophilic cysteine 
residue located inside the ATP-binding site.
26
 This high biochemical efficiency may translate 
to lower doses and reduced off-target effects.
28
  
 
2.3.2 Connecting a warhead to the aminopyrazine scaffold 
This project focuses on converting the reversible GSK-3β aminopyrazine inhibitor, in 
particular 206 (see section 2.2.2), into irreversible inhibitors. The goal here is twofold, to 
develop synthetic methodology associated with creating potential irreversible inhibitors and 
to ascertain whether this approach is viable with respect to GSK-3β. 
 
The AstraZeneca compound 206 was used as the template for this research (as discussed in 
section 2.2.2). This molecule can be conceptually divided into two sections: the scaffold and 
the side chain (Fig. 2.9). The aminopyrazine scaffold is needed for potency
20
 and the side 
chain could be modified to incorporate a warhead. Two general types of warheads were 
selected for this project, namely Michael acceptors and halomethylketones. Clearly, the 
position of the warhead relative to the cysteine residue is crucial to afford the possibility of 
covalent bond formation.  
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Figure 2.9. Modification of 206 to incorporate a warhead 
 
2.3.3 Molecular modelling of the proposed irreversible inhibitors 
The GSK-3β X-ray crystal structure (PDB code: 4ACD) was used to determine the best 
position for the warhead. Cys199 is a cysteine residue located inside the ATP-binding site 
and the electron-rich thiol is within 4 Å from the aminopyrazine scaffold (Fig 2.10.).
20
 This 
suggests that the attachment of a warhead to the aminopyrazine scaffold could be within 
striking distance from the thiol of Cys199. 
 
 
Figure 2.10. The distance between the electron-rich thiol of Cys199 and the potential 
warhead is within 4 Å. 
scaffold 
side chain 
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The position of the warhead needed to be in close proximity to the cysteine to form a 
covalent bond and the possible arrangements for the two types of warheads was determined  
(Figure 2.11). The Michael acceptor could be arranged in three ways to assess the different 
proximities. Two internal arrangements, 210 and 211, were found to be possible with the 
carbonyl or the alkene connected to the aminopyrazine scaffold and a side chain coupled to 
the other side. The third possible arrangement is terminal Michael acceptors, 212 and 213, 
with no side chain that could assist in docking and where the carbonyl is directly connected to 
the aminopyrazine scaffold. For the first library of compounds, the side chain would consist 
of an amine or a heteroaromatic ring.  
For another series, the halomethylketone (HMK) warhead (214 and 215) could be positioned 
directly next to the aminopyrazine scaffold. Bromine and chlorine are generally used in 
halomethylketone warheads due to the ease of synthesis and will be the focus in the first 
library of compounds.
29-31
  
 
 
Figure 2.11. Possible arrangements of the warheads 
 
Before the synthesis of these types of irreversible GSK-3β inhibitors could be carried out, 
molecular modelling techniques were employed to find suitable inhibitors that could fit inside 
the ATP-binding site and to determine whether the warhead was within striking distance from 
Cys199 (less than 4 Å).
30
 The X-ray crystal structure, 4ACD, obtained from the PDB, was 
used for these molecular modelling studies.
20
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The GSK-3β X-ray crystal structure, 4ACD, has a resolution of 2.6 Å, which is not 
sufficiently accurate to identify hydrogen atoms. In general, during the crystallisation 
process, the molecule is in the solid state and crystal packing may misshape the protein.  
Therefore, the protein needs to be prepared to minimise the potential problems caused by the 
aforementioned issues. 
 
The molecular modelling software used in this project was Maestro 11.1, Schrödinger Inc. 
The protein was prepared using the Protein Preparation Wizard option, which included the 
addition of hydrogens, missing side chains and loops. The state of the heteroatoms was 
generated for the pH of 7.0 ± 2.0. The water molecules were then removed manually. 
The next step was to generate a receptor grid. Compound 206, which was co-crystallised with 
GSK-3β by Berg et al.,20 was used as the ligand to define the receptor grid. All ligands were 
prepared beforehand with the LigPrep application using OPLS3
32
 as the force field, which is 
most suited for drug-like small molecules. To check whether additional modifications or 
constraints were needed to obtain accurate docking results, compound 206 was docked into 
the ATP-binding site. The extra precision (XP) setting, which uses more computational time 
to eliminate false positives by extensive sampling and advance scoring, was used to obtain 
the most accurate results. The docking score for compound 206 was determined to be -6.694 
kcal/mol and this was used as a standard reference for the docking studies that will be 
discussed next. The visual representation of the stacked ligands (the co-crystallised 206 and 
the docked 206) in Figure 2.12 suggested that no further modifications or constraints were 
needed. 
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Figure 2.12. Stacked ligands of the co-crystallised- and docked 206. Green: co-crystallised 
206, blue: docked 206  
 
The next step was to dock a series of prepared ligands into the ATP-binding site, followed by 
a post-docking energy minimisation. The docked ligands were then visually inspected for any 
discrepancies such as strained bond angles. The docking results of the ligands are tabulated in 
Tables 2.1 and 2.2. The tables are divided in sections based on the type of warhead 
arrangement. The first two sections are ones based on the internal Michael acceptor warheads 
and the last section involves the terminal warheads.  
The majority of the ligands docked well inside the ATP-binding site of the GSK-3β, when 
compared to the docked 206. Compounds 220 and 223 were the only ligands that failed to fit 
correctly inside the binding site. The possible reasons for the failed docking are steric 
hindrance and bad interactions between the ligand and the receptor. Specifically, the bulky 
cyclohexane ring in 220 forced the ligand to dock incorrectly. In addition, the interactions 
between the N-atom of the pyridine ring in 223 and the receptor resulted in repulsion, which 
led to incorrect docking of this ligand. Different results were obtained for compounds 232 
and 235, where, presumably, the arrangement of the side chain or the hydrogen bonding 
allows for a fixed configuration.    
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Table 2.1. Docking scores of the compounds with an internal Michael acceptor  
  
R Docking 
score 
R Docking 
score 
R Docking 
score 
R Docking 
score 
 
-5.751 
 
-8.198 
 
-7.746 
 
-6.030 
 
-7.205 
 
failed 
 
-5.383 
 
-5.923 
 
-7.439 
 
-6.833 
 
-4.905 
 
-5.862 
 
-7.204 
 
-9.609 
 
-5.338 
 
-5.771 
 
failed 
 
-8.168 
 
-5.138 
 
-5.931 
 
-7.392 
 
-7.808 
 
-5.866 
 
-5.794 
 
Table 2.2. Docking scores of the compounds with a terminal Michael acceptor or HMK 
 
R Docking 
score 
R Docking 
score 
R Docking 
score 
R Docking 
score 
 
-5.713 
 
-5.704 
 
-5.193 
 
-5.561 
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The distance between the electrophilic thiol of Cys199 and the β-carbon of Michael acceptors 
212-219, 221, 222 and 224-239 was measured to be in the region of 3.7 – 4.6 Å.   
As an example, Figure 2.13 shows compound 239 docked into the active site. It has 
hydrogen-bonding interactions with the critical amino acids Asp133 and Val135 in the hinge 
region (1.8 and 2.5 Å, respectively). Furthermore, a pi-cation interaction between Lys85 and 
the imidazole ring was observed. Lastly the distance between the thiol of Cys199 and the  
β-carbon of the Michael acceptor was measured as 3.69 Å.  
 
 
Figure 2.13. Compound 239 interacts with Val135, Asp133 and Lys85. The distance between 
the thiol of Cys199 and the β-carbon of the Michael acceptor is 3.69 Å 
 
With the aforementioned results in hand, the next step was to run the covalent docking 
process. Cys199 was selected as the reactive residue and the co-crystallised molecule 206 
was used to determine the receptor grid box size (coordinates:  : 23.9 Å,  : -18.8 Å,    
 : 9.9 Å). The reaction types that were used to simulate the covalent bond formation were 
Michael addition and nucleophilic substitution. The docking mode was set to thorough pose 
prediction option, which uses more computational time but provides more accurate docking 
results. The docking results of the ligands are tabulated in Tables 2.3 and 2.4. The tables are 
divided in sections based on the type of warhead arrangement in a similar manner to Tables 
2.1 and 2.2.  
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Table 2.3. Covalent docking scores of the compounds with an internal Michael acceptor  
  
R 
Docking 
score 
R 
Docking 
score 
R Docking 
score 
R Docking 
score 
 
-7.903 
 
-5.719 
 
-6.242 
 
failed 
 
-7.995 
 
- 
 
-6.460 
 
-5.913 
 
-6.378 
 
-6.705 
 
-6.542 
 
-7.325 
 
-6.570 
 
-7.454 
 
-7.394 
 
-6.273 
 
- 
 
-5.772 
 
-5.374 
 
-5.658 
 
-5.682 
 
-7.479 
 
-5.911 
 
-6.345 
 
Table 4. Covalent docking scores of the compounds with a terminal Michael acceptor or 
HMK  
 
R Docking 
score 
R Docking 
score 
R Docking 
score 
R Docking 
score 
 
-6.597 
 
-5.955 
 
-7.065 
 
-5.737 
Stellenbosch University  https://scholar.sun.ac.za
117 
 
The results in general showed that the docked ligands exhibited favourable affinity for 
covalent docking. Visual inspection of the covalently docked ligands showed that a large 
group of the ligands retained their interactions with the hinge region after simulated covalent 
bond formation, while maintaining correct bond geometries. Compared to 222, compound 
234 failed to form a simulated covalent bond with Cys199, which could possibly be 
explained by the change in shape of the side chain that resulted in a repulsive interaction 
between the N-atom of the pyridine and the receptor.  
 
Figure 2.14 shows the simulated covalent bond between the thiol of Cys199 and the best 
docked ligand, compound 236. This type of result suggests that it is indeed possible to form a 
covalent bond with Cys199 using the aforementioned warheads without sacrificing the 
conformation of the ligand and preserving interactions with the hinge region. 
 
 
Figure 2.14. Simulated covalent bond formation between the thiol of Cys199 and 236. 
 
The molecular modelling suggested that this series of molecules was worth pursuing. The 
next few chapters will discuss the synthesis of some of the molecules that were described 
here. 
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Chapter 3 
 
Synthesis of (E)-3-(3-aminopyrazin-2-yl)acrylaldehyde 
derivatives  
 
3.1 Overview 
After the molecular modelling had been completed, the results were used to synthesise the 
compounds. The boronic acid scaffold 243 was duly synthesised, followed by the attachment 
of the aminopyrazine core using the Suzuki-Miyaura method. The Suzuki-Miyaura chemistry 
took significant optimisation to produce acceptable yields. A series of side chains with 
warheads were then synthesised and finally coupled to the aminopyrazine core to afford the 
final compounds.  
 
3.2 Retrosynthetic analysis of the library 
As shown in Figure 3.1, the final compounds 240 synthesised in this library consist of the 
scaffold and a side chain. The connection point occurs on the aminopyrazine core of the 
scaffold. Using a retrosynthetic approach, the molecule can be disconnected to the heteroaryl 
bromide 241 and the Michael acceptor 242. In turn, 241 could be disconnected to the boronic 
acid 242 and 5-bromopyrazin-2-amine 244. The boronic acid 243 could be readily produced 
from the sulfonyl chloride 245 and 245 could be obtained from the commercially available 
bromobenzene 246 by way of sulfonation. Finally, the mono-bromo 244 could be synthesised 
from commercially available aminopyrazine 247 
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Figure 3.1 Retrosynthetic analysis of the library  
 
3.3 The synthesis of the scaffold 
3.3.1 The synthesis of {4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}boronic 
acid (243) 
According to the disconnection plan in Figure 3.1, the sulfonation of commercially available 
bromobenzene 246 was carried out using excess chlorosulfonic acid in chloroform. This 
reaction followed the procedure set out by Samanta et al.
1
 and is summarised in Scheme 3.1. 
Chlorosulfonic acid was added dropwise to the solution via a dropping funnel while keeping 
the temperature below 5 °C. The resulting brown solution was left to stir overnight and then 
poured onto crushed ice. After purification by column chromatography, the corresponding 
sulfonated compound was isolated as white-grey solid in a disappointing yield of 38%. An 
unidentified by-product, which was more polar than 245, as well as unreacted 245 were seen 
on the TLC plate.  
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Scheme 3.1. Sulfonation of bromobenzene 246 
 
To improve the yield, the reaction procedure was modified. The amount of chlorosulfonic 
acid was increased to 11 eq. to ensure all starting bromobenzene is consumed. To address the 
problem with the generation of by-products, the reaction was started at -78 °C instead of 0 
°C. The reaction was then left to warm gradually to room temperature overnight. This 
modification afforded the product in a much more acceptable yield of 74%. Two distinctive 
doublets on the 
1
H NMR spectrum at 7.91 and 7.77 ppm confirmed the sulfonation of 
bromobenzene 246 and the values correlated well with data that were reported in the 
literature.
2
  
 
The next step required the mono-alkylation of piperazine with sulfonyl chloride 245 using an 
adapted procedure developed by Henderson et al. (Scheme 3.2).
3
 An excess of piperazine was 
required to avoid dialkylation, but in an attempt to reduce waste, the number of equivalents 
was reduced from six to four without significant loss in yield of the desired product. 
Dissolved 4-bromobenzene-1-sulfonyl chloride 245 was thus added dropwise to a solution of 
piperazine in dichloromethane. The resulting white slurry was stirred further for two hours 
before it was worked up with saturated NaHCO3 solution. The product,          
1-[(4-bromophenyl)sulfonyl]piperazine 248, was isolated in an excellent yield of 91% after 
purification by column chromatography. Mass spectrometry data confirmed that the   
mono-alkylated product had been obtained (see experimental section). Also, the presence of 
the piperazine ring was observed on the 
1
H NMR spectrum as a multiplet at 2.98 – 2.84 ppm.  
 
 
Scheme 3.2. Mono-alkylation of piperazine with 245 
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Next, the methylation of 248 was carried out using the adapted procedure shown in Scheme 
3.2 in which iodomethane was used as the electrophile (Scheme 3.3). Unfortunately, three 
different spots (Rf : 0.57, 0.73, 0.93; 9:1 DCM:MeOH) were observed on the TLC plate. It 
was thus suspected that the piperazine had also quartenised in the presence of iodomethane.  
 
 
Scheme 3.3. Failed methylation of piperazine 248 
 
The reductive amination of 248 was then attempted using the modified procedure of a 
Bristol-Myers Squibb company patent.
4
 As shown in Scheme 3.4, NaCNBH3, a general 
reducing agent for reductive amination, was selected for this reaction.
5-7
 The reaction was 
carried out firstly under basic (Et3N) conditions as stated in the patent, alternatively under 
acidic conditions (AcOH) to protonate the formed alcohol. Unfortunately, in both cases, the 
reaction did not go to completion. Two different products (Rf: 0.64, 0.81; 9:1 DCM:MeOH) 
were also observed on the TLC plate. In our hands, attempts at separation proved futile. It is 
possible that one of the products was the double methylated product, although this was not 
confirmed.  
 
 
Scheme 3.4. Failed reductive amination of piperazine 248 
 
A different reductive amination procedure was then attempted, this time using zinc as the 
electron source in an aqueous acidic medium.
8
 It has been shown that the use of zinc in 
aqueous acetic acid reduces the possibility of over-methylation.
8
 As shown in Scheme 3.5, 
piperazine 248 was added to a solution of dioxane and excess formaldehyde. Zn dust was 
then added and the resulting grey solution was stirred for one day at room temperature. The 
solution was then concentrated, diluted with EtOAc and neutralised with a saturated solution 
of NaHCO3. The product could then be separated from the small amount of dimethylated  
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by-product using column chromatography and was isolated as white solid in good yield of 
85%.     
 
 
Scheme 3.5. Successful methylation of 248  
 
In Figure 3.2, the 
1
H NMR spectrum of methylpiperazine 249 shows a singlet at 2.25 ppm, 
which integrated for three protons. This indicated the successful mono-methylation of 
piperazine 248. The analytical data were in good agreement with the data reported in the 
literature for this compound.
9
 
 
 
Figure 3.2. 
1
H NMR spectrum of methylpiperazine 249  
 
With compound 249 in hand, the next step of the scaffold synthesis required the boronation 
reaction.
10
 To this end, the aryl bromide was first lithiated with n-BuLi at –78 °C and stirred 
for three hours, followed by the addition of trimethyl borate (Scheme 3.6). The resulting dark 
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orange solution was then stirred for a further three hours before it was warmed to 0 °C and 
quenched with 2 M HCl. After the quenching, the clear solution was stirred for an additional 
one hour. The solution was then extracted with Et2O and concentrated to dryness. After 
attempts to work up the reaction it became clear that the product was water soluble and that 
an aqueous work up should be avoided, as no product was isolated.  
 
 
Scheme 3.6. Attempted boronation of compound 249 
 
To work around the water solubility issue, an alternative procedure was used. This procedure 
involved the quenching of the reaction with H2O, followed by concentration under reduced 
pressure. The mixture was then purified using column chromatography.
11, 12
 However, 
trimethyl borate was used instead of the triisopropyl borate as suggested in the literature.
12
 As 
depicted in Scheme 3.7, 249 and trimethyl borate were dissolved in THF and n-BuLi was 
added dropwise to the solution at –78 °C. The solution was then stirred for two hours at   
–78 °C and allowed to warm to room temperature whilst stirring for an additional 20 h. 
Instead of a workup, the reaction was then quenched with a minimum amount of H2O and the 
solution was concentrated under reduced pressure. According to the TLC plate, only starting 
materials were observed. The addition of n-BuLi to a solution containing trimethyl borate 
thus proved to be problematic as the lithium reagent appeared to react with the electrophilic 
trimethyl borate instead of the aryl bromide. 
 
 
Scheme 3.7. Attempted lithiation of 249 
 
The procedure was then adapted slightly by changing the order of addition of reagents.   
n-BuLi was thus allowed to react with the aryl bromide, before the addition of trimethyl 
borate. The reaction was then quenched with 2 M HCl instead of H2O, to ensure complete 
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protonation of the formed borate ester species and to promote the consumption of unreacted 
n-BuLi and trimethyl borate. Scheme 3.8 shows the optimised conditions for the boronation 
of 249. Since the product 243 is very polar, it was determined that purification by column 
chromatography was not feasible, although this has been reported in the literature.
11, 12
 An 
alternative method was tried that involved crystallising the crude product. It was also 
determined experimentally that boronic acid product 243 was poorly soluble in MeOH. The 
generated LiCl,
13
 B(OH)3
14
 and the starting material are all soluble in MeOH, and the product 
could thus be crystallised out of boiling MeOH. In this manner, a white precipitate was 
isolated that was indeed the boronic acid 243 in 65% yield. 
 
 
Scheme 3.8. Successful boronation of 249 involving crystallization as the last step 
 
The 
1
H NMR spectrum of the boronic acid 243 in d6-DMSO can be seen in Figure 3.3 with 
the boronic acid OH groups appearing as a broad singlet at 8.44 ppm. In addition, the boronic 
acid proton peak was not seen in D2O solvent due to proton exchange. Lastly, mass 
spectrometry data correlated well with the expected molecular mass of 243. 
 
 
Figure 3.3. 
1
H NMR spectrum of boronic acid 243 
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3.3.2 The synthesis of 5-bromopyrazin-2-amine (244) 
The last step of the scaffold synthesis began with the synthesis of the required aminopyrazine 
core. Pyrazine 247 can undergo an oxidative amination reaction using potassium amide as the 
nucleophile, liquid NH3 as the solvent and KMnO4 as the oxidant to form aminopyrazine 250 
(Scheme 3.9).
15
 This reaction was attempted using sodium amide but after numerous 
attempts, the product could not be made. For the sake of convenience, the synthesis of 
aminopyrazine 250 was abandoned and the chemical was purchased from Sigma Aldrich. 
 
 
Scheme 3.9. Attempted oxidative amination of pyrazine 250 
 
The next step was the selective mono-bromination of 250. Several papers have reported 
procedures for the bromination of aminopyrazine 250 in various solvents such as DMSO, 
DCM, DMF and CH3CN, but the researchers involved obtained low yields or mixtures of 
mono- and di-brominated compounds.
16-19
 The exception to this is the method reported by 
Mitchell et al.
20
 They describe mono-bromination of aromatic compounds by adding NBS in 
DMF dropwise to a solution of an aromatic compound and DMF at room temperature. This 
method was successfully used to brominate aminopyrazine 250 selectively in the para 
position (Scheme 3.10). After the reaction had been completed, the dark brown solution was 
poured into ice-water and extracted four times with ethyl acetate. The crude brown residue 
was then purified using column chromatography to afford the brominated product 244 in a 
satisfactory 67% yield.  
 
 
Scheme 3.10. Selective mono-bromination of 250 
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Under these conditions, it was determined on the TLC plate that the di-brominated compound 
had also formed. In addition, the workup was found to be tedious and required copious 
amounts of ethyl acetate to extract the product out of the DMF-water layer. An improved 
procedure was thus developed to minimise the formation of the di-brominated compound and 
to eliminate the workup. As shown in Scheme 3.11, the dissolved NBS was added dropwise 
to the solution at 0 °C, instead of at room temperature. After completion of the reaction, the 
solution was concentrated under reduced pressure and the crude reaction mixture was then 
purified using column chromatography. This resulted in 244 being obtained in a good yield of 
86%. The improved conditions resulted in a substantial increase in yield and eliminated the 
need for a workup. In addition, the lower temperature appeared to reduce the formation of the 
di-brominated product. Finally, the characterisation data for 244 correlated well with the data 
reported in the literature.
18
 
 
 
Scheme 3.11. Improved conditions for the para-bromination of 250 
 
3.3.3 The quest for optimal conditions for the Suzuki-Miyaura reactions 
With the boronic acid and the heteroaryl bromide in hand, the scaffold could be assembled 
via a Suzuki-Miyaura reaction. Hachiya et al.
21
 have developed a series of aminopyrazine 
derivatives from 244 through Suzuki-Miyaura couplings. This procedure was adapted for the 
synthesis of compound 251 and the conditions are depicted in Scheme 3.12. The first  
Suzuki-Miyaura reaction was carried out in dioxane using Pd(PPh3)4 as the catalyst and 
Na2CO3 as the base. However, TLC analysis indicated that no product had formed after 
running the reaction overnight. The addition of water to facilitate the solubility of Na2CO3 
and heating the reaction to 95 °C unfortunately failed to make a difference. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
129 
 
 
Scheme 3.12. First attempt of the Suzuki-Miyaura reaction 
 
Suzuki-Miyaura reactions are known to frequently require significant optimisation.
22, 23
 To 
this end, different catalysts, bases and solvents were investigated to find the optimum 
conditions for the Suzuki-Miyaura reaction in this system.  
 
The next catalyst that was investigated was an N-heterocyclic carbene (NHC)-palladium 
complex. Over the years, NHCs have emerged as alternatives to phosphine ligands for the 
Suzuki-Miyaura coupling. The electron-rich NHC ligands are thought to facilitate the 
oxidative addition of the aryl halide, while the steric bulkiness increases the rate of the 
reductive elimination step in the Suzuki-Miyaura cross-coupling cycle.
24, 25
 
In our research group, Lonwabo Ngodwana,
26 
found success using mesityl-NHC as a ligand 
for Pd(OAc)2 for his Suzuki-Miyaura reactions. The palladium complex was prepared in situ 
followed by the addition of the starting materials. His procedure was used for the attempted 
synthesis of 251 and is described in Scheme 3.13. It should be noted that the base was 
changed to Cs2CO3, while the other parameters are the same as in Scheme 3.12. 
Unfortunately, only starting materials were isolated after stirring the reaction overnight. 
 
Scheme 3.13. The use of an N-heterocyclic carbene-palladium complex for the    
Suzuki-Miyaura reaction. 
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Based on the results obtained, it was clear that a specific type of palladium catalyst would be 
required for the synthesis of 251. Suzuki-Miyaura reactions with aminopyrazines have been 
described in a review and one of the catalysts that provided excellent results was 
Pd(dppf)Cl2.
27
 Compared to other palladium catalysts, the effectiveness of Pd(dppf)Cl2 can 
be ascribed to the relatively large P-Pd-P bite angle, which is thought to enhance the rate of 
the reductive elimination step.
27
 In addition, the oxidative addition step of the Suzuki-
Miyaura reaction is expected to be facilitated by the electron-rich ferrocene.
28
 These 
properties could improve the Suzuki-Miyaura reaction between the poorly nucleophilic 
boronic acid 243 and the poorly electrophilic heteroaryl 243.  
 
However, the price of Pd(dppf)Cl2 255 turned out to be prohibitive, and so the catalyst was 
synthesised using established procedures.
29-31
 Scheme 3.14 thus depicts the synthesis of the 
catalyst Pd(dppf)Cl2 255. The commercially available ferrocene 252 was therefore di-
lithiated, followed by the addition of the electrophile, PPh2Cl, to yield the phosphinated 
ferrocene ligand 253 in 30% yield.
29
 The last step
30
 involved the complexation of the ligand 
253 with Pd(CH3CN)2Cl2 254
31
 to afford the catalyst 255 in 90% yield. The spectroscopic 
data of 255 correlated well with the data reported in the literature.
30
 Furthermore, a single 
31
P 
peak at 34.46 ppm was observed for 255 (referenced to H3PO4 in the 
31
P NMR spectrum). 
 
 
Scheme 3.14. Synthesis of Pd(dppf)Cl2 255 
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In addition to the catalyst, it is known that the type of base and solvent play important roles in 
Suzuki-Miyaura reactions.
22, 32
 The amount and the strength of the base play a critical role in 
the transmetallation step
33
 and solvents interact directly with the reaction substrates, which 
can influence the reaction rate and/or selectivity.
34
 Therefore, various bases and solvent 
systems were used to find the optimum conditions for the Suzuki-Miyaura reactions with 
Pd(dppf)Cl2.  
 
The first attempt of the Suzuki-Miyaura reaction with the Pd(dppf)Cl2 catalyst is shown in 
Scheme 3.15. The procedure of Berg et al.
12
 was adapted for this reaction with Na2CO3 as the 
base and a 4:1 ratio of THF:H2O as the solvent. Electron-poor arylboronic acids are known 
for their propensity to undergo protodeboronation under basic aqueous conditions.
35
 To 
counteract this, an excess amount of boronic acid is frequently needed.
36
 Therefore, in this 
attempt, 1.5 eq. of the boronic acid 243 was used. 
  
 
Scheme 3.15. First Suzuki-Miyaura attempt with Pd(dppf)Cl2 
 
The boronic acid 243 was therefore dissolved in THF:H2O, followed by the addition of 
Na2CO3 and the heteroaryl bromide 244. The catalyst, Pd(dppf)Cl2, was added last and the 
yellow-orange solution was heated under reflux overnight. At this point, the TLC plate 
showed that the starting material, 244, was fully consumed. The resulting dark brown 
solution was diluted with ethyl acetate, filtered over celite and then washed with deionized 
water. Several attempts were performed to purify the crude material using column 
chromatography (DCM:MeOH 9:1 as eluent) but to no avail. The main reason for this was 
that byproducts were present, which were difficult to separate from the desired product. 
Nevertheless, the 
1
H NMR spectrum (presence of the methylpiperazine at δ 2.94–2.86,   
2.40–2.32 and 2.12 ppm) of the crude 251 suggested that the Suzuki-Miyaura reaction had 
been a success.  
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In light of the fact that the reaction with Pd(dppf)Cl2 did form the desired product, the next 
step was to change the solvent while keeping the other conditions constant. The reaction was 
thus repeated in neat DMSO; however the reaction failed to go to completion. After workup, 
starting materials were recovered and, as before, the product could not be purified using 
column chromatography. This clearly indicated that the solvent system did indeed play a 
significant role in the product formation. Berg and et al. used another procedure for a  
Suzuki-Miyaura reaction in which a solvent system of toluene and EtOH in a 4:1 ratio was 
used, with Na2CO3 as the base.
12
 After using this procedure, TLC analysis indicated that 
starting material was still present after stirring overnight, however some formation of the 
product was evident. 
 
The side products that were formed during the aforementioned attempts were speculated to 
originate from protodeboronation and/or homocoupling of arylboronic acids. In 2006, 
Lakmini and co-workers investigated the Pd-catalysed homocoupling of arylboronic acids in 
the presence of oxygen through electrochemical techniques and proposed a catalytic cycle for 
this reaction (Fig. 3.4).
37
 They proposed that the initial Pd(0) reacts with O2 to form a 
Pd(II)peroxo complex 256. The next step involves the coordination of one oxygen atom of 
the peroxo complex with one arylboronic acid equivalent, followed by a transfer of the aryl 
group to the Pd(II) center to produce the peroxo complex 258. The perboric acid 259 is then 
released upon hydrolysis. The released perboric acid then reacts with a second equivalent of 
arylboronic acid to produce the phenol derivative 260. Lastly, a third arylboronic acid 
transfers an aryl group to the Ar-Pd(II) and reductively eliminates a homocoupled Ar-Ar 
product 263. 
 
The hypothesis that the side products stem from the oxygenated reaction medium was thus 
put to the test. In the next attempt, the freeze-pump-thaw technique
38
 was used to 
deoxygenate the reaction medium before the Pd catalyst was added. This technique involves 
the flash freezing of the solution in a Schlenk tube with liquid N2 and the application of a 
vacuum thereafter. Upon the subsequent thawing, bubbles of gas escape to the head space of 
the tube. Repeating the process at least three times removes all the gas from the reaction 
vessel and delivers a deoxygenated solution.    
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Figure 3.4. Oxidative Pd-catalysed homocoupling of arylboronic acids.
37
 
 
As shown in Scheme 3.16, the heteroaryl bromide 244, boronic acid 243 and a stronger base, 
Cs2CO3, were dissolved in toluene:EtOH:H2O (4:1:0.05 ratio) in a Schlenk tube. The reason 
for the addition of water was to aid the solubility of Cs2CO3. The solution was then 
deoxygenated using the freeze-pump-thaw technique, followed by the addition of 
Pd(dppf)Cl2 under argon. The Schlenk tube was then sealed and the dark orange solution was 
stirred overnight at 80 °C. Under these conditions, a full conversion of 243 was observed on 
the TLC plate with no detectable side products. The black solution was then diluted with 
EtOAc and filtered on Celite. The yellow solution was then acidified with 2 M HCl to allow 
the removal of the spent ferrocene ligand from the solution. The aqueous layer was then 
basified with saturated NaHCO3 solution and extracted with EtOAc. The organic layer was 
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concentrated and purified using column chromatography (DCM:MeOH 9:1 as eluent) to 
produce the product 251 as cream solid (67% yield). 
 
 
Scheme 3.16. Successful Suzuki-Miyaura reaction using the freeze-pump-thaw technique 
 
The 
1
H NMR spectrum of 251 (Fig. 3.5) shows the compound in pure form with no side 
products.  The two doublets at 8.02 and 7.80 ppm can be assigned to the aromatic ring and 
the two doublets at 8.48 and 8.07 ppm to the aminopyrazine ring (see expansion in Fig. 3.5). 
The -NH2 peak was observed as the broad singlet at 4.86 ppm and the remaining three peaks 
(δ 3.07, 2.47 and 2.25 ppm) for the methylpiperazine portion completes the molecule. 
 
 
Figure 3.5. 
1
H NMR spectrum of aminopyrazine 251 provides evidence for successful 
Suzuki-Miyaura coupling reaction 
 
With the conditions for the Suzuki-Miyaura reaction now optimised, the next step was to 
improve the yield. In our opinion, the replacement of the halogen on 244 to iodine could 
potentially increase the reactivity for the oxidative addition step of the Suzuki cycle. Chou et 
al.
39
 used N-iodosuccinimide (NIS) to iodinate their aminopyrazine precursors and this 
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procedure was employed for the iodination of the aminopyrazine 250 as laid out in Scheme 
3.17. 
 
 
Scheme 3.17. Iodination of aminopyrazine 250 
 
Since the iodinating agent, NIS, is an expensive reagent, it was synthesised from NBS using a 
known procedure from Chaikovskii et al.
40
 The isolated grey solid obtained in this manner 
was used immediately for the next step. With the freshly prepared NIS in hand, 
aminopyrazine 250 was iodinated
39
 and the procedure is laid out in Scheme 3.17. 
Aminopyrazine 250 was dissolved in DMF under N2 and cooled to 0 °C. NIS was next 
dissolved in DMF and added dropwise to the solution. The yellow solution was then allowed 
to stir overnight at room temperature. The dark brown-orange solution was then quenched 
with a saturated solution of Na2S2O3, followed by pouring over ice water. The product was 
extracted with EtOAc three times and the organic layers were pooled and washed once with 
brine. The crude material was purified using column chromatography (7:3 EtOAc:Hex as 
eluent) to offer the product 264 as a yellow-cream coloured solid in 46% yield. The 
spectroscopic data for compound 264 correlated well with the literature data.
39
 The procedure 
of the Suzuki reaction in Scheme 3.16 was carried out with the iodinated aminopyrazine 264 
and the product was isolated in 74% yield. This is a moderate 7% improvement over the 
brominated aminopyrazine 244. It was then decided that the synthesis of iodo-aminopyrazine 
was not worth it for future Suzuki-Miyaura reactions. 
 
At this point the effort involved in further optimisation of this reaction was weighed against 
potential gain in yield. The decision was made to cease further efforts at optimisation and 
deem the yields sufficiently good to continue with the synthetic plan. 
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3.3.4 Attempted bromination of 5-{4-[(4-methylpiperazin-1-
yl)sulfonyl]phenyl}pyrazine-2-amine (251) 
The envisioned route of attachment of the side chains to the aminopyrazine core on the 
scaffold was by way of a Heck reaction. This required bromination of the aminopyrazine core 
of 251. The conditions for the bromination of compound 251 at the ortho-position of the 
aminopyrazine core were adapted from Scheme 3.11. As shown in Scheme 3.18, excess NBS 
was added portion-wise to promote the bromination at the ortho-position related to the -NH2 
group. However, the reaction failed to proceed to completion and only a small amount of the 
product was isolated. In addition, increasing the amount of NBS to 2 equivalents failed to 
improve the results. 
 
 
Scheme 3.18. First bromination attempt of 251 
 
The next attempt was to use the procedure from Jiang et al.
16
 This team used NBS in DMSO 
to double brominate aminopyrazine 250 at the ortho- and para- positions. They isolated the 
corresponding di-brominated product in 85% yield. This procedure was thus tested on 
phenylaminopyrazine 251 to see whether it would be possible to brominate the compound at 
the ortho position via this method. In Scheme 3.19, it is shown that compound 251 was 
dissolved in DMSO:H2O in a ratio of 3:1 followed by the addition of NBS in portions. The 
dark orange solution was then stirred overnight at room temperature. However, based on the 
TLC analysis, it was presumed that no product had formed and the reaction was abandoned.  
 
 
Scheme 3.19. Second bromination attempt of 251 
 
Recently, Chibale and his team
41
 patented their work on anti-malarial agents which are based 
on aminopyrazine scaffolds. In the patent, there is a procedure that demonstrates the ortho 
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bromination of a para substituted aminopyrazine using NBS in DCM, as opposed to the 
DMSO/H2O mix used previously. The procedure is laid out in Scheme 3.20. According to 
this procedure, compound 251 was dissolved in DCM and cooled to 0 °C. NBS was added in 
portions under N2 and the resultant black-brown solution was stirred for one hour at room 
temperature. A full conversion of starting materials was observed on the TLC plate. 
However, a number of side products were also observed. An acid/base workup with 2 M HCl 
and a saturated solution of NaHCO3 was carried out to determine whether the product could 
be separated from the side products. After the workup, the TLC plate showed only one spot, 
which was presumed to be the desired product, and confirmed by 
1
H NMR spectral analysis. 
The brominated compound 241 was sufficiently pure that column purification was not 
needed. It should be noted that the product was isolated as cream-coloured solid in 46% 
yield.  
 
 
Scheme 3.20 Successful bromination of 251 
 
The presence of the halogen was confirmed through spectroscopic analysis as the 
1
H NMR 
spectrum showed only one heteroaromatic singlet at 8.45 ppm (Fig. 3.6). Compared to the 
1
H 
NMR spectrum of compound 251 (Fig. 3.5), the 
5
J-coupled doublet peak at 8.07 ppm had 
disappeared and the 
5
J-coupled doublet at 8.48 ppm was now a singlet (8.45 ppm), as shown 
in Figure 3.6. The presence of the bromine in 251 could also be seen in the IR spectrum at the 
vibrational frequency of 611 cm
-1
. Lastly, the molecular mass of compound 241 correlated 
well with the HRMS data.     
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Figure 3.6. 
1
H NMR spectrum of 241 that indicates the disappearance of the heteroaromatic 
peak at 8.07 ppm (shaded block) 
 
After the successful bromination of compound 251, several attempts were carried out to 
increase the yield using the conditions indicated in Scheme 3.20, but to no avail. It was then 
decided that this synthesis route was to be discarded because of the poor yield in this final 
step of the scaffold synthesis. A different route was suggested, which involved the connection 
of the side chain to the aminopyrazine core before the Suzuki-Miyaura reaction would be 
carried out with the boronic acid 243. The different synthetic route will be discussed in the 
next section. 
 
3.4 A second retrosynthetic analysis of the library 
The route that was discussed previously was initially chosen because the Suzuki-Miyaura 
reaction only has to be carried out once. However, this route proved to be problematic and an 
alternative route was implemented.  
As shown in Figure 3.7, it was envisaged that 240 could be formed by a Suzuki-Miyaura 
reaction between the boronic acid 243 and the heteroaryl bromide derivatives 266. 
Derivatives 266 could, in turn, be  disconnected to the di-halogenated aminopyrazine 265 and 
the Michael acceptors 242 (which could be synthesised from acryloyl chloride and known 
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amines). Lastly, the di-halogenated aminopyrazine 265 could be obtained by halogenation of 
5-bromopyrazin-2-amine 244. 
 
 
Figure 3.7. Second retrosynthetic analysis of the targeted library 
 
3.5 The synthesis of the Michael acceptor derivatives (266) 
3.5.1. The synthesis of 5-bromo-3-iodopyrazin-2-amine (265) 
The ortho-iodination of the already synthesised 5-bromopyrazin-2-amine 244 involved the 
use of NIS that was prepared in situ from N-chlorosuccinimide (NCS) (Scheme 3.21).
42
 To 
this end, NCS was dissolved in DMF at room temperature under N2 and NaI was added 
portion-wise. The resulting yellow-brown solution was stirred for one hour before a solution 
of 247 in DMF was added dropwise. After three hours of stirring at 80 °C, no product was 
observed on the TLC plate and the temperature was increased to 100 °C for 20 hours. Starting 
materials were still present and the temperature was increased once again to 130 °C for four 
hours, but unfortunately no product formed and the starting materials were recovered. 
 
 
Scheme 3.21. First attempt of iodination of 244 
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To eliminate the possibility that the formation of NIS in situ from NCS and NaI was causing 
the failure of the one pot reaction, pure NIS was used instead. Chibale and co-workers
43
 used 
a very similar procedure as in Scheme 3.21 with NIS in dioxane to iodinate 244. However, 
compared to their 58% yield, in our hands only trace amounts of the product were isolated. 
Repeated attempts failed to produce the product in acceptable yield. The obvious solution 
was thus to use an alternative source of iodine. 
Unlike chlorine and bromine, iodine is unreactive towards most aromatic substrates and one 
thus requires more powerful iodinating species than iodine to synthesise iodinated aromatic 
substrates.
44
 Therefore, in the next attempt, the direct iodination of 244 was conducted with 
molecular iodine and periodic acid (H5IO6), the latter being an oxidising agent and iodinating 
agent.
45, 46
 It should be noted that other research teams have used sodium periodate (NaIO4)
45
 
or iodic acid (HIO3),
46
 but due to the unavailability of these chemicals in our laboratory at the 
time, H5IO6 was used instead. In H5IO6, iodine is in an oxidation state of VII, and this species 
react with molecular iodine to provide the electrophilic iodonium cation (I
+
) (Scheme 3.22).
45
 
 
3 I2 + I(VII)  7 I
+
 
Scheme 3.22. Generation of the electrophilic iodinating species 
 
Studies by Kraszkiewicz et al.
45
 have suggested that the iodination reaction can be carried out 
in concentrated H2SO4, which forms the iodinating intermediate, IOSO3H. The traces of 
water present in the concentrated H2SO4 acts as base to deprotonate the acid. As shown in 
Scheme 3.23, 5-bromopyrazin-2-amine 244 was dissolved in wet DMSO at room temperature 
under N2. Excess I2 was added to the solution, followed by the addition of H5IO6 and H2SO4. 
The resultant black-brown solution was stirred overnight at 60 °C and then quenched with a 
saturated solution of Na2S2O3. At this point, a TLC plate indicated full conversion of the 
starting materials and only one product spot was observed. The yellow solution was extracted 
with EtOAc and the organic layer was then washed with brine. The product was purified 
using column chromatography with EtOAc:Hex 7:3 as eluent to offer          
5-bromo-3-iodopyrazin-2-amine 265 as a bright yellow solid in a reasonable yield of 62%.  
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H2O 
 
Scheme 3.23. Successful iodination of 244 
 
In d6-DMSO, only one heteroaromatic singlet at 8.04 ppm was observed in the 
1
H NMR 
spectrum and the singlet at 6.74 ppm could be assigned to the hydrogens of the -NH2 atoms 
(Figure 3.7). In addition, these spectroscopic values correlated well with the data reported by 
Chibale and co-workers.
43
 
 
 
Figure 3.7. 
1
H NMR spectrum of the iodinated compound 265 
 
Even though the results that were obtained were positive, a large amount of starting 265 was 
required for the synthesis of the derivatives 266, given that a variety of side chains would be 
added to this core. Therefore, the reaction was scaled up from 100 mg to 500 mg of starting 
material. Unexpectedly, the yields dropped significantly as the reaction scale increased. 
Multiple attempts to solve this decrease in yield failed. An alternative procedure that would 
allow this reaction to be scaled up without sacrificing the yield was thus sought. Several 
different solvent systems and amounts of iodinating agents were thus investigated.  
 
The iodination procedure of the pyridine version of 244 was reported by de Koning and   
co-workers
47
 and the corresponding product was isolated in 90%. Using their procedure with 
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a slight adaptation,
48
 compound 244 was iodinated and the conditions are laid out in Scheme 
3.24. Catalytic amounts of H5IO6, H2SO4 and AcOH were used to determine whether the 
necessary iodonium cation species were generated. The starting material 244 was dissolved in 
CH3CN, followed by the addition of iodine and the acids. The resulting black-brown solution 
was then heated overnight at 80 °C, followed by quenching with a saturated solution of 
Na2S2O3. Disappointingly, TLC analysis showed unreacted starting materials and after 
purification, the product was only isolated in trace amounts. 
 
 
Scheme 3.24. Attempted iodination of 244 in CH3CN 
 
Nevertheless, the investigation was carried on and in the next attempt, molecular iodine in 
neat DMSO was used.
49
 In a paper by Younis et al.,
49
 this procedure (Scheme 3.25) was used 
for the iodination of 3-bromopyridine-2-amine at the 4-position. Given that we had the 
reagents in hand it was deemed worthwhile to try. Excess molecular iodine was thus added to 
a solution of 244 and DMSO. The purple-black solution was stirred overnight at 100 °C, 
followed by quenching with a saturated solution of Na2S2O3. An almost full conversion of the 
starting materials was observed on the TLC plate. However, after purification by column 
chromatography, only trace amounts of the product were isolated. The fact that only trace 
amounts of the product were isolated from an almost full conversion of the starting 244 and 
the presence of an additional product spot on the baseline of the TLC plate suggested a 
possible formation of an iodinated salt.  
 
 
Scheme 3.25. Attempted iodination of 244 with I2 in DMSO 
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In the next attempt, the procedure of Scheme 3.23 was modified to determine whether the 
formation of an iodine salt could be eliminated, this time by carrying out the reaction without 
H2SO4 (Scheme 3.26). The amount of I2 was also reduced to one equivalent. Full conversion 
of the starting material 244 was observed on the TLC plate and two additional spots were 
observed. One of these spots was the iodinated product 265 and the other spot was on the 
baseline, which was presumably the iodinated salt. No attempts were carried out to isolate the 
salt. After purification by column chromatography, the desired product 265 was isolated in 
52% yield. When the reaction was scaled up from 100 mg to 150 mg, similar results were 
obtained. However, on further scale up to 250 mg, the yield dropped by 10%. Overall, the 
reaction went to completion in the absence of H2SO4 and with reduced amounts of the I2 and 
H5IO6.  
 
 
Scheme 3.26. Successful iodination of 244 in the absence of H2SO4 (but in moderate yield) 
 
The last attempt for the iodination of 244 was a modification
50
 of Scheme 3.24. Instead of 
using a catalytic amount of AcOH, the reaction was carried out in a solvent system of 1:1 
ratio of AcOH:CH3CN (Scheme 3.27). After stirring the reaction overnight, the TLC 
indicated a full conversion of the starting materials but again, the product was only isolated in 
a mediocre yield of 55%. 
 
 
Scheme 3.27. Successful iodination of 244 in a solvent system of CH3CN:AcOH (but in 
moderate yield) 
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Zhao and co-workers faced a similar problem with the bromination of aminopyrazine.
19
 Low 
yields were obtained and when the reaction was scaled up, the yields dropped. They 
hypothesised that the low yield was due to competitive N-bromination, followed by 
dimerisation with the starting material. Using their hypothesis, the low yields for the 
iodination of 244 could be explained in Figure 3.8. The N-iodination of the starting 244 is 
largely favoured due to the presence of the starting 244 to form the N-iodinated product 267. 
The elimination of HI resulted in the formation of the dimer 268 and the next round of N-
iodination gave the iodinated dimer 269. Lastly, the elimination of HI gave the azo-dye type 
compound 270. 
 
 
Figure 3.8. Hypothesis for the possible dimerisation of 247 
 
The optimisation of the yield for the iodination of 244 was subsequently abandon and small 
scale iodination reactions were carried out using the procedure of Scheme 3.27. 
 
3.5.2 The synthesis of the Michael acceptors (242) 
The first four Michael acceptors were synthesised from a commercially available secondary 
amine and acryloyl chloride. In Scheme 3.28, the four secondary amines 271 – 274 were 
reacted with acryloyl chloride using the procedure of Tominey et al.
51
 that had been adapted. 
The secondary amine and Et3N were dissolved in DCM at 0 °C under N2 and acryloyl 
chloride was then added dropwise. The resulting cloudy solution was then stirred for two 
hours at room temperature after which the white solution was diluted with EtOAc and washed 
with a saturated solution of NaHCO3. The crude oil was purified using column 
chromatography with EtOAc as the eluent to offer the corresponding Michael acceptors  
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275 – 278 in good yields. The spectroscopic data of these compounds correlated well with the 
data reported in the literature.
52, 53
 
 
 
Scheme 3.28. Synthesis of secondary amine-coupled Michael acceptors 275 – 278 
 
Using Michael acceptor 275 as an example, the 
1
H NMR spectral data of the acrylic amide 
can be seen in Figure 3.9. The two doublet of doublets at 6.22 and 5.63 ppm could be 
assigned to the two non-equivalent protons of C
10
, each integrating for one proton. The 
remaining doublet of doublets at 6.56 ppm integrating for one proton originated from the 
more shielded C
8
.  
 
 
Figure 3.9. 
1
H NMR spectrum of 275 showing the peaks of the acrylic amide 
 
In addition, three commercially available primary amines 279 – 281 were reacted with 
acryloyl chloride to form the corresponding Michael acceptors 282 – 284. In Scheme 3.29, all 
three reactions followed similar procedures.
51, 54, 55
 The primary amines and Et3N were 
dissolved in DCM and then cooled to –78 °C, followed by the dropwise addition of acryloyl 
chloride. The reactions were started at –78 °C to prevent potential over N-alkylation. The 
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solutions were then gradually warmed to room temperature. After stirring the reactions for a 
specific period of time, dependent on the reactivity of the amine, the solutions were either 
concentrated immediately or diluted with H2O and extracted with EtOAc. Purification of the 
crude material using column chromatography using EtOAc:Hex as eluent then afforded the 
corresponding Michael acceptors 282 – 284 in moderate to good yields. It should be noted 
that, the spectroscopic data of these compounds correlated well with the data reported in the 
literature.
51, 54, 55
  
 
 
Scheme 3.29. Synthesis of primary amine-coupled Michael acceptors 282 – 284 
 
Using Michael acceptor 282 as an example, the 
1
H NMR spectral data of the acrylic amide 
can be seen in Figure 3.10. One of the doublet of doublets of C
11
 shifted downfield to 6.26 
ppm and the other doublet of doublets is observed at 5.62 ppm, both integrating for one 
proton. The remaining doublet of doublets at 6.05 ppm, integrating for one proton, was 
assigned to C
9
.  
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Figure 3.10. 
1
H NMR spectrum of cyclohexylamine 282 showing the peaks of the acrylic 
amide 
 
The last Michael acceptor to be synthesised was the 3-pyridine derivative 288 and the 
procedures are laid out in Scheme 3.30. Commercially available nicotinyl alcohol 285 was 
first oxidised using excess MnO2,
 
to afford the aldehyde 286 in 87% yield. The procedure 
was slightly adapted from that was reported by Quesada et al.
56
 Due to the low boiling point 
(78 °C) of the product, the reaction was done with excess MnO2 in DCM instead of THF, to 
lower the possibility of evaporation of the product on the rotary evaporator. Nicotinaldehyde 
286 then underwent a Grignard reaction
57
 with vinyl magnesium bromide in THF to form 
compound 287 in 98% yield after workup. The last step was the oxidation
57
 of 287 with 
excess MnO2 to form the Michael acceptor 288, which was used immediately for the next 
step due to its air sensitivity and its tendency to polymerise. 
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Scheme 3.30. Synthesis of Michael acceptor 288 from 3-pyridinemethanol 285 
 
3.5.3 The coupling of Michael acceptors to 5-bromo-3-iodopyrazin-2-amine 
using the Heck reaction 
With a library of synthesised Michael acceptor fragments, the next step was the coupling of 
the warheads to the aminopyrazine core. Following the procedure developed by Slavish et 
al.,
58
 a series of the side-chain coupled derivatives of the pyrazine core were 
chemoselectively prepared using thermal Heck conditions. As described, in Scheme 3.31, 
Michael acceptor 275 was the first to undergo an iodo-vinyl exchange reaction using 
phosphine-free Heck conditions. A Schlenk tube was thus charged with compounds 265 and 
275 in the presence of NaHCO3 and DMF. The solution was degassed and flushed with N2 
before the addition of Pd(OAc)2. The deep orange-brown solution was subsequently stirred 
overnight at 70 °C. However, the TLC plate indicated that no product of any kind had 
formed. The temperature of the reaction was then increased to 100 °C. After an additional 2 
days of stirring, unfortunately no formation of the product was observed on the TLC plate. 
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Scheme 3.31. Attempted regioselective Heck reaction between 265 and 275  
 
Fang et al.
59
 have observed that the type of base can influence the outcome of the Heck 
reaction. They determined that Et3N delivered optimal results for the Heck reactions with aryl 
iodide derivatives. Therefore, in the next attempt, the base was changed to Et3N and the 
reaction was repeated (Scheme 3.32). After stirring the reaction overnight, full consumption 
of the starting material 265 was observed on the TLC plate. The black-brown solution was 
then diluted with EtOAc and filtered on celite. Purification using column chromatography 
was done with EtOAc:Hex 7:3 as eluent to afford the product 289 as a luminescent yellow 
solid in 55% yield.  
 
 
Scheme 3.32. Successful Heck reaction with iodopyrazine 265 and Michael acceptor 275 
using Et3N as the base 
 
This procedure was then used for the Heck reactions with the Michael acceptors 275 – 278, 
282, 283 and 288 as depicted in Scheme 3.33. It should be noted that improved yields were 
observed when the base was increased from 2.5 to 4.0 equivalents and the starting Michael 
acceptors from 1.05 to 1.2 equivalents. The corresponding products 289 – 294 were obtained 
in low to moderate yields. It should be noted that all the synthesised Michael acceptors 
exhibited luminescent properties at a wavelength of 365 nm due to the extended conjugation. 
A variety of aminopyrazine derivatives with extended conjugated network have been reported 
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to exhibit luminescent properties.
60
 It should be noted that the Heck reaction with     
1-(pyridin-3-yl)prop-2-en-1-one 288 failed to form the corresponding product and after 
several attempts, it was abandon. The reason for this failed reaction could be ascribed to the 
instability of 288. 
 
 
Scheme 3.33. Heck reactions with six different Michael acceptor fragments 
 
The synthesis of the Michael acceptor fragments 284 and 294 were synthesised at a later 
stage of the project and after receiving the first batch of the biological results (will be 
discussed in Chapter 5), further work on these two Michael acceptors were abandoned.  
 
The new compounds shown in Scheme 3.33 were all fully characterised. Using 290 as 
example, the 
1
H NMR spectrum in Figure 3.11 clearly indicates the (E)-configuration of this 
molecule. The large J-coupling values (14.5 Hz) between the doublets at 7.66 and 7.47 ppm 
clearly indicate that C
8
 and C
9
 are in the trans-conformation.
61
 The proton of C
6
 is assigned 
to the singlet at 8.06 ppm and the singlet at 5.15 ppm can be assigned to the -NH2, integrating 
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for two protons. Lastly, the multiplet at 3.72 ppm was assigned to the protons of the 
morpholine ring, integrating for eight protons.  
 
 
Figure 3.11. 
1
H NMR spectrum of 290 confirming the (E)-configuration of the alkene in the 
molecule 
 
An interesting phenomenon was observed on the 
13
C NMR spectrum of 290 (Fig. 3.12). Not 
two but three carbon peaks were observed for the morpholine ring (66.9, 46.7 and 42.8 ppm). 
A plausible theory is that the hindered rotation of the amide bond forces C
13
 and C
17
 to be in 
different chemical environments and this rotameric effect produces two distinctive carbon 
peaks instead of one peak. The correlation of these three carbon peaks to the multiplet of the 
morpholine on the HSQC spectrum confirmed the theory (Figure 3.13). The assignment of 
the carbon peak at 66.9 ppm to C
14 
and C
16
 completes the morpholine ring. The remainders of 
the carbon peaks were assigned using the aromatic region of the HSQC spectrum as discussed 
below. 
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Figure 3.12. 
13
C NMR spectrum of 290 showing three carbon peaks of the morpholine ring
Figure 3.13. Expanded section of the HSQC spectrum of 290 showing the correlation of the 
three carbon peaks and the multiplet of the morpholine ring 
The HSQC spectrum for the aromatic region (Fig. 3.14) showed the correlation between the 
singlet at 8.02 ppm and the carbon peak at 145.4 ppm, which could be assigned to C
6
. In
addition, the doublet at 7.63 ppm correlated with the carbon peak at 133.7 ppm, which could 
be assigned to C
8
. The last doublet at 7.44 ppm is C
9
, which correlated with the carbon peak
at 122.7 ppm. The remaining four carbon peaks could be assigned using the 
13
C NMR 
spectrum in Figure 3.14. These included the carbon peak at 164.8 ppm for the carbonyl C
10
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and the carbon peak at 152.0 ppm for C
4
. Due to the deshielding effect of the neighbouring 
atoms, the carbon peak at 134.2 ppm was assigned to C
3
. The last carbon peak at 127.3 ppm 
was the brominated C
1
 which would disappear after the Suzuki-Miyaura reaction (which will 
be discussed later).  
 
 
Figure 3.14. HSQC spectrum of 290 showing the aromatic region 
 
3.6 The Suzuki-Miyaura reactions with           
(E)-3-(3-aminopyrazin-2-yl)acrylaldehyde derivatives 
With the synthesised warheads coupled to the aminopyrazine core in hand, the Suzuki-
Miyaura reaction could now be carried out with the boronic acid 243 to form the final 
compounds. The procedure was slightly adapted from the one that was reported in Scheme 
3.19. The amount of Cs2CO3 was increased from 2.0 to 4.0 equivalents to ensure full 
conversion of the boronic acid 243 to the more reactive borate for subsequent 
transmetalation.
22
 Furthermore, the temperature was decreased from 80 °C to 70 °C to 
prolong the reactivity of the Pd catalyst. The adapted procedure is set out in Scheme 3.34 and 
the results are tabulated in Table 4.1. Unfortunately, the Suzuki-Miyaura reaction with 294 
formed the corresponding product 221 in trace amounts, which were only soluble in MeOH. 
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Due to insufficient amounts of starting material, further attempts to improve the yield were 
not carried out. 
 
Scheme 3.34. Suzuki-Miyaura reaction between 266 and 243 to form the final compounds 
216 – 221 
 
Table 3.1. Products obtained from the Suzuki reactions with 243 and the six aminopyrazine 
derivatives 289 - 294 
# R Yield  
216 
 
73% 
217 
 
69% 
218 
 
70% 
219 
 
78% 
220 
 
75% 
221 
 
trace amounts 
 
All the new compounds listed in Table 3.1 were fully characterised by 
1
H, 
13
C, IR and mass 
spectrometric analysis. The piperidine derivative 216 was selected as the representative 
example for the discussion of the NMR spectroscopic characterisation for this series of final 
compounds. The 
1
H NMR spectrum of 216 (Fig. 3.15) shows clearly two sets of doublets in 
the aromatic region, which could be assigned to the phenyl ring (C
15/11
: 8.07 ppm, C
12/14
: 7.82 
ppm) and the Michael acceptor (C
24
 : 7.63 ppm, C
23
 : 7.77 ppm) respectively. The singlet at 
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8.47 ppm, integrating for one proton, was the heteroaryl proton of C
17
. The singlet at 5.31 
ppm, integrating for two protons, was the -NH2 of C
19
. Compared to the 
1
H NMR in Figure 
3.6, the peaks at 3.07, 2.49 and 2.26 ppm could be assigned to the methylpiperazine. 
Therefore, the multiplet integrating for four protons at 3.67 ppm could be assigned to C
32
 and 
C
28
. Lastly, the multiplet at 1.67 ppm was assigned to the remaining protons of C
31
, C
29
 and 
C
30
.  
 
 
Figure 3.15. 
1
H NMR spectrum of piperidine 216 
 
Figure 3.16 shows the 
13
C NMR spectrum of 216 and in the alkane region, 8 carbon peaks 
were observed that are easily identifiable. As explained earlier from the 
13
C NMR spectrum 
of the morpholine derivative 290 (Fig. 3.12), all these compounds have additional carbon 
peaks due to the existence of amide rotamers (see experimental section) and this phenomenon 
was also observed here. The carbon peaks at 47.3 and 43.9 ppm could be assigned to C
32 
and 
C
28
. The other two carbons of the piperidine ring, C
31
 and C
29
, were also observed in different 
chemical environments and could be assigned to 26.9 and 25.8 ppm. The carbon peak at  
24.7 ppm was the last carbon of the piperidine ring, C
30
. The remaining three carbon peaks in 
the alkane region could be assigned to the methylpiperazine. The carbon peak at 54.2 ppm 
could be assigned to C
33
 and the other two carbon peaks at 46.0 and 45.8 ppm are assigned to 
the piperazine ring, C
2
, C
3
, C
5
 and C
6
. 
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Figure 3.16. 
13
C NMR spectrum of piperidine 216 
 
Several carbon peaks in the aromatic region were easily identified since the peaks did not 
shift much when compared to the starting material 289 (see experimental section). The 
carbon peaks at 164.9 and 152.6 ppm could be assigned to C
25
 and C
19
 respectively. One 
carbon peak of the Michael acceptor, C
24
, could be assigned to the peak at 123.8ppm. The 
other carbon peak of the Michael acceptor, C
23
, was sandwiched between the two peaks in the 
region of 134.6 to 133.9 ppm and could not be identified directly from the 
13
C spectrum. The 
remaining carbon peaks were analysed using the HSQC spectrum (Fig. 3.17). 
 
From the HSQC spectrum, the correlation between the doublet at 7.65 ppm and the carbon at 
123.8 ppm could be seen and could be assigned to C
24
. The other doublet of the Michael 
acceptor at 7.77 ppm correlated with the carbon peak at 134.2 ppm and could now be 
assigned to C
23
. The two doublets of the phenyl ring at 8.09 and 7.84 ppm correlated to the 
carbon peaks at 126.3 and 128.5 ppm and could be assigned to both C
15/11
 and C
12/14
. Lastly, 
the heteroaromatic proton peak of C
17
 at 8.49 ppm correlated with the carbon peak at   
140.8 ppm. 
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Figure 3.17. HSQC spectrum of piperidine 216  
 
The HMBC spectrum in Figure 3.18 showed a correlation between the proton of C
17
 at  
8.49 ppm to the carbon peaks at 152.4 and 140.5 ppm. The carbon peak at 152.4 ppm had 
already been assigned to C
19
, so C
13
 must account for the signal at 140.5 ppm. One of the 
doublets of the phenyl ring at 8.09 ppm also correlated to the C
13
 and this suggested that the 
doublet at 8.09 ppm is the proton of C
11
. The other doublet of the phenyl ring at 7.84 ppm 
correlated to a carbon peak at 141.4 ppm and therefore was assigned to C
8
. Both doublets of 
the Michael acceptor at 7.79 and 7.63 ppm correlated to the same carbon peaks at 164.9 and 
133.9 ppm. The carbon peak at 164.9 ppm has already been assigned to C
25
, thus C
20
 was 
assigned to be the other carbon peak at 133.9 ppm. The remaining carbon peak at 134.0 ppm 
could be assigned to C
16
. 
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Figure 3.18. HMBC spectrum of piperidine 216  
 
A series of (E)-3-(3-aminopyrazin-2-yl)acrylaldehyde derivatives have been successfully 
synthesised that involved the Heck and Suzuki-Miyaura methods. The final compounds  
216 – 220 have been subjected to biological testing and will be discussed in Chapter 5. After 
the synthesis of this series, the next chapter will discuss the synthesis of the       
(E)-1-(3-aminopyrazin-2-yl)prop-2-en-1-one derivatives in which the Michael acceptor was 
rotated 180 °. 
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Chapter 4 
 
Synthesis of (E)-1-(3-aminopyrazin-2-yl)prop-2-en-1-one 
derivatives  
 
4.1 Overview 
The second portion of the internal Michael acceptors was synthesised and coupled to the boronic 
acid scaffold using the established Suzuki-Miyaura method. The “warhead” was first installed on 
the aminopyrazine core before the synthesis of the side chains commenced. The side chains were 
synthesised via substitution and aldol condensation. Various synthetic routes that included 
Friedel-Crafts acylation, amine protection and Weinreb coupling were explored to find a viable 
route for the coupling of the “warhead” to the aminopyrazine core.  
 
4.2 Retrosynthetic analysis of the library 
The final compounds 295 in this library comprise the same aminopyrazine-sulfonamide scaffold 
as discussed in Chapter 3, but with side chains consisting of an electrophilic α, β enone warhead 
in a different position. In this library, the Michael acceptor was rotated 180 ° and the carbonyl 
moiety was attached to the aminopyrazine core. The retrosynthetic evaluation depicted in  
Figure 4.1, shows these molecules can be synthesised via Suzuki-Miyaura chemistry from the 
boronic acid 243 and Michael acceptor derivatives 296. The synthesis of 296 could be envisaged 
from a Michael addition reaction between 297 or an Aldol condensation with 298. Compound 
297 and 298 could be further disconnected to the commercially available 2-amino nicotinic acid 
299. 
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Figure 4.1. Retrosynthesis of the targeted library 
 
4.3 Synthesis of 1-(3-amino-6-bromopyrazin-2-yl)prop-2-yn-1-one 
(297) 
Various methods were employed to synthesise compound 297 and will be discussed in the 
different sections that follow. These methods included the use of a Friedel Crafts acylation, 
amine protection and lastly, the Weinreb coupling reaction. 
 
4.3.1 The Friedel-Crafts acylation route  
As shown in Scheme 4.1, commercially available 2-amino nicotinic acid 299 was brominated 
using NBS and sodium hydroxide, followed by quenching the reaction with acetic acid.
1
 The 
solubility of 299 was found to be very low in dimethylformamide and the intramolecular H-bond 
proton exchange between the amine and the carboxylic acid made the molecule less reactive. 
This problem was overcome by the addition of sodium hydroxide to disrupt the proton exchange 
and a clear solution was obtained. After quenching the reaction with acetic acid, the solution was 
diluted with dichloromethane and washed with iced water. The organic layer was concentrated 
and the product was isolated as a cream-coloured solid. However, it should be noted that the 
product was contaminated with dimethylformamide even after several extractions with 
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dichloromethane. The high polarity of the product 300 (Rf = 0.07 in DCM:MeOH 9:1) made 
purification via regular column chromatography unviable. In addition, the use of 
1
H NMR 
spectroscopy to determine the structure of 300 was inconclusive because the obtained solid was 
too impure and thus no percentage yield is listed.   
 
 
Scheme 4.1 Attempted bromination of 299 using NBS under basic conditions 
 
The aforementioned problems could be avoided by converting the carboxylic acid into an ester 
before the bromination step.
2, 3
 As shown in Scheme 4.2, 2-amino nicotinic acid 299 was added 
to methanol and the suspension was cooled to 0 °C. Concentrated sulphuric acid was then added 
dropwise and the suspension was stirred for three days at room temperature. Over time, the 
suspension gradually became a dark brown solution. The solution was then slowly neutralised 
with a saturated solution of NaHCO3 and extracted with dichloromethane. After workup, the 
crude material was recrystallised using water to afford the ester product 301 as an     
orange coloured solid in 72% yield. In terms of structure elucidation, the 
1
H NMR spectrum of 
301 indicated the presence of the methyl ester (3.85 ppm) and the rest of the spectroscopic data 
correlated well with that reported in the literature.
3
 
 
 
Scheme 4.2. Esterification of 2-amino nicotinic acid 299 
 
Methyl-3-aminopyrazine-2-carboxylate 301 could now be conveniently brominated with NBS 
using the procedure of Charrier et al.
4
 As shown in Scheme 4.3, ester 301 was dissolved in 
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acetonitrile and cooled to 0 °C. The dissolved NBS was then added dropwise and the brown 
solution was stirred overnight at room temperature. The dark brown solution was concentrated 
and diluted with ethyl acetate. After a work up with iced water and brine, the crude material was 
purified via column chromatography using dichloromethane as eluent to afford the brominated 
product 302 as peach-white coloured solid in 73% yield. The presence of one heteroaryl proton 
peak at 8.42 ppm in the 
1
H NMR spectrum confirmed the successful bromination of ester 301.  
 
 
Scheme 4.3. Bromination of methyl-3-aminopyrazine-2-carboxylate 301 using NBS 
 
Compound 302 was then hydrolysed under basic conditions to regenerate the carboxylic acid 
(Scheme 4.4).
4
 To this end, compound 302 and lithium hydroxide was dissolved in methanol and 
water (1:1 ratio) and the resulting dark orange solution was stirred at 90 °C for 2.5 hours. The 
dark brown solution was then cooled in ice and neutralised with concentrated hydrochloric acid. 
The white precipitate was basified with a saturated solution of NaHCO3 and extracted with ethyl 
acetate. Finally, the aqueous layer was concentrated to a minimum amount to allow the product 
300 to crystallize out as yellow needles (66% yield). 
 
 
Scheme 4.4. Hydrolysis of methyl-3-amino-6-bromopyrazine-2-carboxylate 302 under basic 
conditions 
 
Stellenbosch University  https://scholar.sun.ac.za
167 
 
With compound 300 in hand, the next step was the Friedel Crafts acylation. The route for the 
synthesis of the Michael acceptor 297 is summarised in Scheme 4.5. The first step required the 
reaction of 300 with thionyl chloride to form the acid chloride product, followed by a Friedel 
Crafts reaction with 1,2-bis(trimethylsilyl)ethyne in the presence of the Lewis acid, aluminium 
chloride, to afford compound 304. The last step involved a deprotection reaction with K2CO3 to 
give the desired compound 297. 
 
 
Scheme 4.5. Proposed synthesis of 1-(3-amino-6-bromopyrazin-2-yl)prop-2-yn-1-one 297 using 
the Friedel Crafts acylation method 
 
A known procedure
5
 for the reaction of 2-amino benzoic acid with thionyl chloride was used for 
the first step and is shown in Scheme 4.6. Due to the fact that 3-amino-6-bromopyrazine-2-
carboxylic acid 300 is highly polar and possibly in the zwitterionic form, the reaction was carried 
out in dimethyl sulfoxide. Unfortunately, the solution thickened over time which suggested a 
polymerisation reaction. In retrospect, it was determined that thionyl chloride had possibly 
reacted with the dimethyl sulfoxide.
6
 
 
 
Scheme 4.6. Attempted synthesis of acid chloride 305 in DMSO 
 
The reaction was then repeated in neat thionyl chloride (Scheme 4.7). However, the starting 
material did not dissolve completely and no changes were observed after stirring the reaction 
overnight. The cream suspension was then stirred at 90 °C for four hours and the solution has 
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gradually decreased in turbidity and became clear in terms of transparency. The solution was 
dark brown-red after four hours and the excess thionyl chloride was removed by evaporation. 
Unfortunately, the NMR spectroscopy data was inconclusive, which suggested that the isolated 
material has possibly decomposed.  
 
 
Scheme 4.7. Attempted synthesis of 305 in neat thionyl chloride 
 
In a patent from Pfizer,
7
 a procedure for the reaction of 6-chloropyrazine-2-carboxylic acid with 
thionyl chloride in acetonitrile was described. This starting material is similar to carboxylic acid 
300, except that it lacks the amine functionality. Nevertheless, this procedure was used for the 
synthesis of acid chloride 305 and this is shown in Scheme 4.8. After the addition of thionyl 
chloride, the resulting cream suspension was stirred at 90 °C for two hours. The suspension was 
not completely homogenous and turned dark brown after two hours of stirring. The excess 
thionyl chloride was then removed by evaporation to provide the crude acid chloride 305 that 
was used immediately for the next step. Bichler et al.
8
 carried out the required Friedel Crafts 
acylation in dichloromethane, but for the second step in our synthesis, (Scheme 4.8) the acylation 
was carried out in dimethylformamide to facilitate the solubility of the starting reagents. The 
crude acid chloride 305 was thus dissolved in dimethylformamide and           
1,2-bis(trimethylsilyl)ethyne was added to the solution at 0 °C. AlCl3 was then added portion-
wise and the dark brown solution was stirred overnight at room temperature, followed by 
quenching the reaction with 2 M HCl. Unfortunately, HPLC analysis of the solution indicated 
that no product had formed and only the starting carboxylic acid 300 was present.    
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Scheme 4.8. Attempted synthesis of 305 in CH3CN, followed by acylation in DMF 
 
Usually, Friedel Crafts acylations are carried out in dichloromethane.
9-12
 Therefore, this reaction 
was repeated in dichloromethane, despite the fact that 300 is poorly soluble in dichloromethane 
(Scheme 4.9). Catalytic amount of dimethylformamide was added to improve the solubility of 
300 in dichloromethane. In addition, dimethylformamide reacts with thionyl chloride to generate 
the Vilsmeier reagent, which is a more reactive chlorinating species than thionyl chloride.
13
 
Unfortunately, after the workup, HPLC analysis again indicated only the presence of the starting 
material 300. 
 
 
Scheme 4.9. Attempted synthesis of 304 using catalytic amount of dimethylformamide in 
dichloromethane 
 
The aforementioned findings suggested two possible reasons as to why the Friedel Crafts 
acylation of 303 failed to form the desired product. Firstly, the zwitterionic form of 300 could 
prevent the carboxylic acid from reacting with thionyl chloride. Secondly, even if the acid 
chloride 305 did form, the amine of 305 could potentially react with AlCl3 to form a salt. To test 
this hypothesis, the reaction was repeated with several modifications.
14
 As shown in Scheme 
4.10, AlCl3 and 1,2-bis(trimethylsilyl)ethyne were replaced with n-butyl amine and Et3N.    
n-Butyl amine was selected as the nucleophile based on the fact that it would lower the polarity 
of the molecule, thus making it possible to purify the compound using column chromatography. 
If the acid chloride did form then n-butyl amine would react with             
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3-amino-6-bromopyrazine-2-carbonyl chloride 305 to form the amide product 306. The reaction 
was thus conducted as specified, and after the workup and purification using column 
chromatography, the amide product was isolated as cream solid in 45% yield. 
 
 
Scheme 4.10. Successful synthesis of butyl amide 306, which indicated that the acid chloride 
305 did form 
 
The 
1
H NMR spectrum of butyl amide 306 (Fig. 4.2) clearly showed the presence of the amide 
N-H functional group at 7.66 ppm. In addition, the proton peak at 8.20 ppm could be assigned to 
C
2
. The remaining peaks in the alkane region, integrated for nine protons, were assigned to the 
butyl chain. Since this was a test reaction to confirm whether the acid chloride 305 had formed, 
no further spectroscopic analysis was carried out. 
 
 
Figure 4.2. 
1
H NMR spectrum of butyl amide 306 
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These findings suggested that the acid chloride 305 did indeed form and was thus not the source 
of the problem. This meant that the amine of 305 reacted with AlCl3 to form a salt, which 
deactivated the acylation reaction. To overcome this problem, a synthetic route was developed 
which involved protection of the amine before the compound underwent a Friedel Crafts 
acylation. This synthetic route will be discussed in the next section. 
 
4.3.2 The aminopyrazine protection route 
The general scheme for the amine protection followed by Friedel Crafts acylation is depicted in 
Scheme 4.11. The first step involved the protection of the amine with a suitable reagent and the 
next step the formation of the acid chloride, followed by the Friedel Crafts acylation to afford 
compound 308. Lastly, both protecting groups needed to be removed to provide compound 297.  
 
 
Scheme 4.11. General procedure for the protection of the amine group, followed by Friedel 
Crafts acylation 
 
Since the trimethylsilyl group can be removed under basic conditions, the protecting group on 
the amine should also be labile under basic conditions to allow for the simultaneous deprotection 
of both groups.   An example of this type of protecting group is the trifluoroacetamide group that 
can be removed using K2CO3.
15-17
 
Stellenbosch University  https://scholar.sun.ac.za
172 
 
As shown in Scheme 4.12, 3-amino-6-bromopyrazine-2-carboxylic acid 303 underwent an amine 
protection reaction with trifluoroacetic anhydride to yield compound 309.
18
 Compound 303 and 
pyridine were added to dichloromethane at room temperature and the resulting cream suspension 
was cooled to 0 °C. Trifluoroacetic anhydride was then added dropwise. After workup, the 
isolated product was identified through TLC and 
1
H NMR analysis as the starting material 303. 
Repeating the reaction firstly with excess Et3N (5 eq.) instead of pyridine, and then with neat 
trifluoroacetic anhydride and excess Et3N (10 eq.) unfortunately proved futile. 
 
 
Scheme 4.12. Attempted protection of the amine group of 303 with trifluoroacetic anhydride 
 
The amine group of 300 was found to be very unreactive towards electrophilic attack. 5-Bromo 
anthranilic acid, can be protected with trifluoroacetic anhydride
19
 which suggests that the 
pyrazine ring of 300 may deactivate the amine towards nucleophilic substitution. Therefore, 
further work on this route was abandoned and a new route was implemented, which will be 
discussed in the next section. 
 
4.3.3 The Weinreb coupling route 
As explained in the previous section, the amine group of 300 proved to be a stumbling block in 
terms of reactivity towards electrophiles. Therefore, an alternative approach was considered 
focusing on the carboxylic acid. As shown in Scheme 4.13, the carboxylic acid 299 can be 
converted into a Weinreb amide 310, followed by bromination using NBS to form compound 
311. The last step involved a Grignard reaction with ethynylmagnesium bromide to afford the 
desired compound 297. 
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Scheme 4.13. The Weinreb coupling route towards the synthesis of 1-(3-amino-6-bromopyrazin-
2-yl)prop-2-yn-1-one 297 
 
Bruce et al.
20
 used N-(3-dimethylaminopropyl)-Nʹ-ethylcarbodiimide hydrochloride (EDC) to 
activate the carboxylic acid of 299 for the reaction with the Weinreb reagent,        
N-methoxy-N-methylamine hydrochloride, to synthesise the Weinreb amide 310. Due to the 
unavailability of EDC, the reagent was replaced with 1,1ʹ-carbonyldiimidazole (CDI) and the 
procedure for the synthesis of 310 was performed as laid out in Scheme 4.14. The starting 
material 299 was dissolved in DMF at 60 °C and CDI was then added portion-wise to the dark 
orange solution. After three hours of stirring, the Weinreb reagent was added in one portion and 
the solution was stirred further at 60 °C overnight. The workup of this reaction with ethyl acetate 
proved to be difficult due to the miscibility of DMF and water. In addition, after column 
purification with dichloromethane and MeOH, trace amounts of DMF were present in the 
product. This problem was solved by allowing the solution to stir at 60 °C overnight in the open 
as the DMF evaporated under these conditions. The dark brown slurry was then directly purified 
using column chromatography to afford the product 310 as a pale yellow solid in 94% yield. The 
1
H NMR spectroscopic analysis revealed two methyl singlets at 3.76 and 3.38 ppm, which 
indicated the successful synthesis of the Weinreb amide 310.   
 
 
Scheme 4.14. Synthesis of 3-amino-N-methoxy-N-methylpyrzine-2-carboxamide 310 
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The next step required the regioselective para-bromination of the Weinreb amide 310 using NBS 
(Scheme 4.15). This procedure was adapted from the literature.
21
 The Weinreb amide 310 was 
dissolved in chloroform and the solution was cooled to 0 °C. NBS was added portion-wise and 
the resulting yellow suspension was stirred at 40 °C overnight. Due to the electron donating 
properties of the -NH2 group, only one product was observed on the TLC which was later 
identified as the para-brominated product. The solution was then concentrated under reduced 
pressure and purified using column chromatography with 7:3 Hex:EtOAc as eluent to afford the 
brominated product 311 as white yellow solid in a good 90% yield.  
 
 
Scheme 4.15. Bromination of 310 using NBS 
 
The last step towards the synthesis of 297 made use of a procedure that was reported in a patent 
(Scheme 4.16).
20
 As in this research, compound 311 was dissolved in THF and cooled to 0 °C. 
Ethynylmagnesium bromide was then added dropwise and the resulting deep orange-yellow 
solution was stirred at 0 °C for two hours. The ice bath was then removed and the solution was 
stirred at room temperature for one hour. Before quenching the reaction with 2 M HCl, the 
solution was cooled to –10 °C using an ice bath of NaCl and ice. After workup, the column 
purification was carried out using 8:2 Hex:EtOAc as eluent to afford the product as a 
luminescent peach-orange solid in a satisfactory 86% yield.  
 
 
Scheme 4.16. Grignard reaction of 311 with ethynylmagnesium bromide 
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In terms of characterisation of this new compound, the 
1
H NMR spectrum of the compound 297 
in Figure 4.3 clearly indicated the presence of a terminal alkyne by the presence of a singlet at 
3.61 ppm. Due to the proton exchange between the amine and the ketone, the singlet peak of N
7
 
at 5.75 ppm was very broad. Lastly, the mass spectrometric data confirmed the molecular mass 
of this compound as the experimental value of 225.9615 amu corresponded well with that 
expected for C7H5N3OBr (225.9616 amu). 
 
 
Figure 4.3. 
1
H NMR spectrum of 297 showing the terminal alkyne proton signal at 3.61 ppm 
 
Based on the successful synthesis of 297, the procedure shown in Scheme 4.16 was also used for 
the synthesis of compound 298. As shown in Scheme 4.17, methylmagnesium bromide was used 
as the Grignard reagent and the methyl ketone 298 was subsequently isolated as bright yellow 
solid in 83% yield. 
 
 
Scheme 4.17. Grignard reaction of 311 with methylmagnesium bromide 
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With compound 297 and 298 in hand, the synthesis of the side chains could now be completed. 
The next section will discuss the synthesis of the side chain derivatives 296.  
 
4.4 Synthesis of 1-(3-amino-6-bromopyrazin-2-yl)prop-2-en-1-one 
derivatives (296) 
Following a procedure developed by Aciro et al.,
22
 a series of the side chain-coupled derivatives 
of the pyrazine core were stereoselectively prepared using a Michael addition approach. As 
shown in Scheme 4.18, compound 297 was dissolved in dichloromethane at 0 °C and morpholine 
was added dropwise to the orange suspension. The suspension cleared up immediately and the 
deep orange solution was stirred at room temperature for two hours. The solution was then 
concentrated under reduced pressure and the mixture was purified using column chromatography 
using dichloromethane to 95:5 DCM:MeOH as eluent, to afford the product as a yellow solid in 
93% yield.     
 
 
Scheme 4.18. Michael addition reaction of 297 with morpholine 
 
As shown in Figure 4.4, the two doublets at 7.71 and 6.55 ppm have large J-coupling values 
(12.9 Hz), which indicated that the morpholine derivative 312 possesses the (E)-configuration. In 
addition, the heteroaromatic singlet at 8.15 ppm could be assigned to C
6
 and the two multiplets at 
3.76 and 3.47 ppm, integrating for eight protons, could be assigned to the morpholine ring 
methylene groups.  
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Figure 4.4. 
1
H NMR spectrum of morpholine 312 confirming the (E)-configuration of the 
molecule 
 
Furthermore, a similar feature of additional carbon peaks due to the extended conjugation system 
was observed for 312. The phenomenon, which can be seen in Figure 4.5, is more intense due to 
the delocalisation of the N-lone pair of the morpholine which restricts the rotation around the  
N-C bond of the enone. To be able to see the peaks in the alkane region, the NMR spectroscopy 
experiment had to be carried out for a longer period of time (over 2000 scans) with a 
concentrated sample. In the alkane region, the carbon peak at 66.5 ppm could be assigned to C
15
 
and C
17
. The remaining two peaks could be assigned to either C
14
 or C
18
. Since the carbon peaks 
of the aminopyrazine core have already been analysed in the previous chapter (section 3.5.3), the 
peaks could be readily identified. In the aromatic region, the carbon peak at 188.2 ppm was the 
carbonyl C
8
 and the carbon peak at 154.1 ppm could be assigned to C
6
. The carbon peaks at 
148.2 and 123.6 ppm could be assigned to C
2
 and C
3
 respectively, while the carbon peak at 131.8 
ppm could be assigned to C
5
. The two unknown carbon peaks at 152.7 and 91.8 ppm could now 
be assigned to C
12 
and C
10
 respectively. Finally, the mass spectrometric analysis confirmed the 
molecular mass of 312 (see experimental section).     
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Figure 4.5. 
13
C NMR spectrum of 312 showing the three broad carbon peaks in the enlarged 
alkane region 
 
A crystal structure of 312 was also obtained to gain further insight in terms of the structural 
elucidation. To support the fact that the peaks at 53.0 and 46.3 ppm in the 
13
C NMR spectrum are 
not contaminants but carbon atoms of the morpholine ring, a crystal structure of 312 was 
obtained. Towards this end, compound 312 was dissolved in boiling MeOH and slow 
evaporation of the cooled solvent resulted small, yellow, block-shaped crystals of diffraction 
quality. Compound 312 crystallised in the triclinic space group, P, with one molecule in the 
asymmetric unit (Figure 4.6 (a)). Hydrogen bonding between the amino group of one molecule 
and the pyrazine nitrogen of a second molecule link the molecules to form dimers that then pack 
in three dimensions. From the crystal structure it is evident that the confirmation of the double 
bond is (E), as initially determined by NMR (above) and that the morpholine ring is indeed 
present.  
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      (a)                       (b) 
Figure 4.6. (a) Asymmetric unit of 312 confirming the (E)-conformation as well as the presence 
of the morpholine ring and (b) the packing diagram of 312 viewed down the a axis showing the 
hydrogen-bonding interactions between the molecules.  
 
A series of secondary amines then underwent similar Michael addition reactions with compound 
297 and the procedure is shown in Scheme 4.19. For the imidazole 319, chloroform was needed 
to improve the solubility and the reaction was carried out at 40 °C overnight. All four products 
317 – 320 were isolated in high yields and the (E)-configuration was confirmed for all four 
compounds by means of NMR analysis. 
 
 
Scheme 4.19. Michael addition reactions of the secondary amines with alkyne 297 
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The procedure for the Michael addition reactions of primary amines with alkyne 297 was similar 
to that mentioned in Scheme 4.19. Cyclohexylamine 321 was the first primary amine to react 
with alkyne 297 and the procedure is laid out in Scheme 4.20.
23
 Alkyne 297 was dissolved in 
dichloromethane and cooled to 0 °C. A solution of cyclohexylamine in dichloromethane was 
then added dropwise and the solution was gradually warmed to room temperature over 3 hours. 
The deep orange solution was concentrated and purified using column chromatography using 1:1 
Hex:EtOAc as eluent to afford the product as a dark cream-coloured solid in 93% yield. 
However, according to the 
1
H NMR spectrum that will be discussed next, and in contrast to 
compounds 312, 317 –320 the isolated product was the undesired (Z)-isomer.  
 
 
Scheme 4.20. Michael addition reaction of cyclohexylamine with alkyne 297 
 
The confirmation that compound 322 possessed the (Z)-configuration is supplied in Figure 4.7. 
In the aromatic region of the 
1
H NMR spectrum, two proton peaks at 7.06 and 6.30 ppm have  
J-coupling constants of 7.5 Hz, which is characteristic of the alkene being in the       
cis-conformation.
24
 Furthermore, the doublet of doublets at 7.06 ppm can be assigned to C
12
 and 
the doublet at 6.30 ppm to C
10
. The broad singlet, integrating for one proton, at 10.17 ppm can be 
assigned to N
13
. The last proton peak at 8.10 ppm is the heteroaromatic proton of C
2
. The proton 
peaks of the cyclohexane ring have been assigned with no difficulty and will not be discussed 
here. Lastly, mass spectrometric data confirmed the molecular mass of this compound as the 
experimental value of 325.0657 amu corresponded well with that expected for C13H18N4OBr of 
325.0664 amu. 
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Figure 4.7. 
1
H NMR spectrum of 322 showing the cis-conformation 
 
The reason as to why only the (Z)-isomer was observed is possibly due to the tendency of 322 to 
form an intramolecular hydrogen bond.
25
 To determine whether the hydrogen bonding could be 
disrupted by using protic solvents, the reaction in Scheme 4.20 was repeated in methanol. 
Unfortunately, similar results were obtained. Repeating the reaction at –78 °C and gradually 
warming the solution to room temperature delivered similar results which suggested that the  
(E)-isomer cannot be obtained by running the reaction under kinetic control.  
 
Several research teams have reported using Lewis acids for various types of Michael 
reactions.
26-30
 Therefore, an attempt was made to determine whether the use of a Lewis acid or a 
Brønsted acid could promote the formation of the (E)-isomer by interacting with the carbonyl 
moiety and subsequently disrupting the intramolecular hydrogen bonding. Using the conditions 
from Scheme 4.21, the acids used and the results obtained are tabulated in Table 4.1.    
 
 
Scheme 4.21. Michael addition reactions of cyclohexylamine 321 with alkyne 297 in the 
presence of various acids 
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According to the 
1
H NMR spectroscopic data, none of the acids afforded the (E)-isomer. Both 
CeCl3.7H2O and citric acid, provided the (Z)-isomer which contained traces of unidentified 
impurities. The reaction with TiCl4
 
was carried out in THF, which yielded a mixture that could 
not be identified by 
1
H NMR spectrum as the proton peaks of the cyclohexylamine were not 
present.   
 
Table 4.1. Results obtained with various acids used for the Michael addition reaction of 
cyclohexylamine 321 with alkyne 301 
# Acid E/Z 
1 B(OH)3 Z 
2 CeCl3.7H2O Z (crude) 
3 TiCl4 (in THF) inconclusive 
4 AcOH Z 
5 citric acid Z (crude) 
6 4-nitrophenol Z 
7 TsOH Z 
8 1M HCl Z 
 
Despite numerous attempts, unfortunately no conditions provided the (E)-isomer. As this 
strategy did not seem to be yielding any of the desired isomer, the decision was made to go back 
to the drawing board and pursue a different route. 
 
Aldol condensation reactions were thus also implemented to incorporate pyridine systems onto 
the side chains. Using the procedure of Bhambra et al.,
31
 3-pyridinecarboxaldehyde 324 readily 
underwent an aldol condensation with methyl ketone 298 (Scheme 4.22). These reagents were 
dissolved in dioxane at room temperature and LiOH·H2O was then added portion-wise to the 
solution. The yellow solution, with the undissolved LiOH·H2O, was then heated at 50 °C for four 
hours. However, no changes were observed on the TLC plate and MeOH was then added to 
facilitate the solubilisation of the LiOH·H2O. The solution had turned dark orange upon the 
addition of methanol and after an additional stirring of 19 hours at 50 °C, the solution had turned 
black-red. The solution was then quenched with water, which resulted in the formation of a 
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brown slurry. Full conversion of the starting materials was observed on the TLC plate; however, 
three different spots, one possibly representing the desired product, were visible. In addition, 
during the workup of the solution, the brown slurry did not dissolved in ethyl acetate or in water 
and so this approach was abandoned. 
 
 
Scheme 4.22. Attempted aldol condensation of 3-pyridine carboxaldehyde 324 with 298  
 
The reaction was repeated with several modifications.
32
 As shown in Scheme 4.23, the solvent 
system was changed to EtOH:DCM in a 4:1 ratio. In addition, the base was changed to sodium 
hydroxide and was used in excess. After stirring the solution overnight at room temperature, the 
black-brown solution was quenched with water. The TLC plate indicated that there was full 
conversion of the starting materials, but also that a large number of side products had formed 
(EtOAc as eluent). Only trace amounts of a solid could be isolated after work up, which was not 
purified further. 
 
Bhambra et al.
31
 have suggested that the use of protic solvents such as methanol could have an 
effect on the aldol condensation of 324. They determined that in methanol, the aldol 
condensation with 324 could lead to the formation of the diketone product. The reaction in 
Scheme 4.22 was thus then repeated albeit with a different solvent system. As shown in Scheme 
4.23, the aldol condensation reaction of 3-pyridinecarboxaldehyde 324 and methyl ketone 298 
was carried out in a solvent system of dioxane and H2O in a ratio of 15:1 respectively. After 
stirring overnight at room temperature, the solution had formed a yellowish suspension instead of 
the black-red solution that was previously observed (Scheme 4.22). A full conversion of the 
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starting materials was again observed on the TLC plate with only one product spot. Furthermore, 
the product spot was yellow and could be seen with the naked eye. After the workup, this 
product was purified using column chromatography using Hex:EtOAc 7:3 as eluent, to afford the 
product as bright yellow solid in quantitative yield. Spectroscopic analysis of this product 
confirmed the structure of the desired molecule 325 (see characterisation later in this section). 
 
The reaction was repeated for the other two pyridine starting materials,          
2-pyridinecarboxaldehyde 326 and 4-pyridinecarboxaldehyde 328, and the corresponding 
products were again isolated in quantitative yields. For the preparation of the NMR spectroscopy 
samples, a trend was observed for the solubility of the products 325, 327 and 329. It was 
observed that ortho-pyridine 327 dissolves moderately in chloroform and that the meta-pyridine 
325 required an additional ten drops of MeOH. Lastly, para-pyridine 329 was insoluble in 
chloroform and required DMSO to fully dissolve the compound. 
 
 
Scheme 4.23. Successful aldol condensation of various pyridinecarboxaldehydes with 298  
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The novel compounds 325, 327 and 329 were analytically characterised and compound 327 was 
selected to discuss the 
1
H NMR spectrum (Fig. 4.8). The large J-coupling values of the two 
doublets at 8.59 and 7.84 ppm indicated that 327 had the (E)-configuration.
24
 These two doublets 
could be assigned to C
12
 and C
10
 respectively. Due to the deshielding effect of the neighbouring 
N-atom, C
15
 could be assigned to the doublet at 8.72 ppm. However, it was expected that this 
peak would be a doublet of doublets, but due to the low resolution of the NMR spectroscopy 
instrument, the peak was detected as a doublet. The doublet of doublet of doublets at 7.30 ppm 
could distinctively be assigned to C
16
. The doublet at 7.61 ppm could be assigned to C
18
 and 
again this peak was expected to be a doublet of doublets. Lastly, the triplet of doublets at   
7.75 ppm could be assigned to C
17
.  
As sometimes occurs with extensively conjugated systems, not all carbon peaks were observed in 
the 
13
C spectrum. A possible explanation for this phenomenon is that the asymmetric pyridine 
ring (325 and 327) has five distinctive aromatic chemical environments and will produce only 
five carbon peaks. For para-pyridine 329, which has a symmetric pyridine ring, only three 
aromatic peaks were detected. 
 
 
Figure 4.8. 
1
H NMR spectrum of ortho pyridine 327 showing the (E)-configuration of the 
molecule 
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With the synthesised warheads in hand, the next step was to carry out a Suzuki-Miyaura reaction 
with boronic acid 243 to produce the desired final compounds. The synthesis of the final 
compounds will be discussed in the next section. 
 
4.5 The Suzuki-Miyaura reactions with 1-(3-amino-6-bromopyrazin-
2-yl)prop-2-en-1-one derivatives 
The procedure used for the Suzuki-Miyaura reactions was similar to that mentioned in Scheme 
3.36. All synthesised warheads 317 – 320, 325 and 327 readily underwent a Suzuki-Miyaura 
reaction with boronic acid 243, except for para-pyridine 329 due to solubility issues. The 
procedure and the results are shown in Scheme 4.24 and Table 4.1. For the imidazole derivative 
239, two spots were observed on the TLC plate (Rf: 0.50 and 0.56, 9:1 EtOAc:MeOH) that could 
not be separated using column chromatography. Several attempts to obtain product 239 in pure 
form proved futile. 
 
 
Scheme 4.24. Suzuki reaction with Michael acceptor derivatives 300 to form the final 
compounds 299 
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Table 4.1. Products obtained from the Suzuki reactions with boronic acid 243 and the six 
aminopyrazine derivatives 317 - 320, 325 and 327 
# R Yield  
228 
 
73% 
229 
 
69% 
230 
 
76% 
231 
 
86% 
236 
 
40% 
237 
 
43% 
239 
 
failed 
 
The piperidine derivative 228 was selected for the discussion of NMR spectroscopic 
characterisation for this series of final compounds. Since the proton peaks of the scaffold have 
already been identified in Section 3.6, it could be readily applied to this compound and using the 
spectroscopic data from Figure 4.4, the proton peaks of the side chain could also be identified. 
As shown in Figure 4.9, one of the doublets of the Michael acceptor was buried under the proton 
peak of C
13/15
 at 7.84 – 7.80 ppm and could be assigned to C27. The other doublet could be 
located at 6.71 ppm with a J-coupling value of 12.8 Hz. The singlet at 8.58 ppm was the 
heteroaromatic C
18
 and the doublet at 8.08 ppm was C
16/12
. The multiplet at 3.45 ppm, integrating 
for four protons, could be assigned to C
29/33
 and the other multiplet at 1.70 ppm, integrating for 
six protons, could be assigned to C
30,31,32
. Finally, the proton peaks 3.08, 2.49 and 2.27 ppm 
could be assigned to the methylpiperazine group. 
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Figure 4.9. 
1
H NMR spectrum of piperidine 228 showing the successful Suzuki-Miyaura 
coupling 
 
The 
13
C NMR spectrum of 228 is shown in Figure 4.10 and several peaks from the aromatic 
region could be readily assigned using the data from Figure 4.5. The carbon peak at 189.0 ppm 
was the carbonyl C
24
 and the carbon peak at 154.6 ppm was C
20
. The carbon peaks at 153.1 and 
90.7 ppm could be assigned to C
27 
and C
25
 respectively. The carbon peak at 132.0 ppm was C
21
. 
In the alkane region, the carbon peaks at 55.5 and 46.8 ppm could be either C
33
 or C
29
. The 
carbon peaks at 26.7 and 25.2 ppm were C
32
 or C
30
. The carbon peak of the piperidine ring, C
31
, 
was 24.2 ppm. The last three peaks that could be readily assigned were 54.2, 46.1 and 45.8 ppm, 
which belong to the methylpiperazine group. From the spectroscopic data that was covered in 
section 3.6, the carbon peaks at 128.5 and 126.0 ppm could be assigned to C
15/13 
and C
16/12
 
respectively. The carbon peaks at 141.7, 138.1 and 134.3 ppm could be assigned to C
11
, C
14
 and 
C
17
 respectively. From the HSQC spectrum (not shown), the carbon peak at 143.2 ppm was 
identified as C
18
.  
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Figure 4.10. 
13
C NMR spectrum of 228 
 
A series of (E)-1-(3-aminopyrazin-2-yl)prop-2-en-1-one derivatives have been successfully 
synthesised that involved the Weinreb coupling, Grignard, aldol condensation and    
Suzuki-Miyaura methods. The final compounds 228 - 231, 236 and 237 have been subjected to 
biological testing and will be discussed in the next chapter.  
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Chapter 5 
 
Biological results 
 
5.1 Overview 
In this chapter, the biological results of the synthesised GSK-3β inhibitors that were discussed in 
chapter three and four will be reviewed. The first biological testing of the compounds involved 
the determination of the IC50 values. The compounds that exhibited an IC50 value lower than 10 
μM were subjected to the GSK-3β time-dependent studies to determine whether or not these 
compounds bind irreversibly to the GSK-3β. 
 
5.2 Biological results of the (E)-3-(3-aminopyrazin-2-
yl)acrylaldehyde derivatives 
The five compounds (216 – 220) that were synthesised as described in section 3.6 were sent for 
in vitro testing using the radiometric and luminescent assays
1
 on the human recombinant  
GSK-3β enzyme. Each compound was incubated with the enzyme for 20 minutes (see 
experimental section, Chapter 8.5) and a full dose-response analysis was performed on all 
compounds to determine the concentration inhibiting 50% of enzyme activity (IC50). The values 
are shown in Table 5.1. Alsterpaullone 298, a known reversible GSK-3β inhibitor,2 was used as a 
reference standard. 
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Table 5.1. GSK-3β IC50 values of compounds 216 – 220 with the obtained docking scores 
(Chapter 2.3.3) 
# 
 
IC50 (GSK-3β) 
(μM) 
Docking score 
(kcal/mol) 
216 
 
5.29 ± 0.22 -5.751 
217 
 
7.47 ± 0.19 -7.205 
218 
 
3.63 ± 0.28 -7.439 
219 
 
 >10 (39%) -7.204 
220 
 
9.90 ± 0.49 failed 
298 
 
0.004 - 
 
The results for the in vitro assay against the human recombinant GSK-3β were very poor when 
compared to the reference standard and the IC50 values were in the lower micromolar range. 
From these results it can be seen that the position of the carbonyl moiety is critical to obtain 
nanomolar activity, as seen in compounds 204 – 208 (Chapter 2, Fig. 4), regardless the type of 
side chains present. From the aforementioned results, the type of amine group on the side chain 
does not give clear insight as to what is required for potency. 
 
A scatter plot of IC50 versus the docking scores (Fig. 5.1) was constructed to compare the 
biological results with the docking scores (Chapter 2.3.3). The biological activities of the 
compounds correlated poorly with the results of the molecular modelling as described in  
chapter 2. It appears that the binding mode used in the molecular modeling does not appear to be 
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a reliable predictor of efficacy. This could mean that the molecules interact at a different site on 
the enzyme or inhabit this binding site in a manner unpredicted by the molecular modeling. 
Lastly, this series does not provide potent inhibitors for GSK-3β and that any future work on this 
series should be carefully thought through.  
 
 
Figure 5.1. A scatter plot of the IC50 versus the docking scores for compounds 216 – 219 
 
Further biological testing included time-dependent studies
1
 to determine whether or not each  
compound binds irreversibly to the GSK-3β. Using the reversible inhibitor, alsterpaullone 298, 
as the standard reference, the enzyme was incubated several times with the synthesised 
compounds. The results shown in Figure 5.2 demonstrated that all of the synthesised compounds 
exhibited a gradual and sustained increase in inhibitory activity over time in comparison to 
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alsterpaullone 298. This suggests that the compounds may indeed exhibit irreversible inhibitory 
activity on the GSK-3β, albeit at a high concentration.   
 
 
Figure 5.2. GSK-3β time-dependent studies on 216 – 220 and alsterpaullone 298 
 
These biological results provided bittersweet information regarding the activity of the 
compounds. All the compounds exhibited poor inhibitory activity but showed the ability to 
inhibit GSK-3β irreversibly at high concentration. Further studies on irreversible GSK-3β 
inhibition to obtain better insight were not carried out due to poor biological results and, as a 
result, further work on this moiety was aborted. 
 
5.3 Biological results of the (E)-1-(3-aminopyrazin-2-yl)prop-2-en-1-
one derivatives 
Six compounds (228 – 231, 236 – 237) that were synthesised as described in chapter 4 were sent 
for in vitro testing using the radiometric and luminescent assays
1
 on the human recombinant 
GSK-3β enzyme. A full dose-response analysis was performed on all compounds to determine 
the concentration inhibiting 50% of enzyme activity (IC50) and the values are shown in Table 
5.2. Alsterpaullone 298, a known reversible GSK-3β inhibitor,2 was used as a reference standard. 
Incubation time E+I (min) 
Incubation time E+I (min) 
 5 μM 
 1 μM 
 10 μM 
  1 μM 
Incubation time E+I (min) 
  0.5 μM 
  5 μM 
Incubation time E+I (min) 
Incubation time E+I (min) 
10 μM 
 5 μM 
       10 μM 
5 μM 
Incubation time E+I (min) 
5 nM 
2.5 nM 
216 217 218 
219 220 
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Table 5.2. GSK-3β IC50 values of compounds 228 – 231, 236 – 237 with the obtained docking 
scores (Chapter 2.3.3) 
# 
 
IC50 (GSK-3β) 
(μM) 
Docking score 
(kcal/mol) 
228 
 
0.91 ± 0.05 -7.746 
229 
 
 0.54 ± 0.04 -5.383 
230 
 
0.40 ± 0.04 -4.905 
231 
 
 0.35 ± 0.03 -5.338 
236 
 
0.12 ± 0.02  -5.862 
237 
 
0.20 ± 0.03 -5.771 
298 
 
0.004 - 
 
The results for the in vitro assay against the human recombinant GSK-3β were substantially 
better than the aforementioned series (section 5.2) and the IC50 values were in the submicromolar 
range. From the results it can be seen that the position of the carbonyl moiety plays an integral 
part in the potency of the compound. The size and type of amine group on the side chain does 
influence the potency of the inhibitor. Compounds 230 and 231, with smaller amine groups in 
comparison to compounds 228 and 229, exhibited stronger inhibitory activity on the GSK-3β. 
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The pyridine series, compounds 236 and 237, delivered the most potent activities in this series. 
As discussed in Chapter 2, the potency could be ascribed to the interaction of the pyridine ring to 
Lys85 inside the ATP-binding site.  
 
A scatter plot of IC50 versus the docking scores (Fig. 5.3) was constructed to compare the 
biological results with the docking scores (Chapter 2.3.3). However, no correlations could be 
made between the docking scores and the biological results.  
 
 
Figure 5.3. A scatter plot of the IC50 versus the docking scores for compounds 228 – 231 and 
236 – 237 
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The results of the time-dependent studies
1
 on the GSK-3β for 227 – 230 are shown in Figure 5.2. 
Using the reversible inhibitor, alsterpaullone 298, as the standard reference, the enzyme was 
incubated several times with the synthesised compounds. It should be noted that 236 and 237 
were synthesised at the last stage of this project and the time-dependent studies will thus be 
carried out in the near future. The results demonstrated that at low concentrations, the 
synthesised compounds exhibited a gradual and sustained increase in inhibitory activity over 
time when compared to alsterpaullone 298. This suggests that the compounds may exhibit 
irreversible inhibitory activity on the GSK-3β.    
 
 
Figure 5.2 GSK-3β time-dependent studies on 227 – 230 and alsterpaullone 298 
 
These biological results are in good agreement with the docking studies carried out    
(Chapter 2, section 2.3.3). Compounds 236 and 237, with the most potent IC50 values of 0.12 and 
0.20 μM respectively, obtained good docking scores (-5.862 and -5.771 kcal/mol respectively). 
However, compounds 229 and 231, with IC50 values of 0.54 and 0.35 μM, obtained similar 
docking scores (-5.383 and -5.338 kcal/mol respectively), which suggests that the pyridine ring 
in 236 and 237 is involved in an additional role such as pi-sigma interactions with the amino acid 
residue, Lys85, which could increase the potency of the compound.  Overall, these biological 
results suggest that this moiety has the potential to inhibit GSK-3β irreversibly at nanomolar 
Incubation time E+I (min) 
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 0.1 μM 
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concentration. Further work on confirming the covalent nature of the interaction of the inhibitors 
will be discussed as future work in chapter 7. In addition, these results warrant the development 
of a 2
nd
 generation of irreversible GSK-3β inhibitors and will be discussed in chapter 7. 
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Chapter 6 
 
Attempted synthesis of terminal electrophilic “warheads” 
 
6.1 Overview 
This section describes the last few months of this PhD project that were used to carry out a 
variety of synthetic procedures, in an attempt to incorporate a terminal electrophilic “warhead”. 
The concept of this terminal “warhead” was to determine whether improved biological results 
could be obtained, in comparison to the two previous series that consisted of an internal 
“warhead”.  
 
6.2 Retrosynthetic analysis of the library 
The retrosynthetic approach for the synthesis of terminal electrophilic “warheads” followed 
similar routes of the internal “warheads” as discussed in chapter three and four. For the synthesis 
of a terminal electrophilic “warhead” (Fig. 6.1), it was envisaged that 334 could be formed by 
using the already established Suzuki-Miyaura procedure between boronic acid 243 and 335. In 
addition, terminal “warhead” derivatives 335 could be obtained from the already synthesised 
Weinreb amide 311 (see section 4.3.3).   
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Figure 6.1. Retrosynthetic analysis of the targeted library. 
 
6.3 Synthesis of the terminal Michael acceptor precursors 
As shown in Scheme 6.1, the synthesis of the Michael acceptor 336 followed the same procedure 
mentioned in Chapter 4.2.3 for the alkyne 301. As such, Weinreb amide 311 was reacted with 
three equivalents of vinylmagnesium bromide and after purification by column chromatography 
the Michael acceptor 332 was isolated as yellow solid in an acceptable 62% yield. 
 
 
Scheme 6.1. Synthesis of Michael acceptor 336 
 
As shown, in Figure 6.2, the presence of the vinyl functional group could readily be identified in 
the 
1
H NMR spectrum. The two doublet of doublets at 6.54 and 5.90 ppm could be assigned to 
the terminal protons of C
12
 and the doublet of doublets at 7.85 ppm could be assigned to the 
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remaining vinyl proton of C
11
. Finally, the singlet at 8.28 ppm was for the heteroaromatic proton 
at C
2
.  
 
Figure 6.2. 
1
H NMR spectrum of 336 
 
With the two different Michael acceptors, 297 (Chapter 4.2.3) and 336, in hand (Fig. 6.3), the 
next step was the Suzuki-Miyaura reaction with boronic acid 243 (Fig. 6.3). The next section will 
discuss the attempted synthesis of these final compounds. 
 
 
Figure 6.3. Synthesized Michael acceptors 301, 336 and the boronic acid 243 
 
6.4 Attempted synthesis of terminal Michael acceptor compounds 
Michael acceptor 297 was the first terminal “warhead” derivative to undergo a Suzuki-Miyaura 
reaction with boronic acid 243 and the procedure is shown in Scheme 6.2. After stirring 
overnight, full consumption of the starting 297 was observed and one product spot was seen on 
the TLC plate. A yellow solid was isolated after column chromatography purification. 
Unfortunately, 
1
H NMR spectroscopic analysis indicated that a mixture of products had formed. 
The additional peaks in the aromatic and alkane regions of this spectrum suggested that the 
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Suzuki-Miyaura coupling appeared to be successful, but that, in addition, the ethanol in the 
solution had reacted with the Michael acceptor.   
 
 
Scheme 6.2. Attempted Suzuki reaction with 297 
 
The mass spectrometric data gave further support to the idea that ethanol had reacted with 213. 
As shown in Table 6.1, three mass to charge (m/z) peaks were observed in the high resolution 
mass spectrometry spectrum. Two of the three peaks suggested the possible formation of the 
mono- and di-alkylated products 337 and 338. The structure of the molecule accounting for the 
third m/z peak, 464.1961 amu, could not be identified. In addition, the m/z peak for 213 was not 
detected. 
 
Table 6.1. The structures of the molecules related to the m/z values. 
Molecule Calculated mass (M+H) (g/mol) m/z (M+H) (amu) 
 
385.4402 not detected 
 
432.1705 432.1704 
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478.2124 478.2130 
unknown – 464.1961 
The reaction was repeated with a solvent system that comprised toluene, t-BuOH and water. In 
comparison to ethanol, t-BuOH is a more sterically hindered nucleophilic solvent and should 
therefore be less reactive. As with the first attempt, the starting material, 297, was fully 
consumed after stirring overnight. However, analysis of the 
1
H NMR spectroscopic data again
showed that a mixture of products had formed, which could be the deboronated and/or 
homocoupled compounds. Replacing t-BuOH with dimethoxyethane, a non-nucleophilic solvent, 
did not improve the results either.  
An alternative route, which reversed the synthetic sequence, was explored. This was to do the 
Suzuki-Miyaura coupling before the addition of the Michael acceptor. This way, the reaction of 
the Michael acceptor with the ethanol in the Suzuki-Miyaura reaction could be avoided. As 
shown in Scheme 5.3, Weinreb amide 311 readily underwent a Suzuki-Miyaura reaction with 
boronic acid 243 to form the corresponding phenylaminopyrazine 337 in 75% yield. Two 
singlets at 3.87 and 3.52 ppm, both integrating for three protons in the 
1
H NMR spectrum,
confirmed the presence of the Weinreb amide on the new structure 337. In addition, the presence 
of five aromatic protons in total confirmed the construction of the biaryl bond. 
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Scheme 6.3. Suzuki reaction of Weinreb amide 311  
 
As shown in Scheme 6.4, the next step involved the Grignard reaction with ethynyl magnesium 
bromide utilising a procedure similar to the one that was reported earlier (Section 4.2.3). 
Unfortunately, after this reaction, only trace amounts of products were isolated with full 
conversion of the starting material. It was considered that during the quenching of the reaction, 
the acid labile methylpiperazine could have been protonated to form an amine salt. Therefore, the 
reaction was repeated and quenched with saturated NH4Cl solution, but similar disappointing 
results were obtained. 
 
 
Scheme 6.4. Attempted Grignard reaction with 335 
 
In the next attempt, a different Grignard intermediate was used to react with 337 (Scheme 6.5).
1
 
Trimethylsilyl acetylene 338 was first lithiated with n-BuLi in THF before a solution of 337 in 
THF was added. The resulting deep orange solution was then allowed to warm to room 
temperature over two hours before the reaction was quenched with saturated NH4Cl solution. 
The solution was diluted with EtOAc and washed with water. On the TLC plate, the 
determination of whether the reaction has gone to completion was complicated by the fact that 
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the product had a similar Rf value to the starting material 337. As the mixture could not be 
separated, the crude mixture was carried to the next step. 
 
 
Scheme 6.5. Grignard reaction with trimethylsilyl acetylene 338 
 
The next step required the deprotection of the alkyne-TMS group and this procedure is shown in 
Scheme 6.5.
2
 The crude mixture from the previous step was dissolved in THF and subsequently 
cooled to 0 °C. Tetra-n-butylammonium fluoride (TBAF·3H2O) was then added portion-wise 
and the resultant brown solution was stirred for one hour at room temperature. It should be noted 
that no significant changes were observed on the TLC plate and the reaction was deemed a 
failure. 
 
Scheme 6.6. Attempted deprotection of 337 with TBAF·3H2O 
  
After this failed attempt, it was decided to abandon this synthetic route of coupling the terminal 
Michael acceptors onto the aminopyrazine core. 
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6.5 Attempted synthesis of halomethyl ketone compounds 
The synthesis of a different terminal electrophilic “warhead”, the halomethylketone, was pursued 
after the aforementioned attempts failed to produce compounds with a terminal Michael 
acceptor. The synthesis of the halomethylketone compounds will be discussed next. 
 
Compound 298 (see chapter 4, Scheme 4.17) readily underwent a Suzuki-Miyaura reaction with 
boronic acid 243 (Scheme 6.7) and the product 340 was isolated as yellow solid in 71% yield. In 
terms of NMR spectroscopic analysis, the presence of the methyl ketone was observed as a 
proton singlet at 2.80 ppm and a carbonyl peak at 202.7 ppm. 
 
 
Scheme 6.7. Suzuki reaction of methyl ketone 298 with 243 
 
The next step involved the bromination of the methyl ketone 340. Using the procedure of 
Kharaman et al.,
3
 methyl ketone 340 was thus brominated with molecular bromine in chloroform 
(Scheme 6.8). According to the TLC plate, three product spots had formed, which suggested the 
formation of mono-, di- and tribrominated products in an unknown ratio and could not be 
separated. Unreacted starting material was also observed on the TLC plate. It has been 
documented that the bromination of a methyl ketone with bromine can lead to the formation of 
polybrominated products, as was experienced in our synthetic attempts.
4, 5
  
 
To eliminate the formation of polybrominated products, it was proposed that the reaction could 
be carried out under acidic conditions.
6-9
 The reaction in Scheme 6.8 was thus repeated in neat 
acetic acid and the solution was stirred overnight. This time, only one product spot and unreacted 
starting methyl ketone 340 were observed on the TLC plate. However, after purification by 
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column chromatography, the desired product 214 was only isolated in trace amounts. The 
reaction proved to be sluggish and further attempts with molecular bromine as the brominating 
agent were abandoned. An alternative synthetic route was pursued and will be discussed next. 
 
 
Scheme 6.8. Attempted bromination of methyl ketone 340 
 
Copper bromide, a known brominating agent,
10, 11
 in chloroform-ethyl acetate is known to react 
with methyl ketones to give selectively the corresponding α-bromo ketones.12 Following the 
procedure of Boominathan et al.,
13
 a solution of methyl ketone 340, copper bromide, chloroform 
and ethyl acetate (1:1 ratio) was heated under reflux overnight (Scheme 6.9). Unfortunately, only 
the starting 340 was observed on the TLC plate after stirring overnight. 
 
Scheme 6.9. Attempted bromination of 340 with copper bromide 
 
Trimethylphenylammonium tribromide (PTAB) is another brominating agent that selectively 
forms α-bromo ketones.14-16 The procedure of Perner et al.17 was slightly adapted and is shown in 
Scheme 6.10. The reaction was carried out at 30 °C instead of at room temperature. Methyl 
ketone 340 was dissolved in THF and PTAB was added in several portions. The dark orange 
solution was stirred for three days, but according to the TLC plate, only starting materials were 
present. 
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Scheme 6.10. Attempted bromination of 340 with PTAB 
 
A different brominating source was used for the last attempt. Several papers have reported the 
successful mono-bromination of acetophenone using NBS and catalytic amount of     
para-toluenesulfonic acid (PTSA).
18-22
 The procedures are all similar, varying only in the solvent 
and the temperature at which the reactions were carried out. The procedure for the mono-
bromination of methyl ketone 340 with NBS and catalytic amount of PTSA is shown in Scheme 
6.11. Methyl ketone 340 and PTSA was thus dissolved in chloroform and NBS was added in 
several portions. The reaction was first carried out at room temperature to minimise the risk of 
over-bromination and the solution was stirred overnight. Unfortunately, three product spots and 
unreacted starting material were observed on the TLC plate, which suggested that     
over-bromination has once again occurred. In addition, the three products could not be separated 
by using column chromatography 
  
 
Scheme 6.11. Attempted bromination of 340 with NBS and PTSA 
 
Due to the failed attempts to mono-brominate the methyl ketone 340, it was decided to abandon 
the synthesis of halomethyl ketone derivatives. To obtain potential irreversible inhibitors with 
these structural features, a new synthetic route would have to be implemented that would 
overcome the aforementioned issues. This will be discussed in the future work section of chapter 
7. 
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Chapter 7 
 
Conclusions and future work 
 
7.1 Conclusions 
The initial aim of this project was to synthesise three libraries of compounds with electrophilic 
“warheads” such as Michael acceptors and halomethyl ketones that could be tested on GSK-3β to 
determine their biological activity and also whether they bind irreversibly to the enzyme. This is 
also the first attempt to synthesise irreversible inhibitors attached to the aminopyrazine class of 
compounds. Two libraries that consisted of a total of 11 compounds with an internal “warhead” 
were successfully synthesised. The third library, which consist of a terminal “warhead” could not 
be synthesised due to various synthetic complications. In addition, our research group also 
develop antimalarial inhibitors, thus the synthesised compounds were also tested on a 
chloroquine sensitive strain of P. falciparum, NK54, to determine their antiplasmodial activity. 
As one of the molecules showed surprising good efficacy, a small number of fragments of this 
molecule were made to see if the pharmacophore could be identified.  
 
The key Suzuki-Miyaura chemistry was thoroughly explored to find the optimal conditions for 
the synthesis of the scaffold, 5-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazin-2-amine 
251.  The conditions were determined to be 1.5 equivalents of boronic acid 243, 0.1 equivalents 
of Pd(dppf)Cl2 and 4.0 equivalents of Cs2CO3 in a solvent system of toluene:ethanol:water 
(4:1:0.05 ratio). In addition, the reaction mixture need to be deoxygenated thoroughly using the 
freeze-pump-thaw technique before the catalyst was added.   
 
Five (E)-3-(3-aminopyrazin-2-yl)acrylaldehyde derivatives were successfully synthesised and 
analytically characterised. The compounds were obtained in good yields, ranging from 69 – 78%. 
m-Aminopyridine 221 was only isolated in trace amounts and further attempts to improve the 
yield were not carried out due to insufficient amounts of starting material. All five of the 
compounds were sent for biological testing on the GSK-3β and were found to be poor (3.63 – 
>10 μM). The most potent compound was pyrrolidine 218 with an IC50 value of 3.63 μM. The 
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time-dependent studies on the GSK-3β suggested that all five compounds possibly might exhibit 
irreversible inhibitory activity at high concentrations (  1 μM). 
 
Six (E)-1-(3-aminopyrazin-2-yl)prop-2-en-1-one derivatives were also successfully synthesised 
and analytically characterised. Imidazole derivative 239 could not be isolated as attempts to 
obtain the product in pure form proved futile. Overall, the compounds were isolated in moderate 
to good yields, ranging from 40 – 86%. All six of the compounds were sent for biological testing 
on the GSK-3β and were found to be better inhibitors than the first five compounds tested. All 
compounds exhibited IC50 values of under 1 μM, with o-pyridine 236 being the most active (IC50 
value of 0.12 μM). The time-dependent studies on the GSK-3β suggested that four of the six 
compounds may exhibit irreversible inhibitory activity at low concentrations (  1 μM). The 
GSK-3β time-dependent studies of pyridines 236 and 237 will be carried out in the near future by 
one of our collaborators. 
 
7.2 Future work 
7.2.1 Future modification on the synthesised compounds 
This project represents the first approach of electrophilic “warheads” attached to the 
aminopyrazine core and therefore has the potential to be further expanded to include a second 
generation with more focused properties. 
The results of the (E)-1-(3-aminopyrazin-2-yl)prop-2-en-1-one derivatives (chapter 4) suggested 
that pyridine rings may play a critical role in achieving minimum IC50 concentration.  By looking 
at the work of Berg et al.
1
 (Fig. 7.1, 208 GSK-3β Ki = 0.22 nM), modifications on the pyridine 
ring may offer an option to improve the potency of the compounds. As shown in Figure 7.1, a 
moiety that consists of a pyrrolidine (341), diethylamine (342), dimethylamine (343) or a 
methoxy group (344) could be inserted onto the pyridine ring. These modifications may allow 
the compounds to fit better inside the GSK-3β ATP-binding site and they have improved 
interactions with the amino acid residues. However, these suggestions have to be modelled first 
inside the GSK-3β ATP-binding site.   
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Figure 7.1.  Possible future modifications on the pyridine ring to improve the potency of the 
GSK-3β inhibitors 
 
Another option to improve the potency would be to reposition the pyridine ring (Fig. 7.2, 345) or 
install a different heteroaromatic moiety (Fig. 7.2), such as a triazole (346), furan (347) or 
pyrrole (348) ring system. This would offer insight into whether the rearrangement or the type of 
heteroaromatic ring plays a role in the inhibitory activity of the GSK-3β. Again, these 
suggestions have to be modelled first inside the GSK-3β ATP-binding site before the synthesis 
of the modified molecules could be carried out. 
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Figure 7.2. Installment of a heteroaromatic ring to improve the potency of the GSK-3β inhibitors 
 
Lastly, the covalent binding of the compounds to GSK-3β could be confirmed biophysically by 
MALDI-TOF analyses.
2
 Each compound could be combined with GSK-3β, and allowed to 
interact with the enzyme for a specific amount of time. The excess unreacted enzyme could be 
washed off and mass analysis of the bound inhibitor-enzyme complex could reveal whether one 
peak is observed, which would suggest the combined mass of the compound and GSK-3β. This 
could possibly indicate that the compound had bound irreversibly to the enzyme. The presence of 
two peaks would indicate that the compound had not bound covalently to GSK-3β, which then 
suggests that the compound is a reversible inhibitor.   
Another experiment that could be carried out is the synthesis of a saturated derivative of 
compound 231 (Fig. 7.3). The double bond of the Michael acceptor could be reduced to 
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deactivate the “warhead” and this new compound, 340, could be subjected to time-dependent 
studies on the GSK-3β. The results could then prove whether compound 340 exhibit a gradual 
and sustained increase in inhibitory activity over time, which would suggest a different mode of 
inhibitory action. 
 
 
Figure 7.3. Reduction of the Michael acceptor to deactivate the “warhead” 
 
7.2.2 Future synthetic attempts to synthesise GSK-3β halomethyl ketone 
inhibitors 
The synthesis of the terminal “warheads” proved to be a stumbling block as described in chapter 
6. As shown in Scheme 7.1, alternative brominating sources could be used to mono-brominate 
methyl ketone 340. One example is the use of bromotrimethylsilane (TMSBr) and potassium 
nitrate (KNO3) in a non-nucleophilic solvent such as DCM to afford the corresponding product 
214.
3
 In this reaction, nitryl bromide (NO2Br) is generated in situ from TMSBr and KNO3, which 
then reacts with the α-methylketone to give the corresponding α-brominated product. 
 
 
Scheme 7.1. Monobromination of methyl ketone 340 with TMSBr and KNO3 
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Another option to selectively synthesise the monobrominated compound would be to form 
enamine 350, which could be then be selectively mono-brominated, followed by hydrolysis of 
the intermediate brominated immonium salt to give the corresponding product 214 (Scheme 
7.2).
4
 The formation of the salt would prevent the molecule  from entering another round of 
bromination to form the undesired dibrominated product. 
 
 
Scheme 7.2. Suggested method to synthesise α-brominated 214 via the enamine 
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Chapter 8 
 
Experimental section 
 
8.1 General procedures 
All chemicals used in this project were purchased from Aldrich or Merck. Tetrahydrofuran was 
distilled under nitrogen from sodium sand with benzophenone as an indicator. Dichloromethane 
was distilled under nitrogen from calcium hydride. Where necessary, purification of other 
reagents was performed according to standard literature procedures.
1
 The molarity of alkyl 
lithiums was determined using a method as described in the literature.
2 
All reactions were performed under anhydrous conditions and a positive pressure of nitrogen. 
Low temperature reactions were performed in a Dewar or plastic bowl using dry ice in acetone  
(–78 °C) or ice in water (0 °C). 
Column chromatography was performed on Merck silica gel 60 (particle size 0.040–0.063 mm) 
using combinations of hexane (Hex), ethyl acetate (EtOAc), methanol (MeOH) and 
dichloromethane (DCM) as solvent. Thin layer chromatography (TLC) was carried out on 
aluminium-backed Merck silica gel 60 F254 plates. Visualisation was achieved with a UV lamp, 
using iodine on silica or by dipping the TLC plate into a Cerium Ammonium Molybdate solution 
(CAM) or ninhydrin solution (NIN) followed by heating.  
All 
1
H, 
13
C nuclear magnetic resonance spectra were obtained using a 300 MHz Varian VNMRS 
(75.5 MHz for 
13
C), 400 MHz (100 MHz for 
13
C) or 600 MHz (150 MHz for 
13
C) using 
deuterated solvents. Chemical shifts (δ) were recorded using the residual peaks of deuterated 
solvents (CDCl3 = δ 7.26 and DMSO–D6 = δ 2.50 in 
1
H NMR, CDCl3 = δ 77.2 and    
DMSO–D6 = δ 39.5 in 
13
C NMR). All chemical shifts are reported in ppm. Spectra were obtained 
at 25 °C. Melting points were obtained using a Gallenkamp Melting Point Apparatus and are 
uncorrected. Infrared spectra were obtained using a Nexus Thermo-Nicolet FT-IR instrument 
using the ATR attachment. High resolution mass spectrometry was performed by the CAF 
(Central Analytical Facility) Institute at Stellenbosch University using a Waters API Q-TOF 
Ultima spectrometer. 
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Additional spectroscopic data can be found at this Google Drive link: 
https://drive.google.com/open?id=14nAI0J6EXssDMP2QhoiRrrHjiGU7iU-i 
 
8.2 Chapter 3 
4-Bromobenzenesulfonyl chloride (245) 
Bromobenzene (5.0 mL, 47 mmol) was dissolved in CHCl3 (180 mL) and 
precooled to –78 °C. Excess HSO3Cl (35.0 mL, 517 mmol) was added 
dropwise to the solution via a pressure-equalising dropping funnel. The reaction was allowed to 
stir overnight while gradually warming to room temperature. The brown solution was then 
poured over crushed ice and extracted with DCM (3   35 mL). The organic layer was dried over 
anhydrous MgSO4, filtered and concentrated under reduced pressure. Chromatography was done 
using 7:3 Hex:DCM as eluent to afford the product as an off-white solid (8.9 g, 74% yield).   
Rf = 0.57 (Hex:DCM, 7:3); 
1
H NMR (CDCl3, 300 MHz): δ = 7.91 (d, J = 8.5 Hz, 2H, CH), 7.78 
(d, J = 8.5 Hz, 2H, CH). The spectroscopic data were in agreement with the reported data.
3
 
 
1-[(4-Bromophenyl)sulfonyl]piperazine (248) 
Piperazine (6.7 g, 78 mmol) was dissolved in DCM (120 mL) and 
cooled to 0 °C. Sulfonyl chloride 245 (5.0 g, 20 mmol) was dissolved in 
DCM (10 mL) and added dropwise to the solution at 0 °C while stirring 
vigorously. The resulting white solution was left to stir for two hours 
and then washed with a saturated solution of NaHCO3 (3   30 mL). The organic layer was dried 
over anhydrous MgSO4, filtered, and concentrated under reduced pressure. Purification was done 
using column chromatography with DCM and then 9:1 DCM:MeOH as eluent to afford the 
product as a white solid (5.4 g, 91% yield). Mp 163–165 °C (neat); Rf = 0.43 (DCM:MeOH, 
9:1); IR (ATR): 2969 (w), 2916 (w), 2859 (w), 1573 (m), 1342 (m), 1161 (vs), 751 (vs) cm
–1
;  
1
H NMR (CDCl3, 300 MHz): δ = 7.65 (d, J = 8.5 Hz, 2H, CH), 7.58 (d, J = 8.5 Hz, 2H, CH), 
2.98–2.84 (m, 8H, CH2), 1.64 (s, 1H, NH); 
13
C NMR (CDCl3, 75.5 MHz): δ = 134.8 (1C, CH), 
132.5 (2C, CH), 129.4 (2C, CH), 128.1 (1C, CH), 47.0 (2C, CH2), 45.4 (2C, CH2); HRMS–ES+: 
m/z [M+H]
+
 calcd for C10H14N2O2SBr: 304.9959; found: 304.9962. 
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1-[(4-Bromophenyl)sulfonyl]-4-methylpiperazine (249) 
Compound 248 (4.7 g, 15 mmol) was dissolved in dioxane (40 mL). 
Formaldehyde (37%, 4.6 mL, 77 mmol) and acetic acid (1.8 mL, 31 
mmol) was added to the solution followed by the addition of zinc (2.0 g, 
31 mmol) in one portion. The resulting grey solution was stirred for one day at room temperature 
and the solid was then removed by filtration. The filtrate was concentrated under reduced 
pressure and diluted with EtOAc (35 mL). The organic layer was washed with a saturated 
solution of NaHCO3 (25 mL) and dried over anhydrous MgSO4. The product was purified using 
column chromatography with 95:5 DCM:MeOH as eluent and was isolated as a white solid  
(4.2 g, 85% yield). Rf = 0.40 (DCM:MeOH, 95:5); 
1
H NMR (CDCl3, 300 MHz): δ = 7.66   
(d, J = 8.7 Hz, 2H, CH), 7.60 (d, J = 8.7 Hz, 2H, CH), 3.03–3.00 (m, 4H, CH2), 2.48–2.44   
(m, 4H, CH2), 2.25 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 134.6 (1C, C), 132.4   
(2C, CH), 129.4 (2C, CH), 128.0 (1C, C), 54.1 (2C, CH2), 46.0 (2C, CH2), 45.8 (1C, CH3). The 
spectroscopic data were in agreement with the reported data.
4
 
 
{4-[(4-Methylpiperazin-1-yl)sulfonyl]phenyl}boronic acid (243) 
Compound 249 (1.0 g, 3.1 mmol) was dissolved in THF (14 mL) 
and precooled to –78 °C. n-BuLi (0.88 M, 5.0 mL, 4.4 mmol) was 
added dropwise to the solution. The resulting dark yellow solution 
was stirred further for one hour followed by the addition of 
B(OMe)3 (0.70 mL, 6.3 mmol). The light yellow solution was stirred further at –78 °C for two 
hours or until the yellow colour had disappeared. The solution was quenched with 2 M HCl  
(20 mL) and then concentrated to dryness. The white solid was dissolved in boiling MeOH   
(5 mL) and upon cooling the product precipitated out. The pale yellow mother liquor was 
removed with a pipette and the white solid was washed twice with MeOH (5 mL), followed by 
concentration to dryness. The product was obtained as a white solid (0.58 g, 65% yield) and was 
sufficiently pure to carry through to the next reaction. Mp 189–191 °C (neat); Rf = 0.10 
(DCM:MeOH, 95:5); IR (ATR): 3551 (s), 3350 (br), 2693 (m), 2614 (m), 1324 (m), 1156 (m), 
943 (m) cm
–1
; 
1
H NMR (DMSO–D6, 300 MHz): δ = 8.45 (br s, 2H, OH), 8.05        
(d, J = 8.3 Hz, 2H, CH), 7.73 (d, J = 8.3 Hz, 2H, CH), 3.82–3.67 (m, 2H, CH2), 3.43–3.37 (m, 
2H, CH2), 3.16 (s, 3H, CH3), 2.71 (m, 4H, CH2); 
13
C NMR (DMSO–D6, 75.5 MHz): δ = 135.6 
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(1C, CH), 135.0 (1C, CH), 126.4 (1C, CH), 51.5 (1C, CH3), 43.0 (2C, CH2), 41.9 (2C, CH2); 
HRMS–ES+: m/z [M+H]+ calcd for C11H18N2O4SB: 285.1080; found: 285.1078. 
 
5-Bromopyrazin-2-amine (244) 
Aminopyrazine (1.0 g, 11 mmol) was dissolved in DMF (10 mL) and cooled to 
0 °C. N-Bromosuccinamide (NBS) (1.9 g, 11 mmol), dissolved in DMF (10 
mL), was added dropwise slowly. The resulting dark brown solution was then 
stirred at room temperature overnight and poured over crushed ice (100 mL). The solution was 
washed with EtOAc (4   40 mL) and the organic layers were combined followed by washing 
with brine (25 mL). The organic layer was dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. Purification using column chromatography was done with 
1:1 Hex:EtOAc as eluent to afford the product as a cream solid (1.1 g, 63% yield). Rf = 0.56 
(Hex:EtOAc, 1:1); 
1
H NMR (CDCl3, 300 MHz): δ = 8.09 (d, J = 1.3 Hz, 1H, CH), 7.77    
(d, J = 1.3 Hz, 1H, CH), 4.65–4.50 (br s, 2H, NH2). The spectroscopic data were in agreement 
with the reported data.
5
 
 
5-(4-((4-Methylpiperazin-1-yl)sulfonyl)phenyl)pyrazin-2-amine (251) 
5-Bromopyrazine 244 (0.10 g, 0.45 mmol), boronic acid 243 
(0.14 g, 0.68 mmol) and Cs2CO3 (0.29 g, 0.90 mmol) were 
charged to a Schlenk tube and dissolved in Tol:EtOH:H2O   
(6 mL, 3:1:0.05). The reaction mixture was degassed three times 
using the freeze-pump-thaw method and then heated at 80 °C 
overnight. The black-brown solution was then diluted with EtOAc and filtered through celite. 
The orange-brown solution was washed with brine (20 mL) and the organic layer was acidified 
with 2M HCl (2   10 mL). The layers were separated and the aqueous layer was then basified 
with a saturated solution of NaHCO3 (25 mL) and extracted with EtOAc (2   20 mL). The 
organic layers were collected, dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure to afford the product as a cream solid (0.11 g, 76% yield) that was sufficiently 
pure to carry through to the next reaction. Mp 176–178 °C (neat); Rf = 0.24 (DCM:MeOH, 9:1); 
IR (ATR): 3444 (m), 2803 (m), 1538 (m), 1454 (m), 1153 (s) cm
–1
; 
1
H NMR (DMSO–D6, 300 
MHz): δ = 8.64 (s, 1H, CH), 8.17 (d, J = 8.5 Hz, 2H, CH), 8.01 (d, J = 8.5 Hz, 2H, CH), 7.74  
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(s, 1H, CH), 6.82 (br s, 2H, NH2), 2.94–2.86 (m, 4H, CH2), 2.40–2.32 (m, 4H, CH2), 2.12 (s, 3H, 
CH3); 
13
C NMR (DMSO–D6, 75.5 MHz): δ = 155.6 (1C, CNH2), 141.6 (1C, CH), 140.2 (1C, C), 
137.0 (1C, C), 133.1 (2C, CH), 132.0 (1C, C), 128.2 (2C, CH), 125.1 (1C, CH), 53.5 (2C, CH2), 
45.8 (2C, CH2), 45.3 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C15H20N5O2S: 334.1338; 
found: 334.1332. 
 
1,1ꞌ-Bis(diphenylphosphino)ferrocene (253) 
n-BuLi (0.88 M, 7.6 mL, 6.7 mmol) was added dropwise to a solution of 
ferrocene (0.50 g, 2.7 mmol), TMEDA (1.0 mL, 6.7 mmol) and hexane (5 mL) 
at 0 °C. The orange slurry was then stirred overnight at room temperature 
followed by cooling to –78 °C and chlorodiphenylphosphine (1.5 mL, 8.1 mmol) was then added 
dropwise. The orange-brown slurry was gradually warmed to room temperature and stirred 
further for two hours before being quenched with H2O (10 mL) and extracted with DCM   
(25 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. Purification was done using column chromatography with 9:1 Hex:DCM as 
eluent to afford the product as orange crystals (0.47 g, 32% yield). The product was used directly 
to the next step. 
 
Dichloro[1,1ꞌ-Bis(diphenylphosphino)-ferrocene]palladium(II) (255) 
1,1ꞌ-Bis(diphenylphosphino)ferrocene 253 (0.77 g, 1.4 mmol) was added to 
dichlorobis(acetonitrile)palladium(II) (0.36 g, 1.4 mmol) dissolved in benzene 
(15 mL). The dark orange solution was stirred at room temperature overnight. 
The resulting orange precipitate was collected by filtration and the residue was washed with 
benzene (2   10 mL). The solid was then dried under reduced pressure to afford the product as 
an orange solid (1.0 g, 88% yield). 
1
H NMR (CDCl3, 300 MHz): δ =7.92–7.88 (m, 8H, CH), 
7.51–7.47 (m, 4H, CH), 7.41–7.36 (m, 8H, CH), 4.41–4.37 (m, 4H, CH), 4.22–4.17 (m, 4H, CH); 
31
P NMR (CDCl3, 162 MHz): δ = 34.4. The spectroscopic data were in agreement with the 
reported data.
6
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5-Iodopyrazin-2-amine (264) 
Aminopyrazine (0.15 g, 1.6 mmol) was dissolved in DMF (5 mL) and cooled to 
0 °C. N-iodosuccinamide (NIS) (0.53 g, 2.4 mmol), dissolved in DMF (3 mL), 
was added dropwise slowly. The resulting yellow solution was then stirred at 
room temperature overnight and quenched with a saturated solution of Na2S2O3 (5 mL). The 
mixture was then poured into ice water (15 mL). The dark yellow-orange solution was washed 
with EtOAc (3   25 mL) and the organic layers were combined, followed by washing with brine 
(30 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. Purification was done using column chromatography with 7:3 EtOAc:Hex as 
eluent to afford the product as a yellow-cream solid (0.16 g, 46% yield). Rf = 0.40 (EtOAc:Hex, 
1:1); 
1
H NMR (CDCl3, 300 MHz): δ = 8.21 (d, J = 1.4 Hz, 1H, CH), 7.83 (d, J = 1.4 Hz, 1H, 
CH), 4.69–4.52 (br s, 2H, NH2). The spectroscopic data were in agreement with the reported 
data.
7
 
 
3-Bromo-5-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-amine (241) 
Compound 251 (0.060 g, 0.18 mmol) was dissolved in DCM  
(1 mL) and NBS (0.040 g, 0.22 mmol) was added portion wise at 
0 °C. The reaction was stirred at room temperature for two hours 
followed by the addition of H2O (5 mL) and the product was 
extracted with DCM (2   10 mL). The organic layer was 
acidified with 2 M HCl (10 mL). The layers were separated and the aqueous layer was then 
basified with a saturated solution of NaHCO3 (20 mL) and washed with DCM (2   15 mL). The 
organic layer was dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure to afford the product as a cream solid (0.035 g, 47% yield) that was sufficiently pure to 
carry through to the next reaction. Mp 184–186 °C (neat); Rf = 0.50 (DCM:MeOH, 9:1); IR 
(ATR): 3199 (br), 1674 (w), 1145 (m), 1065 (s), 611 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz):   
δ = 8.45 (s, 1H, CH), 8.03 (d, J = 8.6 Hz, 2H, CH), 7.81 (d, J = 8.6 Hz, 2H, CH), 5.21 (br s, 2H, 
NH2), 3.15–2.96 (m, 4H, CH2), 2.54–2.42 (m, 4H, CH2), 2.27 (s, 3H, CH3); 
13
C NMR (CDCl3, 
75.5 MHz): δ = 151.9 (1C, CNH2), 147.6 (1C, C), 140.1 (1C, C), 138.6 (1C, CH), 133.4 (1C, C), 
129.6 (1C, CBr), 128.5 (2C, CH2), 126.1 (2C, CH), 54.1 (2C, CH2), 45.9 (2C, CH2), 45.7 (1C, 
CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C15H19N5O2SBr: 412.0443; found: 412.0436. 
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5-Bromo-3-iodopyrazin-2-amine (265) 
5-Bromopyrazin-2-amine (0.15 g, 0.86 mmol) was dissolved in DMSO   
(1.5 mL) at room temperature. Iodine (0.13 g, 0.52 mmol) was added in one 
portion followed by H5IO6 (0.12 g, 0.52 mmol). The reaction was stirred 
overnight at 60 °C and then quenched slowly with a saturated solution of Na2S2O3 (5 mL). The 
mixture was washed with EtOAc (3   15 mL) and the organic layers were then collected and 
washed with brine (20 mL). The organic layer was dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. Purification was done using column chromatography with 
7:3 EtOAc:Hex as eluent to afford the product as a bright yellow solid (0.13 g, 51% yield).   
Rf = 0.78 (EtOAc:Hex, 7:3); 
1
H NMR (DMSO–D6, 300 MHz): δ = 8.05 (s, 1H, CH), 6.75 (br s, 
2H, NH2); 
13
C NMR (DMSO–D6, 75.5 MHz): δ = 155.8 (1C, CH), 142.7 (1C, CH), 121.3 (1C, 
CH), 102.7 (1C, CH). The spectroscopic data were in agreement with the reported data.
8
  
 
1-(Piperidin-1-yl)prop-2-en-1-one (275) 
Piperidine (0.63 mL, 6.5 mmol) and Et3N (1.8 mL, 13 mmol) were dissolved in 
DCM (7 mL). Acryloyl chloride (1.0 mL, 13 mmol) was dissolved in DCM   
(3 mL) and added dropwise to the solution at 0 °C via a dropping funnel. The 
reaction was then stirred at room temperature for two hours, followed by dilution with DCM  
(20 mL) and washing with brine (2   15 mL). The organic layer was dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. Purification was done using column 
chromatography with EtOAc as eluent to afford the product as a yellow oil (0.6 g, 67% yield).  
Rf = 0.50 (EtOAc); 
1
H NMR (CDCl3, 300 MHz): δ = 6.56 (dd, J = 16.9, 10.6 Hz, 1H, CH),  
6.22 (dd, J = 16.9, 2.0 Hz, 1H, CH), 5.63 (dd, J = 10.6, 2.0 Hz, 1H, CH), 3.59–3.47 (m, 4H, 
CH2), 1.67–1.54 (m, 6H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): δ = 165.5 (1C, CO), 128.2   
(1C, CH), 127.1 (1C, CH), 47.1 (1C, CH2), 43.2 (1C, CH2), 26.7 (1C, CH2), 25.6 (1C, CH2), 24.7 
(1C, CH2). The spectroscopic data were in agreement with the reported data.
9
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1-Morpholinoprop-2-en-1-one (276) 
Morpholine (0.56 mL, 6.4 mmol) and Et3N (1.8 mL, 13 mmol) were dissolved in 
DCM (7 mL). Acryloyl chloride (1.0 mL, 13 mmol) was dissolved in DCM  
(3 mL) and added dropwise to the solution at 0 °C via a dropping funnel. The 
reaction was stirred at room temperature for two hours, followed by dilution with DCM (20 mL) 
and washing with brine (2   15 mL). The organic layer was dried over anhydrous MgSO4, 
filtered and concentrated under reduced pressure. Purification was done using column 
chromatography with EtOAc as eluent to afford the product as a yellow oil (0.75 g, 83% yield). 
Rf = 0.40 (EtOAc); 
1
H NMR (CDCl3, 300 MHz): δ = 6.53 (dd, J = 16.8, 10.4 Hz, 1H, CH), 6.31 
(dd, J = 16.8, 2.0 Hz, 1H, CH), 5.71 (dd, J = 10.4, 2.0 Hz, 1H, CH), 3.69–3.56 (m, 8H, CH2); 
13
C 
NMR (CDCl3, 75.5 MHz): δ = 165.6 (1C, CO), 128.4 (1C, CH), 127.2 (1C, CH), 66.9 (2C, CH2), 
46.3 (1C, CH2), 42.4 (1C, CH2). The spectroscopic data were in agreement with the reported 
data.
9
 
 
1-(Pyrrolidin-1-yl)prop-2-en-1-one (277) 
Pyrrolidine (0.60 mL, 7.2 mmol) and Et3N (2.0 mL, 14 mmol) were dissolved in 
DCM (7 mL). Acryloyl chloride (1.2 mL, 14 mmol) was dissolved in DCM   
(3 mL) and added dropwise to the solution at 0 °C via a dropping funnel. The 
reaction was then stirred at room temperature for two hours, followed by dilution with DCM  
(20 mL) and washing with brine (2   15 mL). The organic layer was dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. Purification was done using column 
chromatography with EtOAc as eluent to afford the product as a dark yellow oil (0.70 g, 77% 
yield). Rf = 0.27 (EtOAc); 
1
H NMR (CDCl3, 300 MHz): δ = 6.45 (dd, J = 16.8, 9.6 Hz, 1H, CH), 
6.35 (dd, J = 16.8, 2.8 Hz, 1H, CH), 5.65 (dd, J = 9.6, 2.8 Hz, 1H, CH), 3.56–3.51 (m, 4H, CH2), 
2.01–1.82 (m, 4H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): δ = 164.6 (1C, CO), 129.0 (1C, CH), 
127.4 (1C, CH), 46.7 (1C, CH2), 46.0 (1C, CH2), 26.3 (1C, CH2), 24.4 (1C, CH2). The 
spectroscopic data were in agreement with the reported data.
9
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N,N-Diethylacrylamide (278) 
Diethylamine (0.81 mL, 7.9 mmol) and Et3N (2.2 mL, 16 mmol) were dissolved 
in DCM (7 mL). Acryloyl chloride (1.3 mL, 16 mmol) was dissolved in DCM 
(3 mL) and added dropwise to the solution at 0 °C via a dropping funnel. The 
reaction was then stirred at room temperature for two hours, followed by dilution with DCM 
(20 mL) and washing with brine (2   15 mL). The organic layer was dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. Purification was done using column 
chromatography with 1:1 Hex:EtOAc as eluent to afford the product as a yellow oil (0.73 g, 73% 
yield). Rf = 0.43 (Hex:EtOAc, 1:1); 
1
H NMR (CDCl3, 300 MHz): δ = 6.50 (dd, J = 16.7, 10.4 Hz, 
1H, CH), 6.29 (dd, J = 16.7, 2.3 Hz, 1H, CH), 5.61 (dd, J = 10.4, 2.3 Hz, 1H, CH), 3.43–3.30  
(m, 4H, CH2), 1.18–1.09 (m, 6H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 165.6 (1C, CO), 
128.0 (1C, CH), 127.5 (1C, CH), 42.2 (1C, CH2), 40.8 (1C, CH2), 14.9 (1C, CH3), 13.1 (1C, 
CH3). The spectroscopic data were in agreement with the reported data.
10
 
 
N-Phenylacrylamide (284)  
Aniline (0.43 mL, 4.8 mmol) was dissolved in DCM (10 mL) and Et3N   
(0.74 mL, 5.2 mmol) was added. The solution was cooled to 0 °C followed by 
the dropwise addition of acryloyl chloride (0.42 mL, 5.2 mmol, dissolved in  
5 mL DCM). The reaction was stirred at 0 °C for three hours and then diluted with DCM   
(15 mL). The solution was washed with brine (15 mL) and the organic layer was dried over 
anhydrous MgSO4, filtered and concentrated under reduced pressure. Purification was done 
using column chromatography with 1:1 Hex:EtOAc as eluent to afford the product as a white 
solid (0.63 g, 89% yield). Rf = 0.63 (Hex:EtOAc, 1:1); 
1
H NMR (CDCl3, 300 MHz): δ = 7.76  
(br s, 1H, NH),7.60–7.58 (m, 2H, CH), 7.34–7.29 (m, 2H, CH), 7.14–7.09 (m, 1H, CH), 6.43 
(dd, J = 16.9, 1.6 Hz, 1H, CH), 6.28 (dd, J = 16.9, 10.0, Hz, 1H, CH), 5.74 (dd, J = 10.0, 1.6 Hz, 
1H, CH). The spectroscopic data were in agreement with the reported data.
11
 
 
N-(Pyridin-3-yl)acrylamide (283) 
3-Aminopyridine (0.50 g, 5.3 mmol) was dissolved in DCM (30 mL) and 
Et3N (1.2 mL, 8.5 mmol) was added. The solution was cooled to –78 °C 
followed by slow dropwise addition of acryloyl chloride (0.50 mL, 6.4 mmol). 
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The reaction was gradually warmed to room temperature over four hours. The black-brown 
solution was concentrated and purified using column chromatography with EtOAc as eluent to 
afford the product as a cream solid (0.43 g, 54% yield). Mp 112–116 °C (neat); Rf = 0.3 
(EtOAc); IR (ATR): 3455 (w), 3015 (br), 2970 (s), 1739 (br), 1552 (m), 1371 (s), 1229 (s) cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.61 (dd, J = 2.6, 0.4 Hz, 1H, NH), 8.36 (dd, J = 4.8, 1.5 Hz, 
1H, CH), 8.32–8.23 (m, 1H, CH), 8.17–8.09 (m, 1H, CH), 7.29 (dd, J = 8.4, 4.8 Hz, 1H, CH), 
6.47 (dd, J = 16.9, 1.5 Hz, 1H, CH), 6.30 (dd, J = 16.9, 10.1 Hz, 1H, CH), 5.81 (dd, J = 10.1,1.5 
Hz, 1H). The spectroscopic data were in agreement with the reported data.
12
 
 
N-Cyclohexylacrylamide (282) 
Cyclohexylamine (1.1 mL, 9.8 mmol) and Et3N (5.5 mL, 39 mmol) were 
dissolved in DCM (18 mL) and precooled to –78 °C. Acryloyl chloride   
(3.2 mL, 39 mmol) was dissolved in DCM (3 mL) and added dropwise over 
five minutes. The reaction was stirred overnight at room temperature and then quenched with 
H2O (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. After purification using column chromatography with 1:1 
Hex:EtOAc as eluent, the product was obtained as an off-white solid (0.64 g, 43% yield).    
Rf = 0.43 (Hex:EtOAc, 1:1); 
1
H NMR (CDCl3, 300 MHz): δ = 6.26 (dd, J = 16.9, 1.6 Hz, 1H, 
CH), 6.05 (dd, J = 16.9, 10.2 Hz, 1H, CH), 5.61 (dd, J = 16.9, 1.6 Hz, 1H, CH), 5.44–5.33   
(br s, 1H, NH), 3.92–3.79 (m, 1H, CH), 1.98–1.93 (m, 2H, CH), 1.75–1.60 (m, 3H, CH),   
1.46–1.32 (m, 2H, CH), 1.26–1.09 (m, 3H, CH); 13C NMR (CDCl3, 75.5 MHz): δ = 172.3   
(1C, CO), 131.4 (1C, CH), 126.2 (1C, CH2), 48.4 (1C, CH), 33.3 (2C, CH2), 25.7 (1C, CH2), 
25.0 (2C, CH2). The spectroscopic data were in agreement with the reported data.
13
 
 
Nicotinaldehyde (286) 
2-Pyridinemethanol (0.30 mL, 3.0 mmol) was added to THF (15 mL) at 0 °C. 
Manganese dioxide (1.3 g, 15 mmol) was added portion-wise and the reaction was 
stirred at room temperature overnight. The black mixture was filtered through celite 
and washed with brine (10 mL). The organic layer was dried over anhydrous MgSO4, filtered 
and concentrated under reduced pressure. The crude solution was purified using column 
chromatography with EtOAc to 93:7 EtOAc:MeOH as eluent to afford the product as a 
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colourless oil (0.20 g, 60% yield). Rf = 0.67 (EtOAc:MeOH, 9:1); 
1
H NMR (CDCl3, 300 MHz): 
δ = 10.13 (s, 1H, CH), 9.09 (dd, J = 2.1, 0.7, Hz, 1H, CH), 8.85 (dd, J = 4.9, 1.8 Hz, 1H, CH), 
8.19 (app. dt, ddd, J = 5.9, 2.1, 2.1 Hz, 1H, CH), 7.52–7.48 (m, 1H, CH). The spectroscopic data 
were in agreement with the reported data.
14
 
 
1-(Pyridin-3-yl)prop-2-en-1-ol (287) 
Nicotinaldehyde (0.050 g, 0.46 mmol) was added to THF (2 mL) at 0 °C. Vinyl 
MgBr (1.0 M, 0.90 mL, 0.93 mmol) was added dropwise. The reaction was 
gradually warmed to room temperature in three hours, followed by quenching 
with a saturated solution of NH4Cl (2 mL). The yellow mixture was extracted with EtOAc   
(2   10 mL) and the organic layers were collected and washed with brine (10 mL). The organic 
layer was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The 
crude oil was purified using column chromatography with EtOAc as eluent to afford the product 
as a yellow oil in 98% yield. Rf = 0.2 (EtOAc:Hex, 7:3); 
1
H NMR (CDCl3, 300 MHz): δ = 8.60 
(d, J = 2.2 Hz, 1H, CH), 8.53 (dd, J = 4.8, 1.8 Hz, 1H, CH), 7.72 (app. dt, ddd, J = 6.0, 1.8, 1.8 
Hz, 1H, CH), 7.29 (ddd, J = 7.9, 4.8, 0.8 Hz, 1H, CH), 6.04 (ddd, J = 17.0, 10.3, 6.0 Hz, 1H, 
CH), 5.42–5.36 (m, 1H, CH), 5.29–5.24 (m, 2H, CH). The spectroscopic data were in agreement 
with the reported data.
15
 
 
General procedure for the Heck reaction: 
Aminopyrazine 265 (1.0 eq.), propenone (1.2 eq.), Et3N (4.0 eq.), Pd(OAc)2 (0.1 eq.) and DMF 
(1 mL) were charged to a Schlenk tube. The solution was degassed, filled with N2 and then 
stirred at 70 °C overnight. The black-brown solution was diluted with EtOAc and filtered 
through celite. The organic layer was then washed with brine (2   20 mL), dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. Purification was done using column 
chromatography with an appropriate solvent system as eluent to afford the corresponding 
product. 
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(E)-3-(3-Amino-6-bromopyrazin-2-yl)-1-(piperidine-1-yl)prop-2-en-1-one (289) 
Solvent system: 7:3 EtOAc:Hex. Yellow solid (0.040 g, 56% yield). Mp 
128–130 °C (neat); Rf = 0.25 (EtOAc:Hex, 7:3); IR (ATR): 3319 (m), 
3174 (m), 2937 (m), 2851 (m), 1629 (m), 1588 (s), 1437 (s) cm
–1
;   
1
H NMR (CDCl3, 300 MHz): δ = 8.04 (s, 1H, CH), 7.61 (d, J = 14.5 Hz, 
1H, CH), 7.51 (d, J = 14.5 Hz, 1H, CH), 5.10 (br s, 2H, NH2), 3.67–3.60 (m, 4H, CH2),   
1.63–1.58 (m, 6H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): δ = 164.6 (1C, CO), 152.0 (1C, CNH2), 
145.0 (1C, CH), 134.8 (1C, C), 133.0 (1C, CH), 127.2 (1C, CBr), 124.2 (1C, CH), 47.3    
(1C, CH2), 43.7 (1C, CH2), 27.0 (1C, CH2), 25.8 (1C, CH2), 24.7 (1C, CH2); HRMS–ES+: m/z 
[M+H]
+
 calcd for C12H16N4OBr: 311.0507; found: 311.0502. 
 
(E)-3-(3-Amino-6-bromopyrazin-2-yl)-1-morpholinoprop-2-en-1-one (290) 
Solvent system: 7:3 EtOAc:Hex. Bright yellow solid (0.038 g, 53% 
yield). Mp 174–176 °C (neat); Rf = 0.26 (EtOAc:Hex, 7:3); IR (ATR): 
3371 (m), 3333 (m), 3208 (m), 1438 (s), 1112 (s), 1041 (m) cm
–1
;   
1
H NMR (CDCl3, 300 MHz): δ = 8.07 (s, 1H, CH), 7.63 (d, J = 14.5 Hz, 
1H, CH), 7.47 (d, J = 14.5 Hz, 1H, CH), 5.04 (br s, 2H, NH2), 3.73 (m, 8H, CH2); 
13
C NMR 
(CDCl3, 75.5 MHz): δ = 164.8 (1C, CO), 152.0 (1C, CNH2), 145.5 (1C, CH), 134.2 (1C, C), 
133.7 (1C, CH), 127.3 (1C, CBr), 123.0 (1C, CH), 67.0 (2C, CH2), 46.5 (1C, CH2), 42.8 (1C, 
CH2); HRMS–ES+: m/z [M+H]
+
 calcd for C11H14N4O2Br: 313.0300; found: 313.0301. 
 
(E)-3-(3-Amino-6-bromopyrazin-2-yl)-1-(pyrrolidin-1-yl)prop-2-en-1-one (291) 
Solvent system: 95:5 DCM:MeOH. Yellow solid (0.037 g, 38% yield). 
Mp 126–128 °C (neat); Rf = 0.32 (DCM:MeOH, 9:1); IR (ATR): 3457 
(m), 3308 (m), 3197 (m), 2922 (m), 2850 (m), 1633 (m), 1582 (s), 1426 
(s), 1380 (s), 1114 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.02  
(s, 1H, CH), 7.79 (d, J = 14.7 Hz, 1H, CH), 7.31 (d, J = 14.7 Hz, 1H, CH), 5.46 (br s, 2H, NH2), 
3.73–3.66 (m, 2H, CH2), 3.57–3.53 (m, 2H, CH2), 2.02–1.87 (m, 4H, CH2); 
13
C NMR   
(CDCl3, 75.5 MHz): δ = 164.2 (1C, CO), 152.3 (1C, CNH2), 145.1 (1C, CH), 134.6 (1C, C), 
132.8 (1C, CH), 126.8 (1C, CBr), 125.1 (1C, CH), 47.0 (1C, CH2), 46.4 (1C, CH2), 26.2   
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(1C, CH2), 24.4 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd for C11H14N4OBr: 297.0351; found: 
297.0362.  
 
(E)-3-(3-Amino-6-bromopyrazin-2-yl)-N,N-diethylacrylamide (292) 
Solvent system: 1:1 Hex:EtOAc. Yellow solid (0.074 g, 75% yield). Mp 
126–128 °C (neat); Rf = 0.75 (EtOAc:MeOH, 95:5); IR (ATR): 3345 (s), 
3187 (s), 2970 (s), 1736 (s), 1599 (s), 1442 (s), 1214 (s), 1126 (s) cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.02 (s, 1H), 7.69 (d, J = 14.5 Hz, 1H), 
7.39 (d, J = 14.5 Hz, 1H), 5.32 (s, 2H), 3.53–3.43 (m, 4H), 1.20 (dt, J = 28.8, 7.14 Hz, 6H);  
13
C NMR (CDCl3, 75.5 MHz): δ = 165.3 (1C, CO), 152.2 (1C, CNH2), 145.0 (1C, CH), 134.7 
(1C, C), 133.3 (1C, CH), 127.0 (1C, CBr), 124.2 (1C, CH), 42.6 (1C, CH2), 41.3 (1C, CH2), 15.3 
(1C, CH3), 13.2 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C11H16N4OBr: 299.0507; found: 
299.0501. 
 
(E)-3-(3-Amino-6-bromopyrazin-2-yl)-N-cyclohexylacrylamide (293) 
Solvent system: 7:3 EtOAc:Hex. Bright yellow solid (0.038 g, 53% yield). 
Mp 169–171 °C (neat); Rf = 0.5 (EtOAc:Hex, 7:3); IR (ATR): 3415 (w), 
3269 (m), 3169 (m), 1646 (m), 1544 (s), 1445 (s), 1341 (m), 958 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.05 (s, 1H, CH), 7.58 (d, J = 14.6 Hz, 
1H, CH), 6.96 (d, J = 14.6 Hz, 1H, CH), 5.67 (br s, 1H, NH), 5.06 (br s, 2H, NH2), 3.94–3.82 (m, 
1H, CH), 1.98–1.93 (m, 2H, CH2), 1.79–1.59 (m, 4H, CH2), 1.46–1.32 (m, 2H, CH2), 1.28–1.12 
(m, 2H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): δ = 164.1 (1C, CO), 152.0 (1C, CNH2), 145.2  
(1C, CH), 134.3 (1C, C), 131.5 (1C, CH), 127.8 (1C, CBr), 127.3 (1C, CH), 48.7 (1C, CH), 33.2 
(2C, CH2), 25.6 (2C, CH2), 24.9 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd for C13H18N4OBr: 
325.0664; found: 325.0651. 
 
(E)-3-(3-Amino-6-bromopyrazine-2-yl)-N-(pyridin-3-yl)acrylamide (294) 
Solvent system: EtOAc. Yellow solid (0.033 g, 33% yield). Mp 208 °C 
(neat); Rf = 0.5 (EtOAc); IR (ATR): 3647 (w), 3337 (m), 3186 (s), 2858 
(w), 1428 (s), 1119 (m) cm
–1
; 
1
H NMR (DMSO–D6, 300 MHz): δ = 10.6 
(s, 1H, NH), 8.86 (s, 1H, CH), 8.29–8.14 (m, 3H, CH), 7.81 (d, J = 14.8 
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Hz, 1H, CH), 7.40–7.35 (m, 1H, CH), 7.22 (d, J = 14.8 Hz, 1H, CH), 7.05 (s, 2H, NH2);    
13
C NMR (DMSO–D6, 75.5 MHz): δ = 163.5 (1C, CO), 153.5 (1C, CNH2), 145.6 (1C, CH), 
144.4 (1C, C), 140.8 (1C, CH), 136.0 (1C, C), 133.2 (1C, CH), 132.6 (1C, CH), 126.3 (1C, CBr), 
126.0 (1C, CH), 124.1 (1C, CH), 123.8 (1C, CH) ; HRMS–ES+: m/z [M+H]+ calcd for 
C12H11N5OBr: 320.0147; found: 320.0144. 
 
General method for the Suzuki coupling: 
The heteroaryl Br (1.0 eq.), boronic acid 243 (1.5 eq.), Cs2CO3 (4.0 eq.) and the solvent system 
Tol:EtOH:H2O (1.5 mL, 4:1:0.05) were added to a Schlenk tube. The reaction content was 
degassed using the freeze-pump-thaw technique. Pd(dppf)Cl2 (0.1 eq.) was then added to the 
Schlenk tube under argon and the solution was stirred at 70 °C overnight. Silica was added to the 
black mixture and transferred to the column. Purification was done using column 
chromatography with EtOAc to 9:1 EtOAc:MeOH as eluent to afford the corresponding product 
as a solid. 
 
(E)-3-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-1-(piperidin-
1-yl)prop-2-en-1-one (216) 
Yellow solid (0.056 g, 73% yield). Mp 134–136 °C (neat); Rf = 0.13 
(EtOAc:MeOH, 9:1); IR (ATR): 3367 (br), 2939 (m), 2856 (m), 2803 
(m), 1738 (m), 1638 (m), 1590 (s), 1444 (s), 1347 (s), 1284 (s) cm
–1
;  
1
H NMR (CDCl3, 300 MHz): δ = 8.48 (s, 1H, CH), 8.07 (d, J = 8.6 Hz, 
2H, CH), 7.83 (d, J = 8.6 Hz, 2H, CH), 7.77 (d, J = 14.7 Hz, 1H, CH), 
7.63 (d, J = 14.7 Hz, 1H, CH), 5.30 (br s, 2H, NH2), 3.73–3.62 (m, 4H, 
CH2), 3.17–3.03 (m, 4H, CH2), 2.53–2.42 (m, 4H, CH2), 2.26 (s, 3H, 
CH3), 1.75–1.57 (m, 6H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): δ = 164.9 
(1C, CO), 152.5 (1C, CNH2), 141.5 (1C, C), 140.8 (1C, CH), 140.7 (1C, C), 134.7 (1C, C), 134.0 
(1C, CH), 133.9 (1C, C), 128.5 (2C, CH), 126.2 (2C, CH), 123.9 (1C, CH), 54.2 (2C, CH2), 47.3 
(1C, CH2), 46.1 (2C, CH2), 45.8 (1C, CH3), 43.7 (1C, CH2), 27.0 (1C, CH2), 25.8 (1C, CH2), 
24.7 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd for C23H31N6O3S: 471.2178; found: 471.2177. 
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(E)-3-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-1-
morpholinoprop-2-en-1-one (217) 
Dark yellow solid (0.052 g, 69% yield). Mp 136–140 °C (neat);   
Rf = 0.15 (EtOAc:MeOH, 9:1); IR (ATR): 3391 (br), 1638 (m), 1608 
(m), 1434 (m), 1344 (s), 1280 (s), 1214 (m), 1156 (s), 956 (m) cm
–1
; 
1
H 
NMR (CDCl3, 300 MHz): δ = 8.49 (s, 1H, CH), 8.05 (d, J = 8.4 Hz, 2H, 
CH), 7.82 (d, J = 8.4 Hz, 2H, CH), 7.78 (d, J = 14.5 Hz, 1H, CH), 7.59 
(d, J = 14.5 Hz, 1H, CH), 5.18 (br s, 2H, NH2), 3.76 (m, 8H, CH2), 3.07 
(m, 4H, CH2), 2.49 (m, 4H, CH2), 2.26 (s, 3H, CH3); 
13
C NMR (CDCl3, 
75.5 MHz): δ = 165.1 (1C, CO), 152.5 (1C, CNH2), 141.4 (1C, C), 
141.2 (1C, CH), 141.0 (1C, C), 134.9 (1C, C), 134.8 (1C, CH), 133.4 (1C, C), 128.5 (2C, CH), 
126.3 (2C, CH), 122.6 (1C, CH), 67.0 (2C, CH2), 54.2 (2C, CH2), 46.5 (1C, CH2), 46.1 (2C, 
CH2), 45.8 (1C, CH3), 42.8 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd for C22H29N6O4S: 
473.1971; found: 473.1974.  
 
(E)-3-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-1-(pyrrolidin-
1-yl)prop-2-en-1-one (218) 
Dark cream solid (0.032 g, 70% yield). Mp 131–132 °C (neat); Rf = 0.22 
(EtOAc:MeOH, 9:1); IR (ATR): 3354 (br), 2919 (m), 2802 (m), 1643 (m), 
1593 (s), 1437 (s), 1172 (s), 1154 (s) cm
–1
; 
1
H NMR (CDCl3, 300 MHz):  
δ = 8.51 (s, 1H, CH), 8.09 (d, J = 8.6 Hz, 2H, CH), 7.86–7.80 (m, 3H, 
CH), 7.48 (d, J = 14.6 Hz, 1H, CH), 5.27 (s, 2H, NH2), 3.76 (t, J = 6.7 Hz, 
2H, CH2), 3.64 (t, J = 6.7 Hz, 2H, CH2), 3.14–3.05 (m, 4H, CH2),   
2.53–2.49 (m, 4H, CH2), 2.28 (s, 3H, CH3), 2.11–1.91 (m, 4H, CH2);  
13
C NMR (CDCl3, 75.5 MHz): δ = 164.3 (1C, CO), 152.6 (1C, CNH2), 
141.5 (1C, C), 140.9 (1C, CH), 140.7 (1C, C), 134.7 (1C, C), 133.7  
(1C, CH), 133.5 (1C, C), 128.5 (2C, CH), 126.2 (2C, CH), 125.0 (1C, CH), 54.2 (2C, CH2), 47.0 
(1C, CH2), 46.4 (1C, CH2), 46.1 (2C, CH2), 45.9 (1C, CH3), 26.2 (1C, CH2), 24.5 (1C, CH2); 
HRMS–ES+: m/z [M+H]+ calcd for C22H29N6O3S: 457.2022; found: 457.2019. 
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(E)-3-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-N,N-
diethylacrylamide (219) 
Dark cream solid (0.048 g, 78% yield). Mp 126–128 °C (neat);    
Rf = 0.30 (EtOAc:MeOH, 9:1); IR (ATR): 3336 (br), 2927 (m), 1639 
(m), 1594 (s), 1456 (s), 1286 (s), 1169 (s), 947 (m) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.47 (s, 1H), 8.06 (d, J = 8.5 Hz, 2H),  
7.87–7.80 (m, 3H), 7.55 (d, J = 14.6 Hz, 1H), 5.35 (br s, 2H),  
3.57–3.49 (m, 4H), 3.13–3.00 (m, 4H), 2.51–2.47 (m, 4H), 2.26 (s, 3H), 
1.30 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H); 
13
C NMR (CDCl3, 
75.5 MHz): δ = 165.4 (1C, CO), 152.6 (1C, CNH2), 141.5 (1C, C), 
140.8 (1C, CH), 140.5 (1C, C), 134.6 (1C, C), 134.3 (1C, CH), 133.8 
(1C, C), 128.5 (2C, CH), 126.1 (2C, CH), 123.9 (1C, CH), 54.2 (2C, CH2), 46.1 (2C, CH2), 45.8 
(1C, CH3), 42.7 (1C, CH2), 41.4 (1C, CH2), 15.3 (1C, CH3), 13.3 (1C, CH3); HRMS–ES++: m/z 
[M+H]
+
 calcd for C22H31N6O3S: 459.2178; found: 459.2174. 
 
(E)-3-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-N-
cyclohexylacrylamide (220) 
Yellow solid (0.045 g, 75% yield). Mp 160–163 °C (neat); Rf = 0.26 
(EtOAc:MeOH, 9:1); IR (ATR): 3336 (br), 3207 (br), 2923 (s), 2851 (s), 
1654 (m), 1456 (s), 1345 (m), 1166 (s), 942 (m) cm
–1
; 
1
H NMR (CDCl3, 
300 MHz): δ = 8.45 (s, 1H, CH), 8.04 (d, J = 8.4 Hz, 2H, CH), 7.80–7.73 
(m, 3H, CH), 7.13 (d, J = 14.7 Hz, 1H, CH), 6.00 (d, J = 8.4 Hz, 1H, NH), 
5.32 (br s, 2H, NH2), 3.98–3.84 (m, 1H, CH), 3.12–3.01 (m, 4H, CH2), 
2.49–2.45 (m, 4H, CH2), 2.25 (s, 3H, CH3), 2.03–1.93 (m, 2H, CH2),  
1.80–1.69 (m, 2H, CH2), 1.67–1.59 (m, 1H, CH2), 1.47–1.13 (m, 5H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): δ = 164.5 (1C, CO), 152.6 (1C, CNH2), 
141.4 (1C, C), 140.8 (1C, CH), 140.5 (1C, C), 134.6 (1C, C), 133.4 (1C, CH), 132.6 (1C, C), 
128.4 (2C, CH), 127.4 (1C, CH), 126.1 (2C, CH), 54.1 (2C, CH2), 48.8 (1C, CH), 46.0 (2C, 
CH2), 45.8 (1C, CH3), 32.2 (2C, CH2), 25.6 (2C, CH2), 25.0 (1C, CH2); HRMS–ES+: m/z 
[M+H]
+
 calcd for C24H33N6O3S: 485.2335; found: 485.2336.  
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8.3 Chapter 4 
3-Amino-6-bromopyrazine-2-carboxylic acid (300) 
LiOH (0.35 g, 14 mmol) dissolved in H2O (6 mL) was added slowly to a 
solution of bromine ester 305 (0.63 g, 2.7 mmol) and MeOH (6 mL) at room 
temperature. The dark orange solution was heated to 90 °C for two hours before 
the reaction was quenched with concentrated HCl (pH<2) at 0 °C. The white 
slurry was basified with a saturated solution of NaHCO3 and extracted with EtOAc (20 mL). The 
aqueous layer was concentrated to about 15 mL and left to crystallise at room temperature to 
afford the product as yellow needles (0.39 g, 66% yield). Rf = 0.1 (DCM:MeOH, 95:5); 
1
H NMR 
(DMSO–D6, 600 MHz): δ = 8.05 (s, 1H, CH); 
13
C NMR (DMSO–D6, 150 MHz): δ = 167.2 (1C, 
CO), 155.2 (1C, CNH2), 144.9 (1C, CH), 134.2 (1C, C), 121.9 (1C, CBr). The spectroscopic data 
were in agreement with the reported data.
16
  
 
Methyl-3-aminopyrazine-2-carboxylate (301) 
Concentrated H2SO4 (0.70 mL, 13 mmol) was added dropwise to a solution of   
3-aminopyrazine-2-carboxylic acid (0.70 g, 5.0 mmol) and MeOH (7 mL) at 0 °C. 
The white slurry was left to stir at room temperature for three days and the dark 
brown solution was neutralised with a saturated solution of NaHCO3 at 0 °C. The product was 
extracted with DCM (3   30 mL) and the combined organic layers were washed with brine, 
dried over anhydrous MgSO4, filtered and then concentrated under reduced pressure. The crude 
material was recrystallised using H2O to afford the product as an orange solid (0.56 g, 72% 
yield). Rf = 0.7 (DCM:MeOH, 9:1); 
1
H NMR (DMSO–D6, 600 MHz): δ = 8.25 (d, J = 2.2 Hz, 
2H, CH), 7.90 (d, J = 2.2 Hz, 2H, CH), 7.31 (br s, 2H, NH2), 3.85 (s, 3H, CH3); 
13
C NMR 
(DMSO–D6, 150 MHz): δ = 166.4 (1C, CO), 155.8 (1C, CNH2), 147.7 (1C, CH), 132.5 (1C, 
CH), 123.2 (1C, C), 52.0 (1C, CH3O). The spectroscopic data were in agreement with the 
reported data.
17
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Methyl-3-amino-6-bromopyrazine-2-carboxylate (302) 
Aminopyrazine ester 301 (0.47 g, 3.1 mmol) was dissolved in CH3CN (6 mL) 
and cooled to 0 °C. NBS (0.60 g, 3.4 mmol), dissolved in DMF (1 mL), was 
then added dropwise to the solution and the reaction was allowed to stir 
overnight at room temperature. The dark brown solution was concentrated, 
diluted with EtOAc (20 mL) and washed with ice water (50 mL). The aqueous layer was washed 
with EtOAc (2   30 mL) and the combined organic layers were then washed with brine (20 mL). 
The organic layer was dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. Purification using column chromatography with DCM as eluent afforded the product as 
a light orange solid (0.52 g, 73% yield). Rf = 0.20 (DCM); 
1
H NMR (CDCl3, 300 MHz): δ = 8.42 
(s, 1H, CH), 7.54 (br s, 2H, NH2), 3.85 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 166.2 
(1C, CO), 154.9 (1C, CNH2), 150.4 (1C, CH), 125.0 (1C, C), 123.6 (1C, CBr), 53.1 (1C, CH3). 
The spectroscopic data were in agreement with the reported data.
18 
 
3-Amino-6-bromo-N-butylpyrazine-2-carboxamide (306)  
3-Amino-6-bromopyrazine-2-carboxylic acid 300 (0.025 g, 0.11 mmol) 
was added to DCM (1.5 mL) at room temperature under argon. Thionyl 
chloride (0.030 mL, 0.41 mmol) was added dropwise and the 
suspension was heated at 50 °C for two hours. The dark yellow 
suspension was evaporated under argon and DCM (1 mL) was added. A mixture of butylamine 
(0.015 mL, 0.14 mmol) and Et3N (0.030 mL, 0.22 mmol) was added dropwise at 0 °C and the 
suspension was stirred overnight at room temperature. The suspension cleared over time and the 
orange solution was concentrated under reduced pressure and diluted with EtOAc (10 mL) and 
water (10 mL). The aqueous layer was extracted with EtOAc (2   10 mL) and the combined 
organic layers were dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. Purification using column chromatography with DCM as eluent afforded the product as 
a cream solid in 45% yield. Rf = 0.17 (DCM); 
1
H NMR (CDCl3, 600 MHz): δ = 8.20 (s, 1H), 
7.66 (s, 1H), 3.43–3.39 (m, 2H), 1.63–1.57 (m, 2H), 1.43–1.37 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 
No further spectroscopic analysis was carried out.  
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3-Amino-N-methoxy-N-methylpyrazine-2-carboxamide (310) 
3-Aminopyrazine-2-carboxylic acid 299 (0.50 g, 3.6 mmol) was dissolved in 
DMF (5 mL) at 60 °C. Carbonyldiimidazole (0.70 g, 4.3 mmol) was added to the 
solution in one portion and the reaction was left to stir at 60 °C for three hours. 
N,O-Dimethylhydroxylamine (0.42 g, 4.3 mmol) was then added in one portion and the dark 
orange solution was left to stir further for 16 hours. The reaction mixture was concentrated by 
heating the solution overnight at 60 °C in open air. The dark brown slurry was transferred to the 
column and purified using DCM as eluent to remove impurities before eluting the product with 
95:5 DCM:MeOH. The product was obtained as a white-yellow solid (0.62 g, 94% yield).   
Mp 91–92 °C (neat); Rf = 0.33 (DCM:MeOH, 95:5); IR (ATR): 3466 (m), 3292 (m), 3157 (m), 
2920 (m), 1606 (s), 1463 (m), 1434 (m), 1385 (m), 983 (m), 830 (m) cm
–1
; 
1
H NMR (CDCl3, 300 
MHz): δ = 8.03 (d, J = 2.5 Hz, 1H, CH), 7.84 (d, J = 2.5 Hz, 1H, CH), 5.94 (br s, 2H, NH2), 3.79 
(s, 3H, CH3), 3.41 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 154.6 (1C, CO), 144.8 (1C, 
CH), 132.0 (1C, CH), 61.5 (1C, CH3). The spectroscopic data were in agreement with the 
reported data.
19
  
3-Amino-6-bromo-N-methoxy-N-methylpyrazine-2-carboxamide (311) 
Weinreb ester 310 (0.20 g, 1.1 mmol) was dissolved in CHCl3 (5 mL) at 0 °C. 
NBS (0.22 g, 1.2 mmol) was then added portion wise and the yellow solution 
was left to stir at 40 °C overnight. The brown solution was concentrated and 
purified using column chromatography with 7:3 Hex:EtOAc as eluent to 
afford the product as a white yellow solid (0.26 g, 90% yield). Mp 78–80 °C (neat); Rf = 0.5 (1:1, 
Hex:EtOAc); IR (ATR): 3401 (s), 3313 (m), 3174 (s), 2976 (m), 1622 (vs), 1449 (s), 1373 (m), 
1199 (m), 983 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.14 (s, 1H, CH), 6.03 (br s, 2H, 
NH2), 3.85 (s, 3H, CH3), 3.40 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 153.9 (1C, CO), 
147.3 (1C, CH), 123.3 (1C, C), 61.8 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for 
C7H10N4O2Br: 260.9987; found: 260.9992. 
 
1-(3-Amino-6-bromopyrazin-2-yl)prop-2-yn-1-one (297) 
Weinreb 311 (0.10 g, 0.38 mmol) was dissolved in THF (3 mL) at 0 °C and 
ethynyl MgBr (0.50 M, 2.3 mL, 1.1 mmol,) was then added dropwise. The 
dark orange-yellow solution was stirred for one hour at 0 °C, followed by one 
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hour at room temperature. The orange suspension was cooled to –10 °C, quenched with 2 M HCl 
(4 mL) and then extracted with EtOAc (3   10 mL). The combined organic layers were dried 
over anhydrous MgSO4, filtered and concentrated under reduced pressure. Purification was done 
using column chromatography with 8:2 Hex:EtOAc as eluent to afford the fluorescent product as 
a bright orange solid (0.075 g, 86% yield). Mp 144 °C (neat); Rf = 0.71 (Hex:EtOAc, 1:1); IR 
(ATR): 3396 (s), 3265 (m), 3140 (br), 2100 (m), 1616 (s), 1126 (s), 999 (s) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.32 (s, 1H, CH), 5.76 (br s, 2H, NH2), 3.62 (s, 1H, CH); 
13
C NMR 
(CDCl3, 75.5 MHz): δ = 178.0 (1C, CO), 154.0 (1C, CNH2), 151.6 (1C, CH), 129.7 (1C, C), 
125.6 (1C, CBr), 84.7 (1C, CH), 80.3 (1C, C); HRMS–ES+: m/z [M+H]+ calcd for C7H5N3OBr: 
225.9616; found: 225.9615.  
 
1-(3-Amino-6-bromopyrazin-2-yl)ethanone (298)  
Weinreb 311 (0.50 g, 1.9 mmol) was dissolved in THF (6 mL) at 0 °C and methyl 
MgBr (3.0 M, 1.9 mL, 5.7 mmol,) was then added dropwise. The red-brown 
solution was stirred for one hour at 0 °C, followed by one hour at room 
temperature. The brown solution was cooled to –10 °C, quenched with 2M HCl (5 
mL) and then extracted with EtOAc (3   15 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered and concentrated under reduced pressure. Purification was done 
using column chromatography with 9:1 Hex:EtOAc as eluent to afford the product as a bright 
yellow solid in 83% yield. Mp 149–151 °C (neat); Rf = 0.74 (Hex:EtOAc, 7:3); IR (ATR): 3410 
(s), 3306 (s), 3190 (m), 1656 (s), 1613 (m), 1595 (m), 1131 (m) cm
–1
; 
1
H NMR (CDCl3, 300 
MHz): δ = 8.26 (s, 1H, CH), 2.66 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 201.7 (1C, 
CO), 153.4 (1C, CNH2), 150.6 (1C, CH), 129.6 (1C, C), 124.2 (1C, CBr), 26.4 (1C, CH3); 
HRMS–ES+: m/z [M+H]+ calcd for C6H7N3OBr: 215.9772; found: 215.9765. 
 
General method for the Michael addition:  
Ethynyl pyrazine 297 (1.0 eq.) was dissolved in DCM at 0 °C and the required secondary amine 
(1.3 eq.) was added dropwise. The deep orange solution was left to stir for two hours at room 
temperature and then directly transferred to a column. Purification was done with a suitable 
solvent system to afford the corresponding product. 
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(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-morpholinoprop-2-en-1-one (312)  
Solvent system: DCM to 95:5 DCM:MeOH. Yellow solid (0.13 g, 93% 
yield). Mp 160–161 °C (neat); Rf  = 0.47 (DCM:MeOH, 95:5); IR 
(ATR): 3353 (m), 3258 (m), 3163 (m), 2919 (m), 2851 (m), 1604 (m), 
1559 (s), 1109 (m), 815 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz):    
δ = 8.15 (s, 1H, CH), 7.71 (d, J = 12.9 Hz, 1H, CH), 6.55 (d, J = 12.9 Hz, 1H, CH), 3.78–3.75 
(m, 4H, CH2), 3.48–3.45 (m, 4H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): δ = 188.3 (1C, CO), 
154.1 (1C, CNH2), 152.7 (1C, CH), 148.2 (1C, CH), 131.8 (1C, C), 123.7 (1C, CBr), 91.8   
(1C, CH), 66.5 (2C, CH2), 53.0 (1C, CH2), 46.3 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd for 
C11H14N2O2Br: 313.0300; found: 315.0295. 
 
(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(piperidin-1-yl)prop-2-en-1-one (317)  
Solvent system: EtOAc. Deep orange solid (0.085 g, 89% yield). Mp 
156–158 °C (neat); Rf = 0.64 (EtOAc); IR (ATR): 3343 (m), 2925 (m), 
2853 (m), 1620 (m), 1550 (m), 1139 (m), 811 (m) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.12 (s, 1H, CH), 7.76 (d, J = 12.8 Hz, 1H, 
CH), 6.48 (d, J = 12.8 Hz, 1H, CH), 3.47–3.38 (m, 4H, CH2), 1.75–1.63 (m, 6H, CH2); 
13
C NMR 
(CDCl3, 75.5 MHz): δ = 187.8 (1C, CO), 154.1 (1C, CNH2), 153.1 (1C, CH), 147.7 (1C, CH), 
132.4 (1C, C), 123.6 (1C, CBr), 90.7 (1C, CH), 55.5 (1C, CH2), 46.8 (1C, CH2), 26.7 (1C, CH2), 
25.2 (1C, CH2), 24.1 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd for C12H16N4OBr: 311.0507; 
found: 311.0502. 
 
(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(pyrrolidin-1-yl)prop-2-en-1-one (318)  
Solvent system: 7:3 EtOAc:Hex. Orange-yellow solid (0.080 g, 85% 
yield). Mp 168–171 °C (neat); Rf = 0.53 (EtOAc:Hex, 7:3); IR (ATR): 
3347 (m), 3251 (m), 3161 (m), 2968 (m), 2864 (m), 1545 (s), 1508 (m), 
1452 (m), 1255 (m), 1028 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz):    
δ = 8.12 (s, 1H, CH), 7.99 (d, J = 12.7 Hz, 1H, CH), 6.34 (d, J = 12.7 Hz, 1H, CH), 3.58    
(t, J = 6.6 Hz, 2H, CH2), 3.37 (t, J = 6.9 Hz, 2H, CH2), 2.09–1.88 (m, 4H, CH2); 
13
C NMR 
(CDCl3, 75.5 MHz): δ = 187.3 (1C, CO), 154.1 (1C, CNH2), 150.1 (1C, CH), 147.7 (1C, CH), 
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132.4 (1C, C), 123.6 (1C, CBr), 92.8 (1C, CH), 52.7 (1C, CH2), 47.5 (1C, CH2), 25.4 (1C. CH2), 
25.3 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd for C11H14N4OBr: 297.0351; found: 297.0357. 
 
(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(diethylamino)prop-2-en-1-one (319)  
Solvent system: 1:1 EtOAc:Hex. Light orange solid (0.090 g, 95% 
yield). Mp 146–148 °C (neat); Rf = 0.63 (EtOAc:Hex, 7:3); IR (ATR): 
3395 (m), 3284 (s), 2974 (m), 1623 (m), 1544 (s), 1509 (m), 1260 (m), 
1046 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.12 (s, 1H, CH), 7.80    
(d, J = 12.8 Hz, 1H, CH), 6.44 (d, J = 12.8 Hz, 1H, CH), 3.37 (q, J = 7.2 Hz, 4H, CH2), 1.25  
(t, J = 7.2 Hz, 6H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 187.6 (1C, CO), 154.2 (1C, CNH2), 
152.7 (1C, CH), 147.7 (1C, CH), 132.5 (1C, C), 123.6 (1C, CBr), 91.4 (1C, CH), 50.7 (1C, CH2), 
43.2 (1C, CH2), 14.9 (1C, CH3), 12.0 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for 
C11H16N4OBr: 299.0507; found: 299.0514. 
 
(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(1H-imidazol-1-yl)prop-2-en-1-one (320) 
Solvent system: EtOAc. Orange-white solid (0.050 g, 71% yield). Mp 
188 °C (neat); Rf = 0.44 (EtOAc); IR (ATR): 3450 (m), 3385 (m), 3250 
(m), 3121 (s), 1663 (s), 1490 (vs) cm
–1
; 
1
H NMR (CDCl3, 300 MHz):  
δ = 8.31 (s, 1H, CH), 8.02 (d, J = 14.2 Hz, 1H, CH), 7.88 (br s, 1H, CH), 
7.80 (d, J = 14.2 Hz, 1H, CH), 7.46–7.42 (m, 1H, CH), 7.22–7.19 (m, 1H, CH); 13C NMR 
(CDCl3, 75.5 MHz): δ = 189.3 (1C, CO), 154.4 (1C, CNH2), 151.0 (1C, CH), 138.7 (1C, CH), 
136.2 (1C, C), 132.1 (1C, CH), 129.3 (1C, CH), 124.4 (1C, CBr), 116.8 (1C, CH), 109.5 (1C, 
CH); HRMS–ES+: m/z [M+H]+ calcd for C10H9N5OBr: 293.9990; found: 293.9983.  
 
(Z)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(cyclohexylamino)prop-2-en-1-one (322)  
Ethynyl pyrazine 301 (0.040 g, 0.18 mmol) was dissolved in DCM  
(2 mL) at 0 °C and cyclohexylamine (0.022 mL, 0.19 mmol) was 
added dropwise. The deep orange solution was left to stir for two 
hours at room temperature and then directly transferred to a column. 
Purification was done with 1:1 Hex:EtOAc as solvent system to afford the product as a cream 
solid (0.054 g, 93% yield). Rf = 0.65 (Hex:EtOAc, 7:3); 
1
H NMR (CDCl3, 300 MHz): δ = 10.19 
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(br s, 1H, NH), 8.11 (s, 1H, CH), 7.06 (dd, J = 13.2, 7.6, Hz, 1H, CH), 6.31 (d, J = 7.6 Hz, 1H, 
CH), 3.23–3.09 (m, 1H, CH), 2.03–1.92 (m, 2H, CH2), 1.85–1.74 (m, 2H, CH2), 1.66–1.55   
(m, 2H, CH2), 1.48–1.29 (m, 4H, CH2);
 13
C NMR (CDCl3, 75.5MHz): δ = 188.4 (1C, CO), 153.8 
(1C, CNH2), 153.0 (1C, CH), 147.5 (1C, CH), 132.3 (1C, C), 124.0 (1C, CBr), 90.4 (1C, CH), 
57.8 (1C, CH), 34.2 (2C, CH2), 25.5 (2C, CH2), 24.7 (1C, CH2); HRMS–ES+: m/z [M+H]
+
 calcd 
for C13H18N4OBr: 325.0664; found: 325.0657. 
 
General method for the aldol condensation:  
Methyl ketone 298 (1.0 eq.) and a suitable aldehyde (1.1 eq.) were dissolved in dioxane and 
water (15:1 ratio) at room temperature. LiOH (1.6 eq.) was added and the solution was stirred 
overnight at room temperature. The resulting suspension was diluted with brine (30 mL) and 
extracted with EtOAc (10   10 mL). The combined organic layers were dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. The crude material was purified using 
column chromatography with an appropriate solvent system to afford the corresponding product. 
 
(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(pyridin-3-yl)prop-2-en-1-one (325) 
Solvent system: 7:3 EtOAc:Hex. Bright yellow solid (0.15 g, 
quantitative yield). Mp 179 °C (dec) (neat); Rf = 0.36 (Hex:EtOAc, 7:3); 
IR (ATR): 3392 (s), 3243 (s), 3119 (s), 1652 (s), 1599 (vs), 1519 (m), 
1413 (m), 994 (m) cm
–1
; 
1
H NMR (CDCl3 with 10 drops of MeOH, 300 
MHz): δ = 8.77 (d, J = 1.8 Hz, 1H, CH), 8.52 (dd, J = 4.9, 1.8 Hz, 1H, CH), 8.25–8.20 (m, 2H, 
CH), 8.03 (app. dt, ddd, J = 8.0, 8.0, 1.8 Hz, 1H, CH), 7.74 (d, J = 16.1 Hz, 1H, CH), 7.38–7.33 
(dd, J = 8.0, 4.9 Hz, 1H, CH); 
13
C NMR (CDCl3, 75.5 MHz): δ = 189.3 (1C, CO), 154.6 (1C, 
CNH2), 150.7 (1C, CH), 150.6 (1C, CH), 150.1 (1C, CH), 140.0 (1C, CH), 135.3 (1C, CH), 
131.1 (1C, C), 129.5 (1C, C), 124.1 (1C, CH), 123.9 (1C, CBr), 123.0 (1C, CH); HRMS–ES+: 
m/z [M+H]
+
 calcd for C12H10N4OBr: 305.0038; found: 305.0034. 
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(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(pyridin-2-yl)prop-2-en-1-one (327) 
Solvent system: 7:3 EtOAc:Hex. Bright yellow solid (0.15 g, 
quantitative yield). Mp 172–175 °C (neat); Rf = 0.27 (Hex:EtOAc, 7:3); 
IR (ATR): 3371 (vs), 3250 (m), 3123 (m), 3028 (m), 1738 (m), 1604 (s), 
1463 (m), 1378 (m), 982 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz):    
δ = 8.72 (d, J = 7.2 Hz, 1H, CH), 8.59 (d, J = 15.8 Hz, 1H, CH), 8.29 (s, 1H, CH), 7.84    
(d, J = 15.8 Hz, 1H, CH), 7.75 (app. dt, ddd, J = 7.7, 7.7, 1.8 Hz, 1H, CH), 7.61 (d, J = 7.7 Hz, 
CH), 7.30 (ddd, J = 7.7, 4.8, 1.8 Hz, 1H, CH); 
13
C NMR (CDCl3, 75.5 MHz): δ = 190.3 (1C, 
CO), 154.5 (1C, C), 153.7 (1C, CNH2), 150.7 (1C, CH), 150.4 (1C, CH), 143.1 (1C, CH), 136.9 
(1C, CH), 130.0 (1C, C), 124.9 (1C, CH), 124.7 (1C, CH), 124.5 (1C, CH), 124.4 (1C, CBr); 
HRMS–ES+: m/z [M+H]+ calcd for C12H10N4OBr: 305.0038; found: 305.003. 
 
(E)-1-(3-Amino-6-bromopyrazin-2-yl)-3-(pyridin-4-yl)prop-2-en-1-one (329) 
Solvent system: EtOAc. Bright yellow solid (0.15 g, quantitative yield). 
Mp 172 °C (dec) (neat); Rf = 0.13 (EtOAc); IR (ATR): 3369 (m), 2918 
(m), 1653 (m), 1593 (vs), 1317 (m), 1007 (m) cm
–1
. 
1
H NMR   
(DMSO–D6, 300MHz): δ = 8.67 (d, J = 5.9 Hz, 2H, CH), 8.52 (s, 1H, 
CH), 8.25 (d, J = 16.1 Hz, 1H, CH), 7.74–7.68 (m, 3H, CH); 13C NMR (DMSO–D6, 75.5MHz): 
δ = 188.6 (1C, CO), 154.7 (1C, CNH2), 151.4 (1C, CH), 150.5 (2C, CH), 141.6 (1C, CH), 140.1 
(1C, CH), 128.2 (1C, C), 125.1 (1C, C), 122.4 (1C, CBr), 122.3 (2C, CH); HRMS–ES+: m/z 
[M+H]
+
 calcd for C12H10N4OBr: 305.0038; found: 305.0034. 
 
General method for the Suzuki coupling: 
The suitable heteroaryl Br (1.0 eq.), boronic acid 243 (1.5 eq.), Cs2CO3 (4.0 eq.) and the solvent 
system Tol:EtOH:H2O (1.5 mL, 4:1:0.05) were added to a Schlenk tube. The reaction content 
was degassed using the freeze-pump-thaw technique. Pd(dppf)Cl2 (0.1 eq.) was then added to the 
Schlenk tube under argon and the solution was stirred at 70 °C overnight. Silica was added to the 
black mixture and transferred to the column. Purification using column chromatography was 
done using EtOAc to 9:1 EtOAc:MeOH as eluent to afford the corresponding product as a solid. 
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(E)-1-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-3-(piperidin-
1-yl)prop-2-en-1-one (228) 
Yellow solid (73% yield). Mp 190–191 °C (neat); Rf = 0.33 
(EtOAc:MeOH, 9:1); IR (ATR): 3570 (m), 3343 (m), 2933 (m), 2851 
(m), 2793 (m), 1627 (m), 1565 (s), 1550 (m), 1149 (m) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.59 (s, 1H, CH), 8.08 (d, J = 8.6 Hz, 2H, 
CH), 7.84–7.80 (m, 3H, CH), 6.71 (d, J = 12.8 Hz, 1H, CH), 3.50–3.42 
(m, 4H, CH2), 3.13–3.05 (m, 4H, CH2), 2.53–2.48 (m, 4H, CH2), 2.27 
(s, 3H, CH3), 1.75–1.68 (m, 6H, CH2); 
13
C NMR (CDCl3, 75.5 MHz): 
δ = 189.0 (1C, CO), 154.6 (1C, CNH2), 153.1 (1C, CH), 143.2 (1C, 
CH), 141.7 (1C, C), 138.1 (1C, C), 134.3 (1C, C), 132.0 (1C, C), 128.5 
(2C, CH), 126.0 (2C, CH), 90.7 (1C, CH), 55.5 (1C, CH2), 54.2 (2C, CH2), 46.8 (1C, CH2), 46.1 
(2C, CH2), 45.8 (1C, CH3), 26.7 (1C, CH2), 25.2 (1C, CH2), 24.2 (1C, CH2); HRMS–ES+: m/z 
[M+H]
+
 calcd for C23H31N6O3S: 471.2178; found: 471.2181. 
 
(E)-1-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-3-
morpholinoprop-2-en-1-one (229) 
Dark yellow solid (69% yield). Mp 194–196 °C (neat); Rf = 0.17 
(EtOAc:MeOH, 9:1); IR (ATR): 3608 (w), 3353 (m), 2919 (m), 2800 
(m), 1630 (m), 1563 (s), 1154 (m), 937 (m) cm
–1
; 
1
H NMR (CDCl3, 300 
MHz): δ = 8.61 (s, 1H, CH), 8.06 (d, J = 8.6 Hz, 2H, CH), 7.83    
(d, J = 7.8 Hz, 2H, CH), 7.78 (d, J = 7.8 Hz, 1H, CH), 6.78 (d, J = 8.6 
Hz, 1H, CH), 3.82–3.78 (m, 4H, CH2), 3.51–3.48 (m, 4H, CH2),   
3.12–3.05 (m, 4H, CH2), 2.51–2.48 (m, 4H, CH2), 2.27 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 189.4 (1C, CO), 154.6 (1C, CNH2), 
152.6 (1C, CH), 143.6 (1C, CH), 141.6 (1C, C), 138.3 (1C, C), 134.4 
(1C, C), 131.3 (1C, C), 128.5 (2C, CH), 126.0 (2C, CH), 91.8 (1C, CH), 66.5 (2C, CH2), 54.2 
(2C, CH2), 46.1 (2C, CH2), 45.8 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C22H29N6O4S: 
473.1971; found: 473.1974. 
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(E)-1-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-3-(pyrrolidin-
1-yl)prop-2-en-1-one (230) 
Yellow solid (76% yield). Mp 190–192 °C (neat); Rf = 0.36 
(EtOAc:MeOH, 9:1); IR (ATR): 3346 (m), 2938 (m), 2800 (m), 1630 
(m), 1593 (m), 1561 (s), 1537 (m), 1154 (m), 944 (m) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.59 (s, 1H, CH), 8.09–8.03 (m, 3H, CH), 7.82 
(d, J = 8.9 Hz, 2H, CH), 6.57 (d, J = 12.7 Hz, 1H, CH), 3.76 (t, J = 6.8 
Hz, 2H, CH2), 3.64 (t, J = 6.8 Hz, 2H, CH2) 3.12–3.04 (m, 4H, CH2), 
2.50–2.47 (m, 4H, CH2), 2.26 (s, 3H, CH3), 2.13–1.96 (m, 4H, CH2); 
13
C 
NMR (CDCl3, 75.5 MHz): δ = 188.4 (1C, CO), 154.6 (1C, CNH2), 150.0 
(1C, CH), 143.1 (1C, CH), 141.8 (1C, C), 138.1 (1C, C), 134.3 (1C, C), 
132.0 (1C, C), 128.5 (2C, CH), 125.9 (2C, CH), 92.8 (1C, CH), 54.2 (2C, CH2), 52.7 (1C, CH2), 
47.4 (1C, CH2), 46.1 (2C, CH2), 45.9 (1C, CH3), 25.4 (1C, CH2), 25.3 (1C, CH2); HRMS–ES+: 
m/z [M+H]
+
 calcd for C22H29N6O3S: 457.2022; found: 457.2023. 
 
(E)-1-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-3-
(diethylamino)prop-2-en-1-one (231) 
Yellow solid (86% yield). Mp 176–177 °C (neat); Rf = 0.5 
(EtOAc:MeOH, 9:1); IR (ATR): 3351 (m), 2972 (m), 2802 (m), 1630 
(m), 1561 (s), 1538 (m), 1344 (m), 1046 (m), 952 (m) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.59 (s, 1H), 8.08 (d, J = 8.7 Hz, 2H), 7.88–7.81 
(m, 3H), 6.69 (d, J = 12.9 Hz, 1H), 3.41 (q, J = 7.2 Hz, 4H), 3.13–3.04 
(m, 4H), 2.51–2.47 (m, 4H), 2.26 (s, 3H), 1.29 (t, J = 7.2 Hz, 6H); 13C 
NMR (CDCl3, 75.5 MHz): δ = 188.7 (1C, CO), 154.6 (1C, CNH2), 152.4 
(1C, CH), 143.1 (1C, CH), 141.7 (1C, C), 138.0 (1C, C), 134.3 (1C, C), 
132.0 (1C, C), 128.5 (2C, CH), 125.8 (2C, CH), 91.6 (1C, CH), 54.2 
(2C, CH2), 50.9 (1C, CH2), 46.1 (2C, CH2), 45.9 (1C, CH3), 43.3 (1C, CH2), 15.0 (1C, CH3), 
11.9 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C22H31N6O3S: 459.2178; found: 459.2172. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
245 
 
(E)-1-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-3-(pyridin-2-
yl)prop-2-en-1-one (236)  
Dark yellow solid (40% yield). Mp 196–200 °C (neat); Rf = 0.27 
(EtOAc:MeOH, 9:1); IR (ATR): 3340 (m), 2929 (m), 2815 (m), 1652 
(m), 1601 (s), 1580 (s), 1342 (s), 1151 (s), 952 (s) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.81 (d, J = 15.8 Hz, 1H, CH), 8.74–8.72 (m, 
2H, CH), 8.16 (d, J = 8.4 Hz, 2H, CH), 7.89–7.84 (m, 3H, CH), 7.76 
(app. td, ddd, J = 7.7, 7.7, 1.7 Hz, 1H, CH), 7.59 (d, J = 7.7 Hz, 1H, 
CH), 7.31 (d, J = 7.7, 5.1 Hz, 1H, CH), 3.16–3.04 (m, 4H, CH2),  
2.52–2.48 (m, 4H, CH2), 2.26 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 
MHz): δ = 191.3 (1C, CO), 154.9 (1C, C), 153.7 (1C, CNH2), 150.4 
(1C, CH), 145.7 (1C, CH), 142.8 (1C, CH), 140.7 (1C, C), 139.2 (1C, C), 136.9 (1C, CH), 135.0 
(1C, C), 129.6 (1C, C), 128.6 (2C, CH), 126.2 (2C, CH), 125.0 (1C, CH), 124.9 (1C, CH), 124.5 
(1C, CH), 54.2 (2C, CH2), 46.1 (2C, CH2), 45.8 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for 
C23H25N6O3S: 465.1709; found: 465.1707. 
 
(E)-1-{3-Amino-6-[4-({4-methylpiperazin-1-yl}sulfonyl)phenyl]pyrazin-2-yl}-3-(pyridin-3-
yl)prop-2-en-1-one (237) 
Yellow solid. (43% yield). Mp 170–172 °C (neat); Rf = 0.21 
(EtOAc:MeOH, 9:1); IR (ATR): 3404 (m), 3122 (m), 2806 (m), 1655 
(m), 1595 (s), 1415 (m), 1343 (m), 1171 (m), 1006 (m) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.98–8.90 (m, 1H, CH), 8.75 (s, 1H, CH),  
8.65–8.64 (m, 1H, CH), 8.51 (d, J = 16.1 Hz, 1H, CH), 8.11 (d, J = 8.4 
Hz, 1H, CH), 8.03–8.00 (m, 1H, CH), 7.89–7.83 (m, 3H, CH), 7.41–7.37 
(m, 1H, CH), 3.18–3.04 (m, 4H, CH2), 2.56–2.45 (m, 4H, CH2), 2.26 (s, 
3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 190.4 (1C, CO), 154.9 
(1C, CNH2), 151.3 (1C, CH), 150.4 (1C, CH), 145.9 (1C, CH), 140.7 
(1C, C), 140.2 (1C, CH), 139.3 (1C, C), 135.1 (1C, C), 135.0 (1C, CH), 131.0 (1C, C), 129.3 
(1C, C), 128.7 (2C, CH), 126.1 (2C, CH), 124.0 (1C, CH), 122.9 (1C, CH), 54.2 (2C, CH2), 46.2 
(2C, CH2), 45.8 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C23H25N6O3S: 465.1709; found: 
465.1696. 
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8.4 Chapter 6 
1-(3-Amino-6-bromopyrazin-2-yl)prop-2-en-1-one (336)  
Weinreb 311 (0.10 g, 0.38 mmol) was dissolved in THF (3 mL) at 0 °C and 
vinyl MgBr (1.0 M, 1.2 mL, 1.2 mmol,) was then added dropwise. The   
red-brown solution was stirred for one hour at 0 °C, followed by one hour at 
room temperature. The brown solution was cooled to –10 °C, quenched with 
2M HCl (2 mL) and then extracted with EtOAc (3   15 mL). The combined organic layers were 
dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. Purification was 
done using column chromatography with 9:1 Hex:EtOAc as eluent to afford the product as a 
yellow solid in 62% yield. Mp 118–120 °C (neat); Rf = 0.71 (Hex:EtOAc, 7:3); IR (ATR): 3378 
(m), 3245 (m), 3176 (m), 2970 (m), 2922 (m), 1738 (m), 1659 (m), 1601 (s), 1373 (m), 999 (m) 
cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.28 (s, 1H, CH), 7.85 (dd, J = 17.3, 10.5 Hz, 1H, CH), 
6.54 (dd, J = 17.3, 2.0 Hz, 1H, CH), 5.90 (dd, J = 10.5, 2.0 Hz, 1H, CH); 
13
C NMR (CDCl3, 75.5 
MHz): δ = 190.4 (1C, CO), 154.5 (1C, CNH2), 150.6 (1C, CH), 130.8 (1C, CH), 130.0 (1C, CH), 
129.4 (1C, C), 124.3 (1C, CBr); HRMS–ES+: m/z [M+H]+ calcd for C7H7N3OBr: 227.9772; 
found: 227.9780. 
 
3-Amino-N-methoxy-N-methyl-6-(4-((4-methylpiperazine-1-yl)sulfonyl)phenyl)pyrazine-2-
carboxamide (337) 
Weinreb amide 311 (0.10 g, 0.38 mmol), boronic acid 243 (0.25 g, 0.57 
mmol), Cs2CO3 (0.50 g, 1.5 mmol) and the solvent system Tol:EtOH:H2O 
(3.5 mL, 4:1:0.05) were added to a Schlenk tube. The reaction content was 
degassed using the freeze-pump-thaw technique. Pd(dppf)Cl2 (0.030 g, 
0.040 mmol) was then added to the Schlenk tube under argon and the 
solution was stirred at 70 °C overnight. Silica was added to the black 
mixture and transferred to the column. Purification was done using EtOAc 
to 9:1 EtOAc:MeOH as eluent to afford the product as a dark cream solid in 
81% yield. Mp 116–120 °C (neat); Rf = 0.21 (EtOAc:MeOH, 9:1); IR 
(ATR): 3347 (m), 2798 (m), 1591 (s), 1454 (m), 1328 (m), 1167 (m), 941 (m) cm
–1
; 
1
H NMR 
(CDCl3, 300 MHz): δ = 8.58 (s, 1H, CH), 8.00 (d, J = 8.6 Hz, 2H, CH), 7.81 (d, J = 8.6 Hz, 2H, 
CH), 6.09 (br s, 2H, NH2), 3.87 (s, 3H, CH3), 3.52 (br s, 3H, CH3), 3.13–3.03 (m, 4H, CH2), 
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2.55–2.44 (m, 4H, CH2), 2.26 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 153.9 (1C, 
CNH2), 142.4 (1C, CH), 140.9 (1C, C), 138.1 (1C, C), 134.6 (1C, C), 128.5 (1C, CH3), 125.8 
(2C, CH2), 45.8 (2C, CH2), 61.6 (1C, CH3), 60.4 (1C, CH3), 54.0 (2C, CH3), 46.0 (2C, CH2), 
45.7 (1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C18H25N6O4S: 421.1658; found: 421.1649. 
 
1-(3-Amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)pyrazin-2-yl)ethanone (340) 
Weinreb amide 311 (0.075 g, 0.35 mmol), boronic acid 243 (0.15 g, 0.52 mmol), 
Cs2CO3 (0.46 g, 1.4 mmol) and the solvent system Tol:EtOH:H2O (2.5 mL, 
4:1:0.05) were added to a Schlenk tube. The reaction content was degassed using 
the freeze-pump-thaw technique. Pd(dppf)Cl2 (0.026 g, 0.040 mmol) was then 
added to the Schlenk tube under argon and the solution was stirred at 70 °C 
overnight. Silica was added to the black mixture and transferred to the column. 
Purification was done using EtOAc to 95:5 EtOAc:MeOH as eluent to afford the 
product as a yellow solid in 90% yield. Mp 177 °C (neat); Rf = 0.33 
(EtOAc:MeOH, 95:5); IR (ATR): 3413 (m), 3259 (m), 2800 (m), 1671 (s), 1592 
(vs), 1169 (vs), 1153 (vs), 943 (m) cm
–1
; 
1
H NMR (CDCl3, 300 MHz): δ = 8.73 (s, 1H, CH), 8.10 
(d, J = 8.7 Hz, 2H, CH), 7.85 (d, J = 8.7 Hz, 2H, CH), 3.14–3.04 (m, 4H, CH2), 2.80 (s, 3H, 
CH3), 2.51–2.48 (m, 4H, CH2), 2.27 (s, 3H, CH3); 
13
C NMR (CDCl3, 75.5 MHz): δ = 202.7  
(1C, CO), 153.8 (1C, CNH2), 145.5 (1C, CH), 140.7 (1C, C), 139.0 (1C, C), 135.0 (1C, C), 129.2  
(1C, C), 128.6 (2C, CH), 125.9 (2C, CH), 54.1 (2C, CH2), 46.1 (2C, CH2), 45.8 (1C, CH3), 26.4 
(1C, CH3); HRMS–ES+: m/z [M+H]
+
 calcd for C17H22N5O3S: 376.1443; found: 376.1440. 
 
8.5 Biological testing 
8.5.1 Inhibition of GSK-3 (Radiometric Assay) 
GSK-3β biological testings were carried out at the Centro de Investigaciones Biológicas, Madrid, 
Spain 
 
GSK-3β enzyme (Sigma) was incubated with 15 μM of ATP, 0.2 μCi of [γ-32P]ATP,  GS-1 
substrate, and different concentrations of test compound. GSK-3β activity was assayed in 50 mM 
Tris, pH 7.5, 10 mM MgCl2, 1 mM EGTA, and 1 mMEDTA buffer at 37 °C, in the presence of 
15 mM GS-1 (substrate), 15 μM of ATP, 0.2 μCi of [γ-32P] ATP in a final volume of 12 μL. 
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After 20 min of incubation at 37 °C, 4 μL aliquots of the supernatant were spotted onto 2   2 
pieces of Whatman P81 phosphocellulose paper, and the filter was washed four times (at least 10 
min each time) in 1% phosphoric acid. The dried filters were transferred into scintillation vials, 
and the radioactivity was measured in a liquid scintillation counter. Blank values were 
subtracted, and the GSK-3β activity was expressed in percentage of maximal activity. The IC50 
value is defined as the concentration of each compound that reduces enzyme activity by 50% 
with respect to that without inhibitor present.  
 
8.5.2 Inhibition of GSK-3 (Luminescent Assay).  
Human recombinant GSK-3β was purchased from Millipore (Millipore Iberica S.A.U.) The 
prephosphorylated polypeptide substrate was purchased from Millipore (Millipore Iberica 
S.A.U.). Kinase-Glo Luminescent Kinase Assay was obtained from Promega (Promega Biotech 
Iberica, SL). ATP and all other reagents were from Sigma-Aldrich  (St. Louis, MO). Assay 
buffer contained 50 mM HEPES (pH 7.5), 1 mM EDTA, 1 mM EGTA, and 15 mM magnesium 
acetate. The method of Baki et al.
20
 was followed for the inhibition of GSK-3β. Kinase-Glo 
assays were performed in assay buffer using black  96-well plates. In a typical assay, 10 μL (10 
μM) of test compound (dissolved in dimethyl sulfoxide [DMSO] at 1 mM concentration and 
diluted in advance in assay buffer to the desired concentration) and 10 μL (20 ng) of enzyme 
were added to each well followed by 20 μL of assay buffer containing 25 μM substrate and 1 μM 
ATP. The final DMSO concentration in the reaction mixture did not exceed 1%. After a 30 min 
incubation at  30 °C, the enzymatic reaction was stopped with 40 μL of Kinase-Glo reagent. 
Glow-type luminescence was recorded after 10 min using a FLUOstar Optima (BMG Lab 
technologies GmbH, Offenburg, Germany) multimode reader. The activity is proportional to the 
difference of the total and consumed ATP. The inhibitory activities were calculated on the basis 
of maximal activities measured in the absence of inhibitor. The IC50 value was defined as the 
concentration of each compound that reduces a 50% the enzymatic activity with respect to that 
without inhibitors. 
 
GSK-3β reversibility studies:  
To study the type of enzymatic inhibition for the compounds, assays were performed to 
determine the activity of the enzyme after several times of incubation of the enzyme with the 
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inhibitor. A reversible inhibitor does not increase the inhibition of the enzyme with the time of 
incubation, while an irreversible inhibitor increases the inhibition percentage as it increases the 
time of incubation with the enzyme. 
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Appendix 
 
Additional biological testing on the chloroquine sensitive 
Plasmodium falciparum strain, NF54 
 
1.1 Overview 
This section discusses the additional biological testing that was carried out on the sensitive P. 
falciparum malaria strain, NK54. Our research group also develops novel anti-malarial 
inhibitors
1-5
 and our colleagues at the University of Cape Town, Chibale and co-workers,
6, 7
 have 
reported potent biological activities for the amino-pyridine and -pyrazine series against two 
Plasmodium falciparum strains (K1 and NF54). We envisaged that the synthesised 
aminopyrazine series reported in this thesis could potentially inhibit P. falciparum. Therefore, 
the biological activities of the synthesised compounds were determined in vitro against the 
chloroquine sensitive strain of P. falciparum, NF54. 
 
1.2 Brief background 
Each year malaria affects in the region of 300 – 500 million people and is responsible for the 
death of roughly 2.5 million people.
8
 Since the 1940s, the development of anti-malarial drugs has 
played an important role in the control and treatment of malaria. However, the widespread use of 
antimalarials has caused the development of resistance in P. falciparum parasites, which has 
resulted in an increased malaria mortality.
9
 This has necessitated the need for the development of 
new molecules with novel mechanisms of action.
10
 
Chibale and co-workers,
7
 developed a series of aminopyrazine inhibitors (see Fig. 1.1 for 
representative examples 330 – 333) that showed low nanomolar potency against both the 
sensitive and resistant strains of P. falciparum. In addition, these inhibitors demonstrated good  
in vivo efficacy using the Plasmodium berghei mouse model
11
 and also metabolic stability in 
human microsomes. 
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Figure 1.1. Some of the potent aminopyrazine inhibitors against the P. falciparum strains 
reported by Chibale and co-workers
7
 
 
The inhibitors that were developed by Chibale and co-workers
7
 consisted of a similar 
aminopyrazine core that was described in this thesis. Therefore, the synthesised Michael acceptor 
derivatives discussed in chapter three and four were subjected to in vitro testing on the sensitive 
P. falciparum strain, NF54, and will be discussed in the next section. 
 
1.3 Biological results 
The synthesised compounds 216 – 220 and 228 – 231 were tested for their in vitro activity 
(whole cell assay) using the modified method of Trager
12
 and Makler
13
 against the sensitive P. 
falciparum strain, NF54. A full dose-response analysis was performed on all compounds to 
determine the concentration inhibiting 50% of parasite growth (IC50) and the values are shown in 
Table 1.1. Chloroquine, a known antiplasmodial inhibitor, was used as a reference standard.
14
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Table 1.1. NF54 IC50 values of compounds 216 – 220 and 228 – 231 
# 
 
IC50 (μM) 
216 
 
2.38 
217 
 
0.776 
218 
 
4.85 
219 
 
0.201 
220 
 
15.6 
228 
 
2.70 
229 
 
10.0 
230 
 
4.85 
231 
 
0.106 
Chloroquine  0.007 
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The in vitro assay against the chloroquine-sensitive strain delivered mixed results. The small 
diethylamine side chain-containing compounds, 219 and 231, were the most potent with IC50 
values in the nanomolar range, while the bulky cyclohexylamine 220 perform the poorest  
(15.6 μM).  
Regardless of the position of the Michael acceptor, the biological activities were similar for the 
piperidine (216 and 228), pyrrolidine (218 and 230) and diethylamine (219 and 231) derivatives. 
However, for the morpholine derivatives (217 and 229), a large difference in potency was 
observed, which suggests that the shape of the molecule could result in a possible    
hydrogen-bonding interaction with the oxygen atom of the morpholine ring (217) or a repulsive 
interaction for compound 229. The diethylamine derivatives (219 and 231) are the only 
molecules tested that do not have a ring structure and this could play a role in the potency 
difference between the pyrrolidine (218 and 231) and diethylamine (219 and 231) derivatives. 
This could suggest that one of the diethyl groups is lost to form the NH atoms which could 
enhance the potency of the molecule. In addition, it has been confirmed that molecules that 
consist of a diethylamine fragment, as seen in chloroquine, exhibited enhanced potency.
15, 16
 The 
relative inactivity of cyclohexylamine 220 (which does possess the NH atoms) suggests that 
there is no tolerance for bulky groups at this position.  
 
1.4 The search for the pharmacophore  
The aforementioned antiplasmodial results prompted the search for the active fragment that 
could serve as a pharmacophore for the second generation of antiplasmodial inhibitors. The 
fragments of the most potent compounds, 219 and 231, were tested for their in vitro activity 
(whole cell assay) by using the same procedure as mentioned in section 1.3. The results are 
tabulated in Table 1.2. All three fragments, 292, 319 and 251, were deemed inactive, with IC50 
values in the high micromolar range. For this reason, the fragment that was essential for 
biological activity could not be determined. 
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Table 1.2. NF54 IC50 values of compounds 292, 319 and 251 
# Fragment IC50 (μM) 
292 
 
>10.0 
319 
 
>10.0 
251 
 
8.86 
Chloroquine  0.007 
 
These results have thus necessitated the need for further exploration to determine the active 
pharmacophore. A second round of biological testing could include different fragments of 
compounds 219 and 231 or modifications to the tested fragments 251, 292 and 319. This will be 
discussed as future work in the next section. 
 
1.5 Future antiplasmodial biological testing to determine the 
pharmacophore 
Antiplasmodial biological testing revealed that the most active compound from each series was, 
in both cases, the diethyl derivative (219 and 231) with IC50 values of 0.201 and 0.106 μM 
respectively. Fragments of 219 and 131 were then tested for their antiplasmodial activity to 
identify the pharmacophore. However, all fragments exhibited activity in the high micromolar 
range. This concluded that the pharmacophore must be a fragment that consisted of combined 
moieties of 292/319 and 251. Therefore, a phenotypic screening would be required to identify the 
fragment that is essential for antiplasmodial activity. Using diethyl 292 as an example, three 
fragments could be constructed (Fig. 1.2). Compounds 351 and 352 consist of a side chain and a 
partial sulfonamide core, while compound 353 contains the scaffold that is attached to a portion 
of the side chain. 
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Figure 1.2. Combined moieties of 292 and 251 to construct new fragments 
 
The diethyl derivatives 219 and 231 could also be slightly modified to determine which fragment 
of the molecule is essential for antiplasmodial activity. Using diethyl 219 again as the example, 
this molecule could potentially be modified at six different positions (Figure 1.3). The amino 
group on the pyrazine core could be removed (compound 354) to determine whether this 
functional group is necessary for activity. The pyrazine ring could also be replaced by a pyridine 
ring (compound 355 and 356) to determine whether the position of the nitrogen plays a role in 
the potency of this compound. The sulfonamide core could be modified to replace the sulfone 
with a carbonyl (compound 357) and the methylpiperazine to piperidine (compound 358). Lastly, 
the Michael acceptor could be converted into a simple alkene (compound 359).    
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Figure 1.3. Modified fragments of diethyl 219 to identify the fragment that is essential for 
antiplasmodial activity 
 
Ultimately, this dissertation describes the synthesis of some interesting new compounds. With 
the aid of molecular modelling, two different approaches to drug development have been used. 
The main focus was a target-based approach attempting to develop an inhibitor for GSK-3β with 
the possibility of forming a covalent interaction with Cys199 inside the ATP-binding site. The 
results were moderate but raise some useful points of departure for further exploration. In 
addition, the minor foray into the phenotypic screen against P. falciparum is a good reminder to 
keep one’s mind open to interesting possibilities. The unexpectedly good efficacy of the two 
diethyl compounds could open the door to studies that focus on determining the active 
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pharmacophore of these compounds as well as structure-activity relationships to develop novel 
antiplasmodial agents. 
 
1.6 Experimental section 
1.6.1 Inhibition of NF54 
Biological testings were carried out at the University of Cape Town, Department of 
Pharmacology, Cape Town, South Africa. 
The samples were tested in triplicate on one or two separate occasions against a chloroquine 
sensitive (CQS) strain of Plasmodium falciparum (NF54). Continuous in vitro cultures of 
asexual erythrocyte stages of P. falciparum were maintained using a modified method of Trager 
and Jensen.
12
 Quantitative assessment of anti-plasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified method described by Makler.
13
 The 
samples were prepared to a 20 mg/mL stock solution in 100% DMSO and sonicated to enhance 
solubility. Samples were tested as a suspension if not completely dissolved. Stock solutions were 
stored at ‒20 ºC. Further dilutions were prepared on the day of the experiment. Chloroquine 
(CQ) was used as the reference drug in all experiments. A full dose-response analysis was 
performed for all compounds to determine the concentration inhibiting 50% of parasite growth 
(IC50 value). Samples were tested at a starting concentration of 100 μg/mL, which was then 
serially diluted 2-fold in complete medium to give 10 concentrations; with the lowest 
concentration being 0.2 μg/mL. The same dilution technique was used for all samples. The 
highest concentration of solvent to which the parasites were exposed had no measurable effect on 
the parasite viability (data not shown). The IC50 values were obtained using a non-linear   
dose-response curve fitting analysis via Graph Pad Prism v.4.0 software.  
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